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ABSTRACT 
  Echinacea is a medicinal plant that has a history of use for the treatment of 
respiratory tract infections.  More recently there has been a renewed interest in alternative 
therapies including phytomedicinal preparations of Echinacea. Some important issues 
that remain to be addressed regarding the use of Echinacea therapeutically include plant 
species specific alterations of immune response and the effect of different preparation 
techniques (water as compared to ethanol) on immune response to viral infection.  
Results from multiple studies in mice, in cell culture, and in clinical trials in humans have 
suggested that water preparations provide a stimulatory effect on innate immunity by 
enhancing macrophage activation, whereas ethanol extracts decrease inflammation 
associated cytokines/chemokines.  However, the mechanisms by which different plant 
species enhance immunity against influenza infection and improve disease outcome 
remain to be clearly elucidated.   In this dissertation, both water and ethanol extracts of 
three species of Echinacea were used to assess alterations in the immune response to 
influenza A/PR/8/34 virus infection.  Studies focused on the impact of Echinacea 
treatment during influenza infection on 1) in vitro models of viral load and immune 
responses in the respiratory tract epithelial cells and immune cells, 2) combination 
treatment of water and ethanol extracts delivered at specific phases of influenza infection 
and the impact on “traditional” immune measures as well as a bioinformatics approach to 
lung gene regulation using the Database for Annotation Visualization and integrated 
Discovery (DAVID), and  3) immune response to influenza in obese mice treated with 
Echinacea water extract.  The primary topic of this dissertation was the effect of 
Echinacea on immunity.  However, there was also an emphasis on the topic of obesity 
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and immunity.  The results from many studies have shown diet-induced obesity related 
immune dysfunction in the context of the immune response to influenza virus and 
vaccination.  In this dissertation, the effect of Echinacea treatment on obesity associated 
immune impairments to influenza infection was also evaluated.    
The first Echinacea immunity study (Chapter II) examined the effect of three 
species of Echinacea for anti-viral effects against influenza A/PR/8/34 virus, as well as 
the effect of the same three species of Echinacea on the lung epithelial immune response 
to influenza A/PR/8/34 virus, and on immune cells isolated from the spleens of infected 
BALB/c mice stimulated with A/PR/8/34 in vitro. The findings from this study showed 
that E. purpurea water extracts demonstrated modest anti-viral activity at a low or high 
dose, whereas the ethanol extracts of E. purpurea, E. angustifolia, and E. paradoxa var. 
paradoxa demonstrated modest anti-viral activity only at a high dose. Studies have 
shown that polysaccharides (hydrophilic) and alkamides (lipophilic) isolated from 
Echinacea extracts have anti-viral activity in vitro.  Both water and ethanol extracts 
enhanced the lung epithelial and immune cell response through modulation of 
cytokine/chemokine responses that may be involved in recruiting immune cells to the site 
of infection (such as monocyte inflammatory protein 1 alpha: MIP-1α, monocyte 
inflammatory protein 1 beta: MIP-1β, interleukin 8: IL8, Eotaxin, granulocyte 
macrophage colony stimulating factor: GM-CSF) and differentiation of T cells into 
subtypes (interferon gamma: IFN-γ, interleukin 2: IL2, interleukin 4: IL4, interleukin 5: 
IL5, interleukin 17: IL17), as well as, decreased inflammatory cytokines (interleukin 6: 
IL-6 and tumor necrosis factor alpha: TNFα) in the presence of influenza A/PR/8/34 
infection.  Based on these findings, Echinacea extracts may enhance the immune 
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response to influenza infection by decreasing viral load, regulating cytokines/chemokines 
involved with cellular response to influenza, and limiting influenza associated 
inflammation  
A subsequent study (Chapter III) evaluated the effect of using a combination of 
Echinacea extracts delivered at specific times during the infection in BALB/c mice 
infected with influenza A/PR/8/34 virus using Echinacea angustifolia, and Echinacea 
paradoxa var. paradoxa.  These species were chosen based on previous unpublished 
work and as an extension of the in vitro work completed in Chapter II.  Also, E. 
angustifolia is a species that is commonly found in commercial preparations, whereas, E. 
paradoxa var. paradoxa has not been studied in the context of influenza infection.  In this 
study, the effect of combination treatment on the lung viral load, lung cell populations, 
lung lesion scores, and lung cytokine/chemokine production were evaluated.  We also 
utilized DAVID bioinformatics to determine the effect of Echinacea treatment in the 
lungs of mice infected with influenza at day 8 and 9 post infection.  We demonstrated 
that the combination treatment had no significant effect on illness severity as measured 
by body weight, and no effect on lung lesion scores or lung cell populations.  However, 
there was an anti-inflammatory with respect to the concentration of several inflammatory 
cytokines and chemokines in the lungs observed in mice treated with the E. angustifolia 
water extract followed by the E. angustifolia EtOH extract. Gene expression results are 
suggestive of decreased chemokine expression as well.  The gene profile also suggested 
that there was an activation of immune cells and a down regulation of genes involved in 
wound repair.  Anti-influenza specific antibody was increased in the mice that received 
the combination of E. angustifolia water followed by E. angustifolia ethanol.  The overall 
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results showed that the immuno-modulatory effects are determined by Echinacea species 
utilized.   The data in this study suggest the possibility of enhancing the innate and 
cellular immune response particularly through gene regulation of macrophage 
phagocytosis, lymphocyte activation and differentiation, along with increased antibody 
production by utilizing an Echinacea water extract at the early phase of infection.  Also, 
the data in this study support a decrease in pro-inflammatory cytokines, decreased 
chemokine responsible for neutrophil recruitment, and down-regulation of genes 
associated with the wound response and neutrophil recruitment when Echinacea ethanol 
extract was administered during the late phase of influenza infection.   The conclusions 
from the combination study suggest that Echinacea combination treatment can have a 
beneficial effect on immune cell activation and decreased inflammation in the lung 
dependent on the Echinacea species.   
Finally, in Chapter IV of this dissertation, the effect of Echinacea on the immune 
response to Influenza A/PR/8/34 virus (IAV) infection in diet-induced obese mice was 
evaluated.   Obesity resulting from a high fat diet, genetic deficiencies, and sedentary 
lifestyles has been shown to have a negative impact on the immune system resulting in 
immune dysregulation.  In the 2009 H1N1 pandemic, obesity was found to be a risk 
factor for increased severity of infections.  The purpose of the last study in this 
dissertation was to determine whether Echinacea might improve immune responsiveness 
to IAV in diet-induced obese mice (receiving a high fat diet for eight weeks) compared to 
lean mice (receiving a low fat diet for eight weeks) through immune enhancement of the 
innate and adaptive immune response.  Diet induced obesity has been associated with 
increased pro-inflammatory cytokines in the uninfected state  (interleukin 1 beta: IL-1β, 
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IL-6, TNF-α) and decreased cellular recruitment to  the lung during infection, (decreased 
dendritic cells, natural killer cells, influenza specific CD8 cells, decreased IFN-γ 
production).  The obesity effects seen in the diet induced obesity model used in this study 
correlated with the findings of previous studies.  Echinacea treatment increased alveolar 
macrophage percentage, and decreased CD8 in the lungs of obese mice, and altered the 
IFN-γ production in spleen cells.  Overall the findings suggest that Echinacea was not 
able to restore the obesity associated immune dysfunction. 
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CHAPTER I 
  
GENERAL INTRODUCTION 
 
Organization of the Dissertation: 
This dissertation consists of manuscripts that are being prepared for submission to 
peer-reviewed journals. The dissertation contains a total of five chapters including a 
general introduction, three research papers, and a general conclusion that discusses the 
overall findings from the dissertation, followed by acknowledgements. The references for 
each chapter, including Chapter I (Literature Review), are listed at the end of each 
chapter with figures following the references directly. The General Introduction (Chapter 
I) to the dissertation includes the impact of influenza on public health and a brief 
introduction to Echinacea as a remedy for influenza infection along with a brief 
description of the research objective of the dissertation. The Literature Review provides 
background information on the lifecycle of influenza viruses, followed by a review of the 
host immune response to the virus, along with a review of Echinacea and the known 
effects of Echinacea on the immune system.  Finally, a brief summary of diet-induced 
obesity associated immune impairments closes the review of literature. Chapter II is 
focused primarily on evaluating immune changes with Echinacea treatment during 
influenza infection in vitro. Chapter III is focused on utilizing a combination of 
Echinacea extracts delivered at specific phases of infection to modulate the immune 
response to influenza during the early and late phases of infection.  Chapter IV 
specifically addresses diet induced obesity associated immune dysfunction in influenza 
infection and whether Echinacea treatment can correct those immune impairments  
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This dissertation contains the experimental data and results obtained by the author during 
her Ph.D. study under the supervision of her major professor Dr. Marian L. Kohut at 
Iowa State University, Immunobiology Interdepartmental Program. 
Introduction to the Dissertation: 
Infection with influenza virus remains a significant cause of morbidity and 
mortality.  Approximately 100,000 hospitalizations 36,000 deaths occur every influenza 
season in the US alone [1].  Seasonal vaccination is currently the only prevention for 
infection with influenza virus.  Several anti-viral medications are available for treatment 
of severe cases of influenza; however, there is a risk of viral mutation leading to 
resistance for the current treatments.  With a growing trend towards the use of “natural” 
remedies for infections in general, Echinacea has emerged as a popular treatment for 
upper respiratory infections.  Native to North America, Echinacea was originally used by 
Native Americans.  In the 1900’s, Echinacea was first used to combat colds and flu-like 
symptoms and was introduced into Europe [2].  In recent years, it has re-emerged as a 
popular alternative treatment for influenza infections in the US and is available in 
commercial preparations such as Airborne®, EpiCore® and Echinaforce®.   A lack of 
standardization in botanical remedies and proprietary blends of commercial preparations 
adds to the variability of efficacy achieved with Echinacea.  Studies have shown that 
Echinacea is effective at stimulating the innate immune system, particularly 
macrophages, natural killer (NK) and dendritic cells (DC) and decreasing inflammation 
associated cytokines.  These effects on the immune system vary by Echinacea species 
utilized, preparation techniques, and plant part used for the extraction.  Very few studies 
have investigated the potential benefit of Echinacea during influenza infection to 
determine whether different species of Echinacea have different immunomodulatory 
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effects.  Given that the active constituents of Echinacea may vary by species and type of 
extract preparation, using different species of Echinacea, and/or a combination of 
different types of extract preparations may result in optimal benefits for host defense 
against influenza. In this dissertation, this type of combination approach was used a novel 
approach to balancing the immune stimulatory properties of Echinacea with the anti-
inflammatory properties.  In the 2009 H1N1 influenza pandemic, obesity emerged as a 
risk factor for severe influenza infections with increased morbidity and mortality 
associated with the obese condition.  Obesity (resulting from dietary, genetic, and 
lifestyle factors) is becoming a national epidemic of its own with 35.6% of adults in the 
US classified as obese 2009-2010 [3].  Obesity has been shown to have immune related 
dysfunctions, such as increased pro-inflammatory cytokines and decreased cellular 
function, and really highlights the importance of nutrition in the function of a proper 
immune response.  The effect of Echinacea on influenza in the obese population and 
whether it has benefits for immune enhancement in diet induced obesity has not been 
previously investigated.     
Literature Review 
Influenza structure and pathogenesis 
Influenza is a negative sense, single strand RNA virus in the family 
Orthomyxoviridae.   Influenza remains a respiratory pathogen causing significant yearly 
morbidity and mortality in the US and worldwide, hospitalizing over 200,000 individuals 
and causing approximately 36,000 fatalities per season (November to April) in the US 
alone [1].  Seasonal influenza infections commonly impact the older populations (over 
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65) and the very young (less than 3).  It has been suggested that pandemic infections 
typically impact the middle age population more readily (age 20-40).  Influenza has 
several different strains: A, B, and C with influenza A being the most pathogenic.  
Several pandemics of influenza A have been recorded including 1889, 1918, 1957, 1968, 
and 2009 with the pandemic of 1918 being the most deadly pandemic of influenza on 
record.  Influenza B and C have not been associated with pandemics to date.   
The basic structure of the virus includes a hemagglutination protein (HA), 
neuriminadase protein (NA) and matrix 2 protein (M2).  There are sixteen known HA 
proteins and nine known NA.  HA is responsible for attachment of the virus to the host.  
NA is speculated to be involved in the release of the virus for purposes of transmission to 
a new host or new cell.  The virion RNA is made of eight gene segments allowing for 
large diversity in virus strains.  Natural hosts for influenza A are wild birds although it is 
able to infect a variety of host mammals [4,5].  The ability to adapt and infect new hosts 
(zoonotic transmission) solidifies influenza as a constant pathogenic threat to humans.  
As the virus infects new hosts (host switching), the recombination with other influenza 
viruses present in the new host may occur.  This recombination allows for new 
combinations of HA and NA proteins to emerge in a process called reassortment.  For the 
virus to be transmitted further to a human host, several changes must occur.  It has been 
hypothesized that a single amino acid mutation allows for the HA to switch from a sialic 
acid preference of α2-3Gal linkage found in water fowl to a sialic acid preference of α2-
6Gal linkage found in the respiratory tract of humans [5-7].  The M2 protein forms ion 
channels in the host cell to help facilitate viral replication through pH neutralization of 
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Golgi bodies [8].  The HA, NA, and M2 proteins are the three dominant proteins of the 
viral envelope membrane to which host antibodies are formed.       
The frequent mutation of influenza viruses through “antigenic drifts” and 
“antigenic shifts” confer immune evasive properties to the virus.  Because influenza A 
viruses are RNA based, they have no editing machinery to fix point mutations during the 
replication process.  This lack of machinery coupled with a high replication rate causes 
point mutations to accumulate in the virus leading to an “antigenic drift”.  Antigenic drift 
allows the virus to evade the immune system due to changes in the virus that disables the 
immune system from recognizing the appropriate immunogenic sites by antibody 
binding.  The reassortment that occurs in hosts with multiple concurrent infections can 
lead to a new subtype of virus or “antigenic shift”.  In antigenic shift, the influenza virus 
acquires a new HA or NA protein also allowing evasion of the immune system through 
new immunogenic sites that are no longer recognized by the host antibodies[9].    
Influenza and the immune system of the lung 
The respiratory tract of humans is comprised of two general regions: upper 
respiratory tract and lower respiratory tract.  The upper respiratory tract refers to the nasal 
cavity, mouth, and pharynx and continues to the tracheal region.  The lower respiratory 
tract is comprised of the trachea to the bronchial tree and lungs [10].  Humans and mice 
have similar gross anatomy of the lung with five lung lobes.  In humans, the right lung is 
comprised of 3 lobes and receives 55% of the breath, whereas the left is comprised of 2 
[11].  Mice have three lobes on the right and one large lobe on the left side with a central 
lobe between the left and right lobes termed the caudal lobe [12] .  Following aspiration, 
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where liquid is accidentally inhaled, the caudal lobe of the mice will show evidence of 
the aspiration.  The left lobe is anatomically different from the right in both humans and 
mice to accommodate the location of the heart.   
Microscopically, the lung trachea and bronchi are lined by pseudo-stratified 
ciliated epithelium.  Cells present in the airways are columnar and ciliated cells with 
mucus producing cells (goblet cells) distributed  throughout and increasing in number 
with some types of often chronic  infection and irritation of the lung.  The trachea, 
bronchi, and larger bronchioles are lined with ciliated epithelia that utilize a ciliary beat 
to remove debris, dirt, and pathogens from the lungs.  Submucosal glands are present in 
upper respiratory tract and trachea and bronchi in humans and are responsible for the 
production of the majority of bronchiole secretions including secretory IgA and are 
comprised of serous cells.  Submucosal glands are not present in the bronchi and lung of 
mice and other rodents.  Clara cells are present in the small bronchioles.  These cells are 
secretory and are able to differentiate into either ciliary cells, which are columnar and 
have cilia to remove debris and mucus, or goblet cells, which produce mucin, depending 
on the lung environment (infection, inflammation, etc.).  Clara cells secrete proteins 
(surfactant proteins) that constrict or dilate the bronchiole and other proteins (cytokines, 
mucins, and anti-microbial peptides) that protect against inflammation and infection 
[11,13].  Clara cells produce clara cell 10 kD protein (CC10) which is 
immunomodulatory.  Clara cells also have abundant amounts of smooth endoplasmic 
reticulum that is used for biotransformation of toxins by cytochrome P450 activity.  The 
predominant cell in the lungs of non-primate laboratory animals are Clara cells Mice and 
humans have differences in the number of Clara cells present in the lung, ~50% and 
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~22% respectively.  [14,15].   The alveolar lumen surface is composed of alveolar type I 
and alveolar type II cells.  Type I cells are very thin and elongate and type II cells are 
polygonal to cuboidal.  All these cells work together to provide an environment in the 
lung that is conducive to oxygen exchange.   
 Innate immune cells are also present in the lungs, and include resident alveolar 
macrophages, dendritic cells (DC), and natural killer (NK) cells.  Epithelial and immune 
cells work in tandem with immune proteins (such as collectins, proteins that opsonize 
pathogens), surfactant and mucus proteins (MUC5) produced by epithelial cells to 
provide a pathogen free environment for the lung while allowing for natural host 
microbiota to coexist.  Alveolar macrophages continually sample the lung environment 
for potential pathogens, removing debris, and clearing apoptotic cells from the lung.   
Alveolar macrophages are able to sample the environment from the alveolar lining.   
Resident DCs, DCs that are not migratory and are retained in the lung, sample to the 
lumen of the airway using dendritic projections between epithelia and migrate to the 
draining lymph node for antigen presentation.  NK cells kill infected cells which are then 
cleared by alveolar macrophages.  Other cell types, such as T cells, B cells, and 
intravascular macrophages are also present in the lung, although the numbers of these 
cells present changes dramatically upon infection.  
Mucosa-associated lymphoid tissue has two distinctions in the respiratory tract:  
Nasal associated lymphoid tissue (NALT) and Bronchus-associated lymphoid tissue 
(BALT).  These are lymphoid tissues that are located in the nasal cavity and bronchi, 
respectively.  These areas of lymphoid tissue function similar to lymph nodes; however, 
they are predominantly unorganized lymphoid tissue marked by T and B cell regions.  
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Humans and mice do not have BALT in normal conditions; however, BALT can be 
formed in an inflammatory process and referred to as iBALT or inducible BALT [16,17].  
The function of these tissues is to provide a lymphoid follicle of undifferentiated B cells 
to the site of infection for an expedient response to antigen presented by follicular DCs 
through the antigen acquisition by M cells [11].  Mice that have formed iBALT have 
been shown to have a more rapid immune response and recovery from respiratory 
infections  [16].  DCs found in the NALT have been shown to regulate the T Helper 1 
(TH1) and T Helper 2 (TH2), T helper cell subsets that produce cytokines that dictate the 
immune response, in mucosal tissues through notch ligand signaling when exposed to 
ovalbumin (OVA), a protein found in eggs, given intranasally [18].  These mucosal 
associated lymphoid tissues provide the immune system with an immune response that is 
more protective and less pathogenic than a response mounted in lymph nodes [17].   
Initial infection with influenza requires the inhalation of virus particles.  These 
particles attach to nasal cavity, trachea/bronchial tree, or can also be swallowed as they 
enter the host.  The virus particles attach via the speculated 2-6αGal/HA interaction.  The 
virus gains entry into the cell and begins taking over the cell machinery to produce large 
numbers of virions.  Budding of the virus from a cell requires the NA protein as well as 
the apical layer of the host epithelium to form the viral envelop and to allow for 
dispersion from the cell [4].   
Influenza infection invokes a variety of changes in the lung in response to the 
infection.   With influenza infection, extent of immunopathology in the lung is dependent 
on balance of the immune response and viral clearance.  An overzealous immune 
response characterized by increased cellular infiltration and pro-inflammatory 
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cytokines/chemokines, molecules that signal to the cells to home to the site of infection, 
leads to greater immunopathology in the lung, in contrast to a dampened immune 
response or lack of immune response that leads to a greater viral load and more severe 
immunopathology in the lung as well.   
Because lung tissue is constantly encountering dust and particles with each breath, 
alveolar macrophages and resident DCs continually monitor and sample the lung 
environment.  Alveolar macrophages and lung epithelial cells are the first responders of 
the infection of the innate immune response in the lung [10].  Innate immune responses 
are not specific to a particular pathogen but recognize pathogen associated molecular 
patterns (PAMPs).  PAMPs are proteins and molecules that are conserved and present on 
pathogens such as lipopolysaccharide in bacterial cell walls and viral RNA in viruses and 
are recognized by receptors to initiate the immune response.  Interferons (IFN) are 
produced by plasmacytoid dendritic cells (pDC), specifically IFN-α and IFN-β.  IFN-α 
and IFN-β are potent anti-viral proteins.   Influenza virions are detected by pattern 
recognition receptors (PRRs) that recognize PAMPs.  These PRRs signal to initiate the 
innate immune response.  Toll-like receptors (TLRs) and Nod-like receptors (NLRs) 
recognize single stranded ribonucleic acid (ssRNA) and viral proteins, respectively.  
TLR7 receptors distributed in NK and pDCs recognize ssRNA intracellularly.  Double 
stranded viral RNA (dsRNA) is recognized by TLR3 receptors and retinoic acid inducible 
gene I (RIG-I) in infected epithelial cells during viral replication.   The nod-like receptor 
family protein 3 (NLRP3) forms an inflammasome, an intracellular vacuole that is 
involved in apoptosis and inflammation and has been associated with clearance of 
influenza virus and production of interleukin-1β (IL-1β) and found in human and mouse 
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alveolar macrophages and in human airway epithelial cells [19].   Production of tumor 
necrosis factor α (TNF-α) and interleukin-6 (IL-6) by DCs and macrophages is essential 
for mounting the immune response with CD8 cytotoxic T cells for effective viral 
clearance [20].  Cellular immunity to influenza also plays a role in the defense against 
influenza infection.  Influenza specific T helper cells are pivotal at activating the adaptive 
humoral response to influenza.   
 Influenza infections promote a strong Th1 cellular response.  Th1 responses are 
characterized by increases in interferon γ (IFN-γ), interleukin 12 (IL-12) and interleukin 
2 (IL-2).  Th2 responses are defined by increased production of interleukin 4 (IL-4), 
interleukin (IL-5), and interleukin 13 (IL-13). Th1 responses enhance the effectiveness of 
CTL responses by presenting antigen to CTL in the context of MHC class I molecules 
and has pro-inflammatory characteristics.  Th2 driven responses enhance humoral 
immunity with cross presentation to B-cells and utilizing the MHC class II antigen 
presentation.  Th2 responses have also been associated with allergic responses and 
immune responses to parasite infections.   
The role of pDCs, an innate immune cell that recognizes viruses through TLR7, in 
resolving influenza infection is currently in dispute.  While dogmatically accepted as 
anti-viral in nature, the ablation of pDCs using monoclonal antibodies specific for pDCs 
in BALB/c mice provided no evidence of impact on the disease outcome in the short term 
(study was terminated at day 6) and revealed a decrease in interferon α (IFN-α) 
production coupled with a decrease in viral lung load compared with normal mice [21].  
The immune system often compensates by increasing other cell populations and the 
detrimental effects of the decrease in pDCs may not have been revealed in the short term.  
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pDCs also function as a regulatory cell by increasing production of anti-inflammatory 
cytokines such as IL-10 in the later phases of infection.   It remains unknown if these 
cells are recruited or differentiate from resident DCs or are monocyte derived.  Monocyte 
derived dendritic cells (CCR2+ DCs) are recruited to the lung during influenza infection.  
CCR2 (also known as monocyte chemotactic protein -1 or MCP-1) receptor positive cells 
have been associated with increased immunopathology in influenza infections 
demonstrated by decreased lung injury in CCR2 deficient mice [22].   A delicate balance 
is necessary to recruit and activate dendritic cells in response to infection without the 
deleterious effects of over recruitment.   
Natural killer cells (NK) and CD8 cytotoxic T cells play a role in viral clearance 
and possibly in the severity and immunopathology of influenza infection.  NK cells have 
been shown to be pivotal in viral clearance and serve to recruit CD8 cytotoxic T-cells to 
the site of infection and signal to lung dendritic cells [23,24].  Interleukin 22 (IL-22) 
production by NK cells has been shown to be reduced during influenza infection in the 
lung; while the mechanism is currently unknown, it is thought to decrease the number of 
host cells available for infection by the virus [25].  Without NK cells, infections with 
influenza are markedly more severe.  A recent study shows that an increase in NK due to 
higher viral load in the lung results in increased severity of lung damage [26].  These 
studies highlight the importance of balance in the NK, NKT and CD8 cytotoxic T cell 
populations during influenza infections.    
Influenza has been shown to infect a variety of host immune cells including 
macrophages, DCs, and NKs [27-29].  By infecting the immune cells, influenza drives a 
change in the expression of cytokines and chemokines by the infected cell and may evade 
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immune detection.  NK cells infected by influenza demonstrate a decrease in IFN-γ 
production [27].  This can lead to increased severity of influenza infection as increases in 
IFN-γ production during the early onset of infection have been found to be advantageous 
[30].  
Immunopathology of influenza virus infections has been associated with an 
unregulated host immune response more so than the infection alone as demonstrated by 
recent studies.  One such mechanism has been referred to as the “cytokine storm”.  This 
cytokine storm is the over production of inflammatory cytokines and chemokines by the 
host immune system due to the infection with influenza.  When left unregulated this 
“cytokine storm” accentuates the inflammation, recruits inflammatory cellular infiltrate 
and essentially obscures the small bronchioles in the lung leading to cellular necrosis and 
edema and acute lung injury.  Current theory on the cytokine storm has been focused on 
the innate cellular response to influenza.  Recent studies have demonstrated that the 
cytokine production is originated by the pulmonary endothelium in absence of the 
cellular response [31].  Other studies focus on the T cell response to the infection as 
modulators of the cytokine storm through hyperactivity [32].  TLR4 mediated immune 
response through the adaptor molecule TRIF (TIR domain containing adapter-inducing 
interferon β) have also been a potential source of acute lung injury in influenza infection 
by signaling through oxidized phospholipids resulting in the activation of nuclear factor 
kappa-B (NFκ-B), a transcription factor, and production of IL-6 [33,34].   Pathogenic and 
pandemic strains have often been linked with a characteristic cytokinemia, increased 
release of pro-inflammatory cytokines such as IFN-γ, IL-6, TNF-α. These 
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overabundances of cytokines and chemokines result in an overactive immune response, 
inflammation, and cellular recruitment leading to acute lung injury. 
Secondary bacterial infections with Streptococcus pneumonia, Streptococcus 
aureus, and Hemophilus influenza have also been associated with increased morbidity 
and mortality with both seasonal and pandemic influenza infections [35,36].  Acute lung 
injury caused by the influenza viral infection can allow for opportunistic bacteria to 
invade the damaged tissue.  Superinfection with bacteria has been a hallmark of lethal 
influenza infections [35].  Increased production of macrophage inflammatory protein 2 
(MIP-2 or CXCL2) has been associated with increased susceptibility to secondary 
bacterial infections.  Although the mechanism for the bacterial susceptibility is not 
known, a study using C57BL/6 mice model of co-infection with Bordetella parapertussis 
and the influenza A (A/FM/1/47) blockage of MIP-2 with anti-mouse antibodies 
demonstrated a decreased pulmonary infiltration of neutrophils, pulmonary inflammation 
and decreased illness severity measures in mice treated with anti-MIP-2 compared to 
mice who were co-infected without the anti-MIP-2  [37]. 
Severe cases of influenza have resulted in a diffuse alveolar damage (DAD).  
Mutations in the virus H1N1 associated with 2009 pandemic were demonstrated to infect 
alveolar epithelial cells and cause DAD.  Several factors were linked to an increase in 
lung lesion presence and severity including increased signaling through TLRs, NFκ-B, 
prolactin, IFN, Janus kinase/signal transducers and activators of transcription 
(JAK/STAT), complement, granulocyte macrophage colony stimulating factor (GM-
CSF), interleukin 9 (IL-9) and interleukin 17 (IL-17) [38].  Increase in lesions with 
pandemic strains adds to the morbidity and mortality associated with these viruses.  DAD 
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and acute lung injury (ALI) following influenza infection lead to acute respiratory 
distress syndrome (ARDS).  ARDS has been identified as a complication of severe 
influenza infection and pneumonia and is linked with variant strains that are able to infect 
alveolar epithelial cells with production of large amounts of IFN-γ, TNF-α and IL-6 
during the late stages of infection [39].   
 
The graphical representation shown above of influenza infection is from Crisci et 
al, 2013 Molecular Immunology [40]. 
Influenza epidemiology and treatment 
The pandemic influenza outbreak of 2009 reminded the global population about 
the importance of having reliable supplements and medications to prevent and treat the 
symptoms of this potentially deadly virus.  The CDC reported that 2012-2013 influenza 
season might have been the worst seasonal epidemic outbreak in the last decade based on 
the numbers of influenza cases recorded and hospitalization data which reiterated the 
importance of treatments and preventatives to the public.  Current approved preventatives 
are limited to seasonal vaccination, requiring individuals to be re-vaccinated every year 
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with a vaccine designed to predict the strains of influenza that may be circulating through 
the population during the influenza season that typically lasts from November to April.   
Shortages of anti-viral remedies, such as Tamiflu®, demonstrate the need for further 
treatments for influenza.  
Clinical symptoms of influenza infection include headache, muscle aches, high 
fever, and extreme fatigue.  These symptoms are fairly common among viral infections 
and leads to the theory that influenza infections are highly unreported.  Anyone is 
susceptible to infection with the seasonal influenza, although the pediatric, geriatric, and 
immune compromised populations are at the highest risk for complications and possible 
fatality from this virus.  This is dramatically different from the pandemic influenza strains 
that typically impact the teenaged to middle aged populations.   
  While progress on a universal vaccine is ongoing, current preventatives for 
influenza infection require seasonal vaccination with vaccines that consist of the virus 
strains that are predicted to emerge in during the influenza season.   Several antiviral 
medications exist; however, some viral strains have become resistant to these treatments.   
These treatments target the basic structures of the virus including the NA and M2 ion 
channel structures.  Treatments targeting the ion channels have been discontinued due to 
the developed resistance.  These drugs include amantadine and rimantadine.  While some 
influenza A and B viruses have started demonstrate resistance against the neuraminidase 
inhibitors, the majority of these are still susceptible if the treatment is started early during 
infection.  These treatments include zanamivir and oseltamivir.  Other drugs that target 
virus replication and transmission are being investigated [41].   Due to the high mutation 
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rates of influenza and the potential for viral resistance to current therapies, the need for 
alternative medicines and preventatives remains high.     
Other alternative preventative strategies/natural treatments have been utilized over 
the years from garlic, vitamin C, vitamin D, exercise, to anti-inflammatories with varying 
success.  In MDCK cultures, garlic extracts have been shown to decrease influenza 
A/New Caledonia/20/99 (H1N1) virus growth at 10 μg/ml concentration when applied 
directly to the virus [42].  Vitamin C has been used in studies with influenza.  One study 
utilized a genetically modified mouse strain on a C57BL/6 background to assess the role 
of vitamin C in influenza infection.  The mice were genetically deficient in Vitamin C 
(with and without administration of Vitamin C) and infected with H3N2 A/Hong 
Kong/1/68.  Increased viral titers were observed in mice deficient in Vitamin C (without 
administration of Vitamin C) and had lower IFNα/β levels in the lung than mice who 
received Vitamin C [43].  Vitamin D has been evaluated as a supplement to vaccination 
strategies to enhance the efficacy of vaccination, as well as, a supplement to restore 
vitamin D levels in hypovitaminosis in obesity [44].   
Exercise has also been studied in the context of influenza infection prevention and 
vaccination enhancement.  The level of exercise becomes an important factor in 
addressing the effect of exercise on infection and vaccination enhancement, similar to 
affect the dosage of a vitamin or medication would have on the outcome.  Moderate 
exercise has been shown to enhance the antibody levels in older adults after vaccination 
with influenza vaccine [45].  In treadmill exercised mice, a reduction in mortality, 
cytokines and influenza specific antibody was observed after infection with influenza 
A/PR/8/34 virus.  Despite the reduction in antibody, these mice were protected on 
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secondary challenge with the same virus[46].  While moderate exercise can be protective 
and beneficial to influenza infection, exhaustive exercise has been shown to be 
deleterious to the outcome of mice infected with influenza resulting in a higher mortality 
rate [47].  This reiterates the importance of establishing a dose not only for oral 
supplements, but also for exercise.  
Another common treatment used in influenza infection is the use of anti-pyretics 
or non-steroidal anti-inflammatory (NSAID) medications, such as ibuprofen and 
acetaminophen, to reduce the clinical symptoms associated with influenza infection.  
There is debate on whether ibuprofen is beneficial or harmful in the context of influenza 
infection [48].  It may prolong the infection due to the reduction in fever and the optimal 
temperature of influenza replication.  A study with paracetamol, or acetaminophen that 
inhibits COX-2 and prostaglandin formation, was conducted using C57BL/6 mouse strain 
model of influenza infection.  In this study, mice treated with paracetamol demonstrated 
decreased influenza related inflammation and cellular recruitment in the lung compared 
to mice treated with celecoxib, a selective COX-2 inhibitor, and mice without treatment.  
These mice also had protective immunity to secondary challenge with the same virus 
[49].  Other anti-inflammatory treatments could provide similar benefits.                
Echinacea history and usage 
Interest in natural remedies for ailments and diseases such as respiratory illnesses 
has been on the rise in the last decade.   Treatments such as Hypericum, Prunella, and 
Echinacea have gained popularity.   Studies have tried to confirm the efficacy of these 
treatments, but have produced widely variable results.   
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Echinacea species are a group of herbaceous plants in the family Asteraceae.  
Native to the United States, Echinacea species grow commonly in the wild and have been 
cultivated for medicinal use for centuries.  The Native Americans were the first to use the 
plant to treat respiratory ailments such as colds or flu by boiling in water or directly 
consuming the roots of the plant.  Used topically, it has also been used to treat skin 
ailments, wounds, and burns [2].   
Variations of effectiveness reported in the literature could be attributed to the 
variety of species, plant parts, and preparation techniques available.  There are nine 
known species of Echinacea.  Three of these have shown to be of medical importance: E. 
purpurea, E. angustifolia, and E. pallida commonly known as the purple coneflower, the 
narrow leaf coneflower, and the pale purple coneflower, respectively.  Various parts of 
the plant can be utilized for each preparation: the whole plant, stem, roots, leaves, and 
aerial parts.  The part of the plant selected can then be extracted by boiling in water or 
through an ethanolic extraction preparation.  Each of these preparation techniques creates 
extracts with different constituents present.  Water preparations yield extracts with 
hydrophilic compounds such as polysaccharides.  Ethanolic preparations yield extracts 
with lipophilic compounds such as alkamides, caffeic acid derivatives, and other phenolic 
compounds.  Both water and ethanolic preparations contain each of these constituents.  
The extraction method dictates which compounds will predominate in each mixture.  
Even growing season has been demonstrated to impact the nutrients and compounds 
present in an extract [2,50,51].  Longer growing seasons have a reduction in alkamides 
and increase in phenolic compounds, whereas detrimental growing conditions, such as 
drought, have been shown to increase chicoric acid content of E. purpurea roots[52].  
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With all these variables to consider, evaluating the efficacy of an Echinacea extract can 
pose a challenge. 
Echinacea extracts and immunity       
Many studies with Echinacea species have shown the enhancement of cellular 
innate immunity.  Enhanced phagocytosis has been demonstrated in vivo and in vitro with 
the application of Echinacea extracts.  Adaptive immunity has largely been unexplored; 
however, some studies have shown that T cell maturation, B cell proliferation and 
antibody production remain unchanged when treated with Echinacea [53]   Variations of 
efficacy in the literature can be explained through the varied species, plant anatomical 
parts, and extraction methods used for each study.  These studies are further complicated 
by variations in animal models utilized and immune parameters measured.  Active 
chemical components have been isolated from Echinacea and tested for immune 
modulation.   While the mechanisms of the whole extract remain to be elucidated, several 
chemical constituents have been researched for immune stimulatory (polysaccharides) 
and anti-inflammatory properties (alkamides and caffeic acid derivatives).  Other 
properties such as phagocytosis, cytokine/chemokine expression, cellular migration, and 
cellular proliferation and differentiation have also been explored with polysaccharides, 
alkamides, caffeic acid derivatives, ketones, and phenolics. 
Hydrophilic compounds in Echinacea extracts and the immune response 
  Echinacea water extracts are rich in polysaccharides.  Although each species has 
varying chemical constituents and chemical concentrations, several compounds remain 
consistent among the genus.  Polysaccharides isolated from Echinacea species have been 
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shown to enhance the innate immune response through activation and enhanced activities 
of phagocytes, but have not been shown to enhance adaptive cellular or humoral 
immunity.  Polysaccharides (xyloglucanes and one arabinogalactane mixed at the ratio of 
2:1) isolated from E. purpurea given in vivo (by intravenous injection into test subjects) 
enhanced the proliferation of macrophages in presence of GM-CSF in vitro and enhanced 
the phagocytic activity of the human macrophages in vivo and in vitro [53].  While these 
polysaccharides were able to modulate the non-specific immune response, these 
polysaccharides (xyloglucans and arabinogalactan) were not found to enhance antibody 
production to sheep red blood cell stimulation in male BALB/c and LPS resistant 
C3H/HeJ mice[54].  Studies of the adaptive cellular and humoral immune responses with 
Echinacea extracts need to be further explored.  
Several Echinacea polysaccharides have been further characterized and found to 
have immunomodulatory activities: fucogalactoxyloglucans and arabinogalactan.  The 
immune stimulating properties of these polysaccharides have been explored in the non-
specific innate immune cells such as macrophages and NK cells.  The 
fucogalactoxyloglucans were found to increase phagocytosis, and arabinogalactan 
stimulated TNF-α production in macrophages [55,56].  Larch tree derived 
arabinogalactan was also shown to increase nitric oxide production and enhanced 
phagocytosis by RAW 264.7 murine macrophages in vitro [57].  Arabinogalactan 
stimulates the production of IL-1β, IFN-β and TNFα in murine macrophages and 
stimulates NK cells [58].  NK cell production and function was enhanced by the 
supplementation of Echinacea in BALB/cByJ male mice (without exposure to pathogens 
or immune stimulants), which was considered the attribute that added to the longevity of 
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the mice receiving the Echinacea from youth [59].  Similarly, aged DBA/2 male mice fed 
ground E. purpurea for 14 days were assessed to have increased number of NK cells in 
the bone marrow and spleen with increased cytotoxicity to labeled tumor cells compared 
to mice receiving control [60].  Additional studies have shown that the polysaccharide 
arabinogalactan activates complement in an in vitro complement activation assay [61]. 
While the signaling mechanisms of Echinacea polysaccharides in macrophage 
activation remains unclear, several mechanisms have been suggested for other plant 
derived polysaccharides.  Signaling through pattern recognition receptors such as 
mannose receptors, complement receptors, scavenger receptors, Dectin-1, and TLR4 have 
all been suggested mechanisms [62].  These receptors signal downstream resulting in 
activation of pro-inflammatory cytokines, such as IL-1β, IFN-β and TNF-α, NFκ-B, and 
enhancement of phagocytosis.  
  Other cellular immune responses have been evaluated for enhancement by 
Echinacea water preparations.  More recently, dendritic cells (DCs) have become a focus 
for immunostimulatory effects of Echinacea.   Polysaccharides in Echinacea purpurea 
extract (150 μg/ml and 450 μg/ml of the root extract) applied in culture may be 
responsible for the activation and maturation of dendritic cells in C57BL/6 and OT 
II/Thy1.1 male mice challenged with OVA evidenced by the increase in stimulatory 
markers such as CD86, MHC II and CD11c in the E. purpurea treatment group compared 
to vehicle [63].  
Echinacea enhances cellular activation and also modulates the production of 
cytokines and chemokines.  Extracts are able to both enhance the expression of 
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cytokines/chemokines as well as suppress pro-inflammatory cytokines in response to 
infections owing to the different immunomodulatory effects observed with the extracts.  
Water extracts from Echinacea purpurea were able to stimulate the production of IL-6, 
TNF-α, IL-10, and MIP-1α from BALB/c mouse non-adherent splenocyte cultures treated 
for 48 hours with 1 mg/ml Echinacea root and leaf extract without exposure to stimuli or 
pathogens [64].  Echinaforce®, a commercially available Echinacea water preparation, 
showed anti-bacterial activity against respiratory pathogens Streptococcus pyogenes, 
Hemophilus influenzae, and Legionella pneumophila and demonstrated anti-inflammatory 
properties with decreased bacterial infection associated inflammatory cytokines IL-6 and 
IL-8 in vitro [65].  Increased total white blood cell counts were observed in Sprague–
Dawley rats fed Echinacea aerial parts (50mg/kg) of a commercial preparation and 
proprietary blend (Nature’s Resource) over the course of an eight week study with 
lymphocytes and monocytes populations increasing in number; while also observing an 
increased serum IL-2 level compared with control rats [66].  The polysaccharides present 
in the extracts have been demonstrated to have immune stimulating properties with the 
increase in white blood cell counts, increase in lymphocyte and monocyte populations, 
and pro-inflammatory cytokines/chemokines. 
Specific polysaccharides derived from Echinacea have not been evaluated in the 
context of adaptive humoral immunity.  However, arabinogalactan isolated from other 
plant species has been evaluated as an adjuvant to vaccination with pneumococcal 
vaccines.  In a human trial of a proprietary arabinogalactan extract (isolated from Larch 
tree),  increased levels of antibody (IgG) to Streptococcus pneumonia were seen in the 
group receiving the arabinogalactan compared to control without evidence of increased 
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serum cytokines, white blood cells, or salivary IgA [67].  This observation could give 
credence to the potential of arabinogalactan from Echinacea having an 
immunostimulatory effect on the adaptive humoral immunity as well.  
Caffeic acid derivatives in Echinacea extracts and immune function 
Caffeic acid derivatives are another important class of constituents commonly 
found in Echinacea extracts.  Caftaric acid, chlorogenic acid, chicoric acid, cynarin and 
echinacoside are all caffeic acid derivatives found in Echinacea species.  The 
concentrations of each of these derivatives vary from species to species.   In general, E. 
angustifolia and E. paradaoxa contain chlorogenic acid and echinacoside, and lack 
chicoric acid and caftaric acid.  E. angustifolia extracts have been shown to contain 
cynarin.  E. purpurea extracts contain caftaric, chlorogenic, and chicoric acid, but cynarin 
and echinacoside have been shown to be absent in extracts prepared from E. purpurea 
[2,50,68].  These molecules are somewhat water soluble phenolic compounds that are 
ubiquitous in plants and are known anti-oxidants.   Caffeic acid derivatives have been 
evaluated for their effect on innate immune cell populations (macrophages, NKs, and 
DCs), T cell populations, cytokine/chemokine expression, antioxidant properties, and 
anti-viral capabilities.   
Caffeic acid derivatives have antioxidant properties and modulate cellular growth.  
Chicoric acid was demonstrated to be an antioxidant scavenges free radicals [69].  
Chicoric acid was not able to inhibit pro-inflammatory cytokines to the same extent as 
alkamides isolated from three different Echinacea species: E. purpurea, E. angustifolia, 
and E. pallida due to the decreased inhibition of iNOS and COX-2 by chicoric acid [70].  
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Caffeic acid (10, 25, 50, 100 μM) and chlorogenic acid (10, 25, 50, 100 μM) were 
demonstrated to inhibit COX-2 and Fyn kinase, a kinase involved in cellular growth often 
associated with unregulated cell growth and tumor formation, during UVB exposure in 
the JB6P+ cell line (mouse skin epidermal cells) with decreased PGE2 concentrations and 
NFκ-B transcription in a dose dependent manner [71].  Fyn kinase has also been shown to 
be utilized during differentiation of T-cells; however, the Fyn kinase in T-cells has been 
characterized as a different isoform [72].  
Modulation of T cells by caffeic acid derivatives has been evaluated in vitro.  In 
one study, IL-2 production by Jurkat E6.1 cells T cell cultures was evaluated in the 
presence of caffeic acid derivatives (caftaric acid, cichoric acid, and chlorogenic acid at a 
concentration of 6.25 to 25μg/mL) with mitogenic stimulation using phytohemagglutinin 
and phorbol myristate acetate (PHA/PMA).  No effect on IL-2 levels was observed with 
the caffeic acid derivatives; however, chicoric acid was shown to increase proliferation of 
the Jurkat T cells [73].  Increased NFκ-B expression was observed using Jurkat T cell 
cultures in response to stimulation with LPS or PMA and treatment with chicoric acid 
(0.8 or 8 μg/ml) [74].  Some caution should be used in interpreting this data since 
chicoric acid has poor bioavailability.  NFκ-B positively regulates the expression of 
cytokines and chemokines by the T cells and also the expression of adhesion molecules.  
Taken together chicoric acid may enhance the proliferation and differentiation of T cells. 
The role of caffeic acid derivatives on dendritic cells has been evaluated in vitro.  
Isolated human dendritic cells from patients sensitized to dust mites were exposed in 
vitro to LPS or dust mite challenge and treated with caffeic acid derivative from 
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Echinacea purpurea (10 μM -100 μM) in dimethyl sulfoxide (DMSO).  The caffeic acid 
was shown to decrease in a dose dependent manner the production of IL-12 and IL-10 in 
lipopolysaccharide (LPS) challenged monocyte derived DCs compared to IL-10 and IP-
10 in the dust mite challenged DCs through decreased signaling in the NFκ-B pathway 
[75].  A butanol fraction of Echinacea extracts were used to assess the activation of iDCs 
through increased expression of the maturation marker CD83.  Caffeic acid, chlorogenic 
acid and chicoric acid were present in this butanol fraction (1, 10 or 50 μg/ml) and may 
play a role in the increased activation of iDCs in Echinacea purpurea extract application 
on human DCs in vitro [76].  Although further investigation is necessary, the 
enhancement of dendritic cells by Echinacea may enhance the adaptive immune response 
to infections.   
Anti-viral activity of Echinacea extracts has been demonstrated in vitro but does 
not translate to in vivo models.  Chicoric acid may be involved in the anti-viral activity 
seen in vitro.  Although cellular uptake of cichoric acid is inefficient and slow, chicoric 
acid has been shown to be anti-viral in vitro at 1 μM against human immunodeficiency 
virus 1 (HIV 1) by inhibiting integrase, an enzyme required for viral replication, and thus, 
preventing viral integration in vivo [77].  Polysaccharides in Echinacea also demonstrate 
anti-viral activity.  Polysaccharides from Echinacea have been thought to influence the 
macrophage function and contribute to the direct anti-viral activity [78].   Fractions 
containing polysaccharides and chicoric acid from Echinacea extracts have been shown 
to have anti-viral activity against influenza and herpes simplex virus-1 [79].   Alkamides 
and ethanol fractions of Echinacea have been shown to have anti-viral activity against 
influenza, but not as robust as the chicoric acid and polysaccharide fractions [78] 
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Lipophilic compounds in Echinacea extracts and Immune Response 
The lipophilic compounds alkylamides (isobutylamides) and polyacetylenes are 
found in the ethanol preparations of Echinacea extracts.  These compounds have been 
associated with the anti-inflammatory properties of Echinacea extracts.  Debate has 
ensued over the efficacy of ethanoalic extracts and whether the ethanol has the anti-
inflammatory effect.  This criticism has been addressed by utilizing ethanolic controls 
containing the same concentration of ethanol that was used with the extracts.   
Anti-inflammatory effects due to alkylamides and polyacetylenes have been 
evaluated in macrophages, T-cells, and cytokines/chemokines.  Alkamides 
(isobutylamides) isolated from Echinacea purpurea were able to inhibit the production of 
inflammatory cytokines from RAW 264.7 murine macrophages in vitro [80].  Echinacea 
polyacetylenes (ketones), particularly ketone 23, isolated from E. angustifolia and E. 
pallida extracts, were able to inhibit PGE2 production in RAW264.7 with LPS challenge 
[81].  In a study using RAW 264.7 and influenza A/PR/8/34 infections, alkylamides 
decreased the production of TNF-α in a dose dependent manner [80].  IL-2 production by 
Jurkat E6.1 cells T-cell cultures was evaluated in the presence of ethanolic E. purpurea 
extract and several alkamides with mitogenic stimulation using PHA/PMA.  Decreased 
IL-2 production was observed with the whole E. purpurea extract and alkamides 
(isobutylamides) [73].  Pro-inflammatory cytokines have been shown to be inhibited by 
whole ethanolic extracts.  Ethanol based extracts from Echinacea purpurea inhibited IL-6 
production in BALB/c mouse splenocyte cultures [64].  The decrease in IL-2 and 
inflammatory cytokines from macrophages together may depress the immune response.  
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Aerial parts of E. purpurea were extracted in a water/70% ethanol combination and 
reconstituted in phosphate buffered saline (PBS) to be given to Female C57BL/6 mice 
infected with influenza A/WSN/33 (H1N1) for 5 days post infection beginning on the day 
of infection.  Mice receiving the extract demonstrated a decreased amount of IFN-γ, IL-
10, and KC both in the lungs and serum of infected mice compared to the vehicle control 
who received PBS only [82].  While these mice did not show decreased viral titer, these 
mice had reduced weight loss at the late phase of infection.  These findings are consistent 
with results obtained from our laboratory.  The capability to decrease inflammatory 
cytokines/chemokines at the site of infection could be utilized to decrease the 
inflammatory response at the late phases of infection to reduce tissue damage and 
recovery time from infections.   
Alkamides (isobutylamides and methylbutylamide) inhibit the production of 5-
lipoxygenase and cyclooxygenase [83,84].  These enzymes are crucial to the production 
of prostaglandin (PGE2), and the inhibition of the enzymes results in decreased PGE2.  
PGE2 is involved in the pain signaling pathway and has been linked with the production 
of TH2 cytokines [85].  Using RAW264.7 macrophages, alkylamides from E. 
angustifolia were analyzed for production of PGE2 and NO.  Bauer alkylamide 11 was 
shown to decrease the production of PGE and NO from murine macrophages [81].  PGE2 
is also a known inhibitor of NK cells.  By inhibiting PGE2, NK cells increase in number 
and function [60].  Increasing NK number and function would stimulate the non-specific 
immune response and enhance the killing of virally infected cells.  This enhancement is 
in contrast to the inhibition of macrophage cytokines and T-cell proliferation, but may be 
advantageous during viral infections that rely on NK cells for viral clearance.   
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Alveolar macrophage enhancement by alkamides has been reported.  While 
RAW264.7 murine macrophages demonstrated an inhibition and anti-inflammatory 
response to alkamides, alveolar macrophages are stimulated.  Increased phagocytosis and 
increased expression of TNF-α and NO were observed in alveolar macrophages from 
Sprague-Dawley rats stimulated with LPS and treated with alkamides (12μg/kg/day for 4 
days) isolated from E. purpurea [86,87].  When the same alkamides were applied to the 
splenocytes, no changes were observed.  This suggests that the cellular source of 
macrophages exposed to the extract components are also a factor in the effect the extract 
has on the immune system.  Enhanced alveolar macrophage function may enhance the 
immune response to respiratory infections.   
While the exact mechanisms of immune activation and modulation remain largely 
unexplored, a recent study utilizing proteomics and genomics evaluated the effect of 
Echinacea extracts on DC trafficking and a stem and leaf preparation of E. purpurea in 
DMSO was demonstrated to enhance the in vivo DC trafficking in BALB/c female mice 
with in vitro proteomic analysis suggesting the involvement of JNK2 (c-Jun NH2-
terminal kinase 2), PP2C-α (protein phosphatase 2C-alpha), AKT (protein kinase B), 
ERK (extracellular signal-related kinase) and MAPKAPK (MAPK-activated protein 
kinase 2) signaling pathways in the increased ability for DC trafficking [88].  These 
signaling pathways need further exploration for the impact on immune function in the 
presence of Echinacea.  
Adaptive immune responses in the context of Echinacea treatment have not been 
evaluated in depth.  Primarily, the impact of Echinacea on non-specific immune 
responses has been the focus of research.  Male BALB/c mice were gavaged with one of 
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three Echinacea extracts (E. purpurea, E. angustifolia, and E. pallida) and challenged 
with sheep red blood cells (sRBC) and immune parameters were evaluated in vitro 
through stimulation with LPS or concanavalin A (Con A).  All three extracts 
demonstrated increased lymphoctyes in spleens, NK cytotoxicity, and antibody responses 
to sRBC, while E. angustifolia and E. pallida showed more anti-inflammatory potential 
with decreased TNF-α and IL-1β and increased IL-10 and Th2 cytokines [89].   
Besides direct immune enhancement and modulation, Echinacea extracts have 
been shown to enhance wound healing.  Particularly, an alcohol extract of E. pallida was 
given to male SKH-1 mice for three days prior to cutaneous injury and for four days post 
injury, and then evaluated for stress related wound healing.  These mice demonstrated a 
reduced healing time compared to the vehicle treated group [90].  This wound healing 
could potentially be beneficial in the course of infection, although further investigation of 
this possibility is necessary.   
  Echinacea extracts may be comprised of compounds that have opposing effects 
depending on the concentration and chemical composition in each extract.  The 
mechanisms for the interaction of these molecules is unexplored and needs further 
investigation but may contribute to the variability in the results seen between extracts and 
even intra-extract variability.  Despite the variability of preparation and models utilized 
Echinacea demonstrates the potential to be a powerful immunomodulatory supplement 
when taken in the water phase and anti-inflammatory when taken in the alcohol or 
tincture phase.   
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Echinacea compounds bioavailability  
          Efficacy of Echinacea extracts hinges on a variety of variables.  Chemical 
constituents vary by extract preparation, species, and plant parts utilized.  Also, 
bioavailability of the extracts at the site of interest is also a potential obstacle to the 
efficacy of the extracts.  Not all chemical constituents are absorbed and there appears to 
be molecular interactions that may accelerate or inhibit the active constituents in the 
extract.  Polysaccharides are water soluble and are actively absorbed and digested.  
Chlorogenic acid present in coffee has been demonstrated to be partially absorbed 
intestinally while the majority of the molecule is converted to caffeic acid that is readily 
absorbed or converted to other molecules in the lower gut [71,91].  This is in contrast to 
the investigation demonstrating the inability of caffeic acid derivatives (chicoric acid, 
caftaric acid, and echinacoside)  to diffuse through Caco-2 monolayers, a cell line utilized 
to examine the ability of compounds to cross the intestinal barrier, and lack of caffeic 
acid derivatives found in human serum twelve hours post consumption of Echinacea 
[92].   In H9 or MT-2 cells (T-cell lines used in HIV-1 research), caffeic acid was taken 
up by the cell lines but with poor kinetics increasing with larger quantities of caffeic acid 
present [77].  Caffeic acid derivatives from Echinacea plants may not be bioavailable 
when ingested orally and may be more efficacious when delivered directly to the cells of 
interest.  Alkamides are readily absorbed through the intestine and are often used in the 
dosing of Echinacea extracts.  Echinacea angustifolia alkamides were analyzed using 
fasting human subjects and were found to be actively and quickly absorbed [93].   
Because Echinacea is administered orally, the bioavailability of the constituents impacts 
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the efficacy of the extract.  Compounds not readily absorbed by the intestine would not 
be bioavailable in the lung for effective treatment of influenza infection. 
Echinacea dosing 
           Echinacea dosing remains in debate.  In general, the suggestion is to consume the 
supplement for short durations 1-2 weeks [2].  Although the concern of continual 
stimulation of the immune system exists, a study using BALB/cByJ male mice explored 
the effect of long term (life time of the mouse) daily use and concluded that there were no 
deleterious effects observed with a consistent increase in total NK cells during the 
duration [59].  For respiratory infection and prevention, the recommended dosing is either 
a short term prophylactic (dosing before travel or exposure) or an early infection 
immunostimulant (dosing with early symptoms for best results).    
Echinacea side effects and drug interactions 
          Botanical remedies are often used without regard to side effects or potential drug 
interactions.  Side effects of most herbal remedies are limited and therefore make herbal 
remedies more attractive to potential consumers.  Echinacea is similar to other herbal 
remedies in this regard with few side effects reported.  The most common side effect of 
Echinacea is allergic reaction to the extract or preparation [2].  Because of the 
unregulated nature of herbal remedies, content and constituents present in the 
preparations available are not standardized or even fully disclosed due to the proprietary 
nature of many herbal combinations.  This adds to difficulty in evaluating the efficacy of 
preparations available to the public for consumption.   
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          Ultimately, botanical products are taken without regard to interaction with 
prescribed pharmaceuticals or even other over the counter medications.  These 
interactions can inhibit the effect of prescribed medications or even enhance the effects of 
other medications.  Echinacea has been demonstrated to have interactions with 
pharmaceuticals, particularly those functioning through the cytochrome P450 pathways.  
Alkylamides (N-isobutyldodeca-2E, 4E, 8Z, 10Z-tetraenamide, Alkylamide 8, 
isobutyldone) derived from Echinacea have been sown to inhibit cytochrome P450 in a 
concentration dependent manner [94-96].  Pharmaceuticals utilizing the cytochrome P450 
include immunosuppressants, anticoagulants, calcium channel blockers (anti-epileptics, 
cardiomyopathy treatments, blood pressure medications), and benzodiazepines 
(psychiatric medication given for anxiety, depression, and muscle relaxation).  A 
decreased clearance of caffeine has been shown in conjunction with the use of Echinacea 
extracts [2].  There are some conflicting data in the literature for the interaction of 
particular constituents of Echinacea extracts with cytochrome P450 [94,95,97].  While 
these interactions are not contraindicated for the general use of Echinacea products, the 
interactions should be noted, particularly in an aging population and the increased use of 
pharmaceuticals such as calcium channel blockers. 
Obesity and immunity 
           The impact of nutrition on immune function is becoming increasingly apparent.  
From calorie restriction to diet induced obesity, the calories consumed directly impact the 
ability of the immune system to fight infections.  In a country where obesity is becoming 
more prevalent, the importance of evaluating the effects of obesity is increasingly 
important.  The CDC estimates that 30% of the American population was overweight or 
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obese as defined by body mass index (BMI) in 2009-2010 with the obesity trend on the 
rise [3].  BMI is an indicator based on height and weight that is used to predict risk for 
obesity, cardiac risk, and other diseases.  While in general the BMI is a good predictor of 
risk, the calculation does not account for body structure and can be misleading in 
individuals with a smaller or larger bone and body structure.  A BMI measurement can be 
categorized by underweight (BMI <18.5), normal healthy weight (18.5<BMI <24.9), 
overweight (25<BMI<29.9), and obese (BMI >30) [98]. 
Several mouse models have been developed to study the role of obesity in 
immune dysfunction.  Genetically altered models (ob/ob and lp/lp knockouts) offer 
models without leptin signaling.  These models have genetic knockouts or mutations of 
the leptin gene and therefore may not be the most accurate model for translational studies 
since leptin deficiency is not a common cause of obesity in humans.  Diet induced obesity 
models utilizing high fat diets proffer a more realistic modeling of immune dysfunction 
in human obesity with increased leptin production seen in the mice.  Leptin functions in 
immune signaling during infection [99].  In diet induced obesity, the increased leptin 
production leads to a leptin resistance state and impairs immune function.   
Obesity is associated with both insulin and leptin resistance states.   In obese 
individuals, increased insulin is produced and cells become resistant to the insulin present 
in circulation.  This requires increased insulin levels for a similar glucose uptake [100].  
Similar responses have been observed with leptin.  Leptin is critical for the engagement 
of the immune response and utilizes a pathway similar interleukin 6 (IL-6) to initiate 
immune responses in the lung [99,101-103].  In obesity, baseline levels of leptin are 
chronically increased.  During infection, the leptin level is not altered in obese C57BL/6J 
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mice, however, signaling downstream of leptin is attenuated [102].  To investigate the 
time frame required to induce leptin sensitivity, a diet induced mouse model of C57BL/6 
mice receiving a high fat diet for 20 weeks were evaluated at different weeks to 
determine leptin sensitivity.   Mice received intraperitoneal injections of leptin at 1 week 
and at 8 weeks after initiation of the high fat diet.  At 1 week, the mice were sensitive to 2 
μg/g mouse weight of leptin.  At week 8, the mice were insensitive to the same dose of 
leptin [104].  It is possible that this downstream signaling could result in a decreased 
immune response. 
Innate cellular immunity is impacted by the obese condition.  The ability of NK 
cells from lean (non-obese) volunteers to kill a tumor cell line (K562) in vitro was 
inhibited in the presence of dose 10 μg/ml leptin [105].  Obese human populations 
demonstrate a decrease in CD3+, CD8, CD4, and NK cells [102,106].  A similar trend 
was seen in an obese rat study using hepatitis B surface antigen (HBsAg) vaccination that 
determined that genetically obese male rats (WNIN/Ob) have decreased cytotoxic CD8+ 
populations and genetically obese female rats have decreased CD3+ and CD4+ T cell 
populations in the spleen after challenge with HBsAg in vitro following vaccination in 
vivo  [107].  
The importance of nutrition in immunology is constantly being reiterated.  Calorie 
restriction and obesity both impact the immune system in a negative way.  Calorie 
restriction in mice by gradual underfeeding (up to 40% decrease in caloric intake) has 
been shown to decrease the ability of the immune response to control viral replication 
through decreased NK function [102].  This may be a key to increased viral infections (in 
particular influenza) with ageing populations [108].  NK cell number and function were 
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also shown to be decreased in obese volunteers compared to lean control group in 
cytotoxicity studies against a tumor cell line (K562) in vitro [105].  
Obesity has been associated with an overall inflammatory state.  Increases in IL-6 
and TNF-α are hallmarks of inflammation and have been demonstrated to be increased in 
obese individuals in absence of infection.  A recent study has shown an increase in 
suppressor of cytokine signaling 3 (SOCS3) transcription in obese individuals [109].  
SOCS3 is involved in leptin signaling and in viral infection.  Using peripheral blood 
white blood cells, Teran-Cabanillas et al stimulated TLR3 and TLR7 using TLR 
antagonists and found that obese individuals had increased SOCS3 and decreased 
production of IFN-α/β [109].  These findings suggest that obese individuals would 
produce less IFN-α/β in response to influenza infections leading to a higher viral load and 
consequently increased morbidity in obese populations.  Despite similar viral titers, diet 
induced (high fat/high sucrose for 22 weeks prior to infection) obese C57BL/6J mice 
infected with influenza A/PR/8/34 showed a decrease in IFNα/β, MCP-1, RANTES, and 
NK cell function in the lungs at day 3 post-infection compared with C57BL/6J mice who 
received low fat/low sucrose diets [110].   
Memory CD8 T cells are important in protecting a host from a secondary 
infection.  Two types of memory T cells have been categorized: effecter memory and 
central memory. Reductions in the effecter memory cell populations could lead to 
impaired secondary immune responses.  In diet induced obese male C57BL/6J (received 
high fat/high sucrose diet for 20 weeks prior to infection), number of effecter CD8 
memory cells decreased faster post infection in obese mice compared to lean control mice 
despite elevated levels of IL-15 and similar levels of central memory T cells [111].   
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     Male, db/db, diabetic mice, were used to evaluate the impact of leptin resistance in the 
formation of acute respiratory distress syndrome (ARDS) following lung infection.  
These mice have no leptin receptor and therefore have increased circulating leptin 
concentrations [99,103].  This model has been used as a leptin resistance model.  Diabetic 
mice and humans have demonstrated a decrease in ARDS, and leptin resistance has been 
implicated as the precipitating factor by inhibiting TGF-β initiated fibroproliferation and 
enhancing the effects of peroxisome proliferator activated receptor gamma, PPAR-γ 
[112].  Leptin resistance is a consequence of long term diet induced obesity.  The 
duration of the diet to acquire leptin resistance remains under investigation.   
Overall, obesity immune dysfunction impacts both the innate and adaptive 
immune responses.  These dysfunctions either individually or in complex could lead to 
the increased morbidity and mortality associated with influenza infection in obese 
individuals.  It is unknown whether resolving just one of the dysfunctions (the innate or 
adaptive dysfunction) would decrease disease severity and lead to influenza resolution.  
In this dissertation, the effects of Echinacea treatment on influenza infection in 
vitro and in vitro were evaluated utilizing several different species of Echinacea using 
both water and ethanol preparations of each species.  Several in vitro methods were 
utilized to determine the effect of Echinacea directly on lung epithelial cells and mix 
cellular cultures.  A combination of water and ethanol extracts was administered to mice 
infected with influenza virus to assess the efficacy of modulating the immune response 
during different phases of infection (early vs. late).  Lastly, Echinacea extracts were 
evaluated for efficacy in diet induced obese mice to determine if Echinacea could correct 
obesity associated immune impairment. With respect to the in vitro studies, it was 
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hypothesized that Echinacea would exhibit antiviral activity, that the water extracts 
would increase chemokine production by influenza-infected lung epithelial cells, and that 
the ethanol extracts would modulate spleen responses to induced a decreased in 
inflammatory cytokine and chemokines.  It was hypothesized that Echinacea water 
extracts would stimulate the immune response to influenza infection and the ethanol 
extracts would attenuate the influenza-associated lung inflammation.  In the obese model, 
it was hypothesized that the Echinacea extract treatment would enhance the immune 
response and would correct the obesity associated immune impairments associated with 
influenza infection in obese individuals.            
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Abstract: 
Background:  Echinacea is a popular dietary supplement typically used to treat 
respiratory infections.  However, the potential immunomodulatory and/or anti-viral 
properties of Echinacea may vary by species and/or type of extract, and are not well-
characterized in response to respiratory viral infection.  In this investigation, the antiviral 
and immunomodulatory effects of Echinacea in response to Influenza A H1N1 infection 
were identified for 3 species of Echinacea (E. purpurea, E. angustifolia, and E. paradoxa 
var. paradoxa), comparing water and ethanol preparations for each species.  Three 
potential pathways by which Echinacea may protect against Influenza infection were 
evaluated: 1) direct antiviral action, 2) enhancement of host defense in respiratory 
epithelial cells, and 3) alteration of innate or adaptive immune response.  
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 Methods:   Water and ethanol extracts were prepared from each of the Echinacea 
species. To assess direct antiviral response, Influenza-permissive MDCK cells were 
incubated with Echinacea extracts prior to virus infection with Influenza A/PR/8/34 
H1N1 to determine the extent to which plant extracts may inhibit viral growth.  A549 
respiratory epithelial cells were cultured with Echinacea plant extracts plus influenza 
virus to measure cytokine and chemokine response to infection.  An ex vivo culture of 
spleen cells harvested from mice infected with Influenza A/PR/8/34 or from non-infected 
mice was used to evaluate the effect of Echinacea treatment on influenza-induced 
cytokine production. 
Results:   The E. purpurea H2O extract demonstrated limited anti-viral activity in vitro at 
both low and high concentrations tested, whereas Echinacea EtOH extracts from all three 
species demonstrated anti-viral activity only at high concentrations of extract.  The A549 
cells responded to influenza infection by increasing the production of IL-6, IL-8, eotaxin, 
G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP1β, RANTES, and VEGF.  Echinacea 
water extracts from all species enhanced chemokine production influenza-infected A549 
cells (eotaxin, GM-CSF, IL-8, MIP-1α, and MCP-1) to a greater extent than ethanol 
extracts from the same species. In spleen cells obtained from non-infected mice, only 
water extracts from E. purpurea increased IL-17, IL-5, MIP-1α and MIP-1β, whereas 
water extracts from all species decreased inflammatory cytokines IL-1β, IL-6 and IFN-γ.  
Ethanol extracts from all species generally decreased cytokine and chemokine production 
by spleen cells from uninfected mice.  When spleen cells were obtained from influenza-
infected mice and re-stimulated in vitro with influenza virus, the ethanol extracts from all 
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three species inhibited cytokine and chemokine production, and water extracts had 
minimal effects.   
Conclusions:    Extracts prepared from all three species (E. purpurea, E. angustifolia, E. 
paradoxa var. paradoxa) had similar effects.  Instead, the type of extract preparation was 
more important in determining the immunomodulatory response.  The most consistent 
effects of water extracts were an enhancement of A549 cell chemokine response to 
influenza virus, and a reduction of inflammatory cytokine production by spleen cells 
from infected mice.  In contrast, ethanol extracts generally had little effect on A549 cell 
response, but did result in significant inhibition of cytokine and chemokine response in 
splenocytes obtained from uninfected and infected mice. Based on these findings, it is 
possible that  Echinacea water extracts may stimulate early innate host defense to viral 
infection by increasing respiratory epithelial cells chemokine response, and Echinacea 
ethanol extracts may inhibit infection-associated inflammatory response by host immune 
cells.   
Introduction: 
Influenza continues to be a global health concern with the disease being a major 
cause of morbidity and mortality in the United States and throughout the world [1].  
While no universal influenza vaccine is available, annual vaccination is the primary 
prevention against infection.  However, these vaccines are prepared to prevent seasonal 
infections and may not be available quickly enough during a pandemic.  Also, a 
significant number of individuals do not receive the vaccine and remain vulnerable to 
infection [2,3].  Although anti-viral medications are available, resistant influenza strains 
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have emerged [3-6].  Given these limitations with vaccine and anti-viral treatments, along 
with a recent interest on “natural remedies” by the consumer, Echinacea has emerged as 
a popular dietary supplement for treating colds and influenza.  Echinacea efficacy has 
been questioned largely due to the variation in preparations and species available for use, 
and a potential role for Echinacea in improving resistance to influenza infection has not 
been well characterized.   
Some studies have suggested that certain species of Echinacea exhibit direct anti-
viral effects on influenza virus, particularly the water extract of E. purpurea, while 
remaining ineffective against Rhinovirus replication, and other data suggest that E. 
pallida var. angustifolia may be more effective against Rhinovirus [7,8].  Multiple 
studies have shown that Echinacea augments the innate immune response, especially in 
the activation of macrophages (increased nitric oxide production, TNF-α, enhanced 
phagocytosis), dendritic cells (increased co-stimulatory molecules), and T-cells 
(increased cytokines) [9-13].  NK cytotoxicity has been shown to be enhanced with 
Echinacea treatment as well [14].  It has been suggested that Echinacea has a greater 
effect on alveolar macrophage response compared with splenocytes [15], a finding which 
may support the use of Echinacea for respiratory infection in particular.  In addition to 
these immunostimulatory effects, Echinacea has also been shown to have an anti-
inflammatory effect with the decreased production of IL-1β and TNFα [14] and 
decreased IL-6 in spleen cells [16].  
Effects of different chemical constituents of Echinacea have been found to be 
active in modulating the immune response.  The composition varies based on preparation 
type and part of the plant utilized.  Polysaccharides are found in water extracts, whereas 
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alkamides are typically found in ethanol extracts.  Caffeic acid derivatives and phenolic 
compounds are found in both water and ethanol preparations of Echinacea extracts [17].   
Polysaccharides from Echinacea have been thought to influence the macrophage function 
and contribute to the direct anti-viral activity [7].   Alkamides and caffeic acid derivatives 
play a larger role in decreasing the effects of pro-inflammatory cytokines and providing 
an anti-inflammatory component [18,19].  Alkamides present in Echinacea extracts may 
be responsible for a decrease in NFk-B mediated inflammation [10].  Also, the 
phytochemical content may vary by Echinacea species.  The varied chemical constituents 
and concentrations of these constituents found in different extracts likely contribute to the 
varying results that have been reported in the literature [20].  Given the variability in 
plant species and type of extract, along with the diverse possible mechanisms of action, 
the goal of this study was to systematically assess the multiple ways in which Echinacea 
may contribute to host defense against influenza infection using standardized water and 
ethanol extracts prepared from three species grown in defined conditions.  The three 
species evaluated were E. purpurea, E. angustifolia, and E. paradoxa var. paradoxa.  E. 
angustifolia and E. purpurea have been widely studied, whereas E. paradoxa var. 
paradoxa, used in this experiment, has not been as widely investigated for its medicinal 
properties.  Given that E. purpurea and E. angustifolia have been commonly used, two 
different accessions of each of these species were tested to determine whether variability 
due to plant growing conditions could impact immunomodulatory response. The potential 
mechanisms by which Echinacea may contribute to host defense against influenza that 
were evaluated in this study were: 1) direct effects of Echinacea on influenza virus 
replication, 2) innate host defense at the initial site of influenza virus infection 
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(respiratory epithelial cells), and 3) immunomodulatory and anti-inflammatory action of 
Echinacea on host immune cell populations (spleen) under influenza-virus infected or 
non-infected conditions.  
The initial hypotheses were that the three Echinacea species (both water and 
ethanol extracts) may have anti-viral effects, and the water extracts may increase the 
cytokine and chemokine response to influenza infection in spleen cells and A549 cells.  
In addition, the initial hypothesis predicted that the ethanol extracts would decrease 
cytokine and chemokine concentration, similar to previous findings of anti-inflammatory 
effects with ethanol extracts.  
Materials and Methods: 
Plant & Extract.  
Echinacea angustifolia (Eang) (accessions PI631285 -Eang1, accession A28187-
Eang2), Echinacea purpurea (Epur) (accession PI 631307 Epur1, accession PI633669 
Epur2), and Echinacea paradoxa var. paradoxa (Epara) (accession PI633663 Epara) 
plants were grown at the USDA-ARS Regional Plant Introduction Station (Ames, IA).  
Water extracts were prepared by boiling 6 g of dried root in 100 ml of endotoxin free 
water in an endotoxin free flask, and stirred for 1 hour at room temperature.  Extracts 
were filtered using endotoxin free glass filter paper, centrifuged for 15 min at 10,000 rpm 
and pellets discarded before freeze drying. Extracts were diluted to 14.67 mg/ml of 
extract.  The ethanol extracts were prepared from the dried ground root powder which 
was placed into a Whatman 43 × 123-mm cellulose extraction thimble (Whatman 
International Ltd., Maidstone, UK) with glass wool.  The roots were refluxed with 250 
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mL of organic solvents, 100% ethanol, for 6 hours using a Soxhlet extraction device 
(Zhai et al 2007).  The extract dried using an R-114 rotary evaporator (Brinkman 
Instruments, Westbury, NY) at <30°C under reduced pressure and re-suspended in 55% 
ethanol for Eang1 and Epur1, or 43% ethanol for Eang2,  Epur 2 and Epara.  These 
extracts were stored in concentration solution at -20°C until used in each experiment.   
In vitro experiments.   
Anti-viral assay.   
The anti-viral activity of the extracts was assessed using the Madin-Darby Canine 
Kidney cell line (MDCK).  Cells were plated in 96-well plates (flat bottom) at 
2x10
5
cells/ml suspended in complete DMEM (Dulbecco's Modified Eagle Medium 
DMEM + 10% fetal bovine serum HyClone Laboratories Inc, 1% PenStrep- 
penicillin/streptomycin -Gibco , 0.1% Gentimicin - Sigma, 1% fungizone or 
Amphotericin B Gibco) and allowed to become confluent.  Cells were treated with high 
(1500µg/ml) and low (300µg/ml) concentrations of extract (Eang1 H2O, Eang2 H2O, 
Epur1 H2O, Epur2 H2O, Epara H2O, Epur1 EtOH, Epur2 EtOH, Eang1 EtOH, Eang2 
EtOH, and Epara EtOH) prepared in post-inoculation media (DMEM +0.01% Bovine 
serum albumin , 1% PenStrep- penicillin/streptomycin -Gibco , 0.1% Gentamicin - 
Sigma, 1% fungizone or Amphotericin B -Gibco, and 0.11125%TPCK-treated Trypsin-
Worthington Biomedical Corporation).  Two extracts were tested per 96-well plate.  
Immediately after adding the extracts, 10μl of undiluted Influenza A/34/PR/8 (HA 1024, 
5.5X10
6
 EID50) virus was added.  Serial 1:10 dilutions of the virus were performed. 
Positive and negative controls were performed with each assay run (1 plate).  Positive 
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control received virus only with no extracts or vehicle.  Negative control received no 
virus or extract.  Plates were incubated for 1 hour at 37°C in a 5% CO2 humidified 
incubator.  Extracts and virus mix were removed from each sample by gentle pipetting 
using a multichannel pipette starting at the highest dilution to the lowest dilution to 
prevent cross contamination of the wells.  Fresh post-inoculation media was added (100μl 
per well), and the plates were incubated at 37°C in a 5% CO2 humidified incubator.  At 
48 hours post infection, 50μl of the supernatants were transferred to a second 96-well 
plate (U-bottom) for viral titer analysis by hemagglutination testing.  50μl of a 0.05% 
dilution of rooster red blood cells was added to each well in the U bottom plate and 
incubated at room temp for at least 1 hour.  Positive wells were indicated by lattice 
formation due to viral cross-linking of the red blood cells; negative wells were indicated 
by a red cell button at the bottom of the well.  Positive and negative results for each well 
in the assay were recorded on a 96 well plate map and numerated.  These quantifications 
were then evaluated using the Spearman-Karber method of calculating TCID50: m=xk+d 
[0.5-(1/n)r] where xk is the highest dilution, d is the spacing between dilutions, n is 
number of replicates for each dilution, r is the number of negative responses, and 
10
m
=TCID50.  Inverse log of this value was used for reporting anti-viral activity.   
A549 Cell Culture. 
A549 cells, a human type II pulmonary epithelial cell model, were cultured into 
24-well plates at a concentration of 2x10
5
cells/ml. The cells were allowed to become 
confluent (24-48hrs post-plating) before extracts  (Eang1 H2O, Eang2 H2O, Epur1 H2O, 
Epur2 H2O, Epara H2O, Epur1 EtOH, Epur2 EtOH, Eang2 EtOH, and Epara EtOH) 
diluted to 30mg/ml in complete FK media (ATCC) (FK plus 1% PenStrep- 
56 
 
penicillin/streptomycin, 0.1% Gentamicin - Sigma, 1% fungizone or Amphotericin B 
Gibco, 10% fetal bovine serum HyClone Laboratories Inc.) or Vehicle (H2O only or 
EtOH only - at the same dilution present in the extract) were applied to the cells for 2 
hours at 37°C in a 5%CO2 humidified incubator.  Extracts were removed by gentle 
pipetting to avoid disruption of the cell monolayer, and fresh media plus Influenza 
A/34/PR/8 (HA 4096, EID50 = 10
9
)
 
or (HA1024, EID50=5.5X10
6
) were added at a dilution 
of 1:100 and incubated at 37°C in a 5% CO2 humidified incubator for 1 hour with gentle 
rotation every 15 minutes to ensure equal viral distribution.  Complete FK media was 
used to adjust the volume to 1ml in each well.  Samples were incubated at 37°C in a 
5%CO2 humidified incubator.  Supernatants were collected 24 hours post infection and 
frozen at -20°C until further analysis.  
Ex vivo experiments. 
In the experiments involving uninfected mice, spleens were collected from 
untreated BALB/c male mice.  In the experiments with infected mice, untreated BALB/c 
male mice were infected via an intranasal route with 30 µl of 5.5X10
6
 EID50 (HAU1024) 
Influenza A/PR/8/34 H1N1 virus under isoflurane anesthesia.  Spleens were harvested 
from uninfected mice, and at 9 days post-infection from the infected mice.  Spleens were 
harvested in stomacher bags containing 5 ml of digestion media (RPMI with 2% fetal 
bovine serum (FBS) with collagenase D at a concentration of 1mg/ml).  Spleen tissues 
were subjected to Seward Stomacher® (Port St. Lucie, FL) paddle blender.  Spleens were 
processed through 0.4µ cell filters with digestion media.  The plunger of a syringe was 
used to break up the remaining tissue through the filter.  The filtrate was suspended in 10 
ml of digestion media.  Samples were centrifuged for 10 min at 1200 RPM, washed twice 
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with complete RPMI (cRPMI), and re-suspended in 5 ml of cRPMI (RPMI with Hepes, 
glutamate, sodium pyruvate, penicillin/streptomycin, fungizone, 2-mercaptoethanol and 
10% FBS) without collagenase D.  Samples were treated with 2 mls of ice cold 0.015M 
ammonium chloride red blood cell lysing agent for 10 min, washed in cRPMI and re-
suspended in 5 ml of cRPMI.  Cell counts were obtained using the Z™ series Coulter 
Counter® (Beckman-Coulter, Inc., Brea, CA).  Cells were re-suspended in cRPMI at 
2.5x10
6
cells/ml, and cultured into 96-well plates (100µl per well, 22 wells per spleen).  
On the same day as culture, four wells of each spleen were treated with of the following: 
H2O only, Eang1 H2O, Eang2 H2O, Epur1 H2O, Epur2 H2O, Epara H2O, EtOH only, 
Epur1 EtOH, Epur2 EtOH, Eang2 EtOH, and Epara EtOH.  In the spleen cell experiment 
using cells obtained from virus-infected mice, two additional wells for each extract 
treated spleen were stimulated with 10µl of A/PR/8/34, H1N1 (HA=1024, 
EID50=5.5X10
6
) diluted to 100 HAU/ 1x10
6
 cells, and UV inactivated for 30 min, and 
two wells for each extract treated spleen received 10µl of media alone for negative 
control.  Samples were incubated at 37°C in a 5%CO2 humidified incubator, and 
supernatants were collected at 48 hours and 96 hours post stimulation.  Supernatants were 
frozen at -20°C until further analysis.  
Multiplex Assay.  
Supernatants were collected from A549 cell culture and analyzed for 
cytokine/chemokine expression.  The Milliplex® microsphere (EMD Millipore 
Corporation, Billerica, MA) assay was used to analyze A549 or spleen supernatants for 
expression of different cytokines and chemokines.  The assay was performed following 
manufacturer’s instructions. The plate was read using Bio-plex® Suspension Array 
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System (Bio-Rad laboratories, Inc., Hercules, CA) instrumentation.  Data was exported 
from Bio-plex® Manager to Microsoft® Excel (Microsoft, Redmond, WA) for further 
analysis.   
Analysis. 
Statistical analysis was performed using student T-test of independent samples 
comparing extracts to vehicle control with SPSS® software version 20 (IBM 
Corporation, Armonk, New York).  Graphs were made using SigmaPlot® (Systat 
Software Inc., San Jose, CA).   
Results:  
In order to evaluate the anti-viral effect of the extracts, two different 
concentrations were analyzed.  A low dose (300μg/ml) and a high dose (1500μg/ml) of 
each extract were analyzed to determine if the concentration of the extract would have an 
effect on the viral load.  Under conditions with a low dose of H2O extracts (Figure 1), a 
trend towards increased anti-viral activity (decreased viral titer/ml) was observed in 
Epur2 H2O (p=0.06), Eang2 H2O (p=0.1) and Epara H2O (p=0.08) treatment compared 
to H2O controls.   The high dose application of H2O extracts (Figure 1b) demonstrated 
significantly increased anti-viral activity only with Epur2 H2O (p<0.05) compared to 
H2O controls, although there was a trend towards decreased viral titer/ml with Epur1 
H2O (p=0.1) treatment.  These data suggest that the Epur extracts have a modest increase 
in anti-viral activity in vitro,  and reduced viral load by ~ 1 log.  Ethanol extracts were 
also evaluated using the anti-viral assay.  The low dose of EtOH extracts (Figure 1c) had 
no significant effect on the viral activity.  The high dose of EtOH demonstrated increased 
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anti-viral activity with Epur1 EtOH (p<0.05), Epur2 EtOH (p<0.05), and trends toward a 
decrease in viral titer/ml with Eang2 EtOH (p=0.1) and Epara EtOH (p=0.09) treatments 
compared to the EtOH contols.  Eang1 EtOH was unavailable for testing at the high dose 
in this assay.  At the high dose of extract, the Epur EtOH extracts resulted in nearly a 2 
log reduction in viral load.  These data suggest that the high dose of Echinacea extracts 
were more effective at decreasing the viral titer, although possibility that this same 
concentration could be attained in vivo remains to be established.  By comparing these 
values to an EtOH control, the anti-viral activity of the extract was not a result of the 
EtOH present in the extract.   
Extracts were applied to A549 lung epithelial cells to observe the change in 
cytokine/chemokines in absence of viral infection (Figure 2).  The results in Table 1 
show that Influenza A/PR/8/34 infection of A549 cells for 24 hours results in a 
significant increase in the production of chemokines and cytokines (IL-6, IL-8, TNFα, 
IFNγ, eotaxin, G-CSF, GM-CSF, IP-10, MCP-1, MIP1β, RANTES, and VEGF).  Only 
Eang1 and Epur1 were evaluated for the potential effects on uninfected cells, and the 
results showed minimal effects with a reduction in IL-9 with H2O Eang1 treatment, but 
an increase in IL-8 and MCP-1 (Figure 2 and Table 1).  The Epur1 H2O extract 
decreased RANTES but increased VEGF.  The ethanol extracts had little effect, although 
ethanol vehicle control resulted in a slight reduction of IL-6, IL-8, MCP-1, and RANTES.  
The only ethanal extract that altered chemokine production significantly was Epur1 
which increased MCP-1 to only a modest extent.   
In contrast to the findings with uninfected A549 cells, when Echinacea extracts 
were incubated with A549 cells followed by infection with influenza virus, more 
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consistent effects of the extracts were observed.  The H2O extracts from all three species 
increased eotaxin, GM-CSF, IL-8, MIP-1α, and MCP-1 to the greatest extent (~ 2 fold or 
greater), whereas IL-1β, TNFα, TNF-β, and IL-15 were modestly increased by Echinacea 
(Figure 3).   Similarly, the A549 model was used to evaluate the effect of Echinacea 
EtOH extracts during influenza infection of lung cells (Figure 3).   The EtOH vehicle 
control was compared to H2O vehicle control to determine whether the concentration of 
EtOH used had any effect on the A549 cells.   There were no significant changes 
observed in the production of cytokines/chemokines in cells treated with EtOH compared 
to those treated with H2O vehicle. With respect to the EtOH extracts, pre-treatment of 
A549 cells with E. purpurea, E. angustifolia, and E. paradoxa resulted in a modest 
increase or trend towards an increase in IL-8 and IL-1β, with variable effects on eotaxin 
and IL-15.  The effect of EtOH extracts was not of the same magnitude as H2O extracts, 
and EtOH extract effects were generally inconsistent.  
To assess the effect of Echinacea extracts on an immune cell mixed populations, 
spleens from uninfected mice were cultured and treated with each extract (Figure 4).  In 
this experiment the immunomodulatory potential of Echinacea was examined under 
conditions in which virus was not present. Overall, greater levels of cytokine or 
chemokine production were observed by spleen cells compared with A549 cells, as 
would be expected.   Treatment with the H2O extracts from all species either 
significantly reduced (p < 0.05) or tended to decrease (p < 0.10) the inflammatory 
cytokines IL-1α, IL-1β, IL-6, and IL-12p40.  However the E. purpurea H2O extracts 
increased IL-4, IL-5, and IL-17 which may suggest an effect on T helper cytokines.   The 
EtOH extracts from all three species significantly decreased nearly all of the cytokines 
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and chemokines, and the results showed that E. purpurea treatment was associated with 
the strongest immunosuppressive effect.  These findings with immune cell populations 
from uninfected mice show that EtOH extracts have consistent anti-inflammatory effects. 
To assess the impact of viral infection and extract treatment on a mixed immune 
cell population, mice were infected in vivo with influenza virus, and on day 9 post-
infection the splenocytes were cultured and treated with extracts, without virus present in 
the culture.  The effect of the virus infection in the mouse without stimulation in the 
culture is shown in Table 2 (H2O and EtOH vehicle treatment only).  When splenocytes 
were obtained from infected mice, it is apparent that the baseline (no in vitro stimulus) 
production of several cytokines and chemokines was increased relative to non-infected 
mice (IFN-γ, IL-1α, IL-6, IL-12p70, MCP-1, and a trend towards increased TNFα and 
MIP2).  The effect of the addition of H2O extracts to the splenocytes is shown in Figure 
5.  In general, the H2O extract from all three species decreased the inflammatory factors 
MCP-1, IL-1α, IL-1β, IL-6, and IFN-γ.  However, the H2O extracts increased the 
immunomodulatory cytokines IL-2, IL-4, and IL-10, although the increase was relatively 
modest and somewhat variable.   
The EtOH extracts were also applied to splenocytes from infected mice without 
influenza stimulation in vitro (Figure 6).  Treatment with all the extracts tested (Epur1, 
Eang2, Epur2, and Epara EtOH) decreased concentrations of G-CSF, GM-CSF, 
RANTES, IL-1α, IL-1β, IL-6, IFN-γ, IL-5, IL-10, and IL12p40 (p<0.05) compared to 
EtOH vehicle control.  In addition, Epur1, Epur2, and Epara EtOH extracts decreased 
MIP-2, MCP-1, IL-2, and IL-15.  These results were similar to the findings with spleen 
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cells obtained from uninfected mice in that EtOH extracts generally exhibit anti-
inflammatory effects.   
The use of spleen cultures from mice previously infected with influenza virus and 
re-stimulated with UV-inactivated influenza in vitro was a means of addressing the effect 
of Echinacea on influenza antigen-primed cytokine responses.  This model provided 
some insight as to how Echinacea may influence adaptive immunity. The effects of UV 
inactivated virus on primed splenocyte cultures treated with vehicle control only (H2O 
and EtOH) are shown in Table 3.  The addition of UV-inactivated virus to primed 
splenocytes resulted in increased production of IL-2, IL-4, IL-5, and IL-10.  The effect of 
H2O extracts on UV-inactivated virus stimulated splenocytes from previously infected 
(primed) mice is shown in Figure 7.  The addition of H2O extracts did not further 
enhance the production of the cytokines, although E. purpurea extracts tended to increase 
IL-2, IL-4, or IL-5, but reduced inflammatory factors IL-6, IFN-γ, and IP-10.  The 
findings with respect to EtOH extracts revealed a pattern similar to previous results on 
splenocytes in that EtOH extracts from all species decreased both cytokine and 
chemokine response to UV-inactivated virus (Figure 8).  One exception to this finding 
was that only one of the E. angustifolia extracts (Eang2) had less of an anti-inflammatory 
effect and instead actually increased IL-2 and IL-5.  All cytokine and chemokine data 
with all spleen cell conditions are included in Table 2 and Table 3. 
Discussion:  
The results of this investigation demonstrate that Echinacea extracts have effects 
at multiple levels of defense against influenza virus infection including: modest anti-viral 
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activity, stimulation of innate host defense (chemokine response) by lung epithelial cells, 
and modulation of cytokine and chemokine response by host immune cells (both innate 
and adaptive immunity). In this study, we have shown that Epur H2O extracts 
demonstrate limited anti-viral activity in vitro at both the low and high doses tested, 
whereas Echinacea EtOH extracts demonstrated anti-viral activity in the high dose only.  
Although the extracts reduced viral load, the reduction was approximately a one log 
difference which may or may not be of a sufficient magnitude to have effects in vivo.  
Therefore, it will be essential to follow-up these experiments to determine Echinacea 
administration in vivo can limit viral replication.  It will also be important to identify the 
constituents that may contribute to the antiviral effect, particularly in the species in which 
an effect was observed at both low and high concentrations (E. purpurea).  Fractions 
containing polysaccharides and chicoric acid from Echinacea extracts have been shown 
to have anti-viral activity against influenza and herpes simplex virus [8].  In another 
study, chicoric acid has been shown to have anti-viral activity against herpes simplex 
virus [21]  Chicoric acid has also been shown to have anti-viral activity in vitro against 
human immunodeficiency virus 1 [22].  While polysaccharides and chicoric acid are 
present in both water and ethanol extracts, water extracts contain a higher percentage due 
to the water-solubility of these compounds.  Alkamides and ethanol fractions of 
Echinacea have been shown to have anti-viral activity against influenza, but not as robust 
as the chicoric acid and polysaccharide fractions [7].  Therefore, future studies are 
warranted to identify the components that may contribute to the antiviral effects, and 
establish whether the quantity of the antiviral component is sufficient to limit viral load in 
vivo. 
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The spleen cells served as model to investigate the effect of Echinacea on 
immune cells, and this question was addressed in the context of viral infection 
(previously infected primed mice), or without virus (uninfected mice).  The findings 
revealed that the effect of Echinacea water extracts varied based on whether virus was or 
was not involved.  When spleen cells were obtained from uninfected mice, H2O extracts 
from all species had some immunostimulatory effects including increased IL-10, IL-17, 
IL-5, IL-5, MIP-1α and MIP-1β.  However when spleen cells were obtained from 
influenza-primed mice, modest increases in IL-10, IL-2, were found with E. angustifolia, 
E. purpurea, and E. paradoxa, but only E. purpurea extracts resulted in increased IL-5, 
IL-17, MIP-1α and MIP-1β.  If UV-inactivated virus was added to re-stimulate antigen-
specific spleen cells, the results showed that only E. purpurea resulted in increased IL-2, 
IL-4, and IL-5.  Therefore, it is possible that the constituents responsible for immuno-
stimulation may be found at a greater concentration in E. purpurea as compared to the 
other species.   Another interesting finding related to the H2O extracts was that the 
extracts tended to decrease production of inflammation-associated cytokines IL-6, IL-1β, 
IFN-γ, regardless of whether spleen cells were obtained from uninfected or infected mice.   
One finding observed in this study was that E. purpurea water extracts 
demonstrated an increase in cytokines involved in the differentiation of T-cell subtypes 
(IL2, IL4, IL5, and IL17) in the spleen cultures stimulated with UV-inactivated virus.  IL-
2 and IL-4 promote the proliferation and differentiation of T-cells [23].  IL-4 and IL5 are 
considered Th2 cytokines.  Th2 responses enhance humoral immunity and could provide 
a benefit if this enhancement were to lead to increased anti-influenza specific antibody.  
Also, the increase in IL-4 may contribute to a decrease in cytotoxic T cell response and 
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promote the differentiation of B cells [24,25].   This shift may also contribute to change 
in the balance of Th1/Th2 responses and with a reduction in Th1 it is possible that a 
reduction in Th1 associated immunopathology may be decreased [26-28].  In further 
support of this possibility, it was observed that the H2O extracts decreased inflammatory 
cytokine production (IL-1β, IL-6) but enhanced the production of the anti-inflammatory 
cytokine IL-10.  To our knowledge, these are the first results to demonstrate that IL-17 
response was affected by Echinacea extracts in an influenza infection model. While the 
role of IL-17 is currently under investigation, increased IL-17 has been shown to be 
beneficial in preventing lethal influenza infections in humans during the 2009 pandemic 
[29].  IL-17 has also been proposed as an adjuvant in mucosal vaccines [30].   The 
enhanced modulation of the T-cell differentiation associated cytokines suggests that E. 
purpurea could alter the course of influenza infection and could provide a benefit for 
enhancing the immune response to a second influenza exposure an area of study that has 
not been explored with Echinacea.   
The ethanol extracts clearly had different effects than water extracts on cultured 
splenocytes. In conditions in which cells were obtained from uninfected mice and in 
conditions in which cells were obtained from previously infected mice, EtOH extracts 
had the same effect, a consistent reduction of cytokines and chemokines.  These 
decreases are similar to those observed in studies conducted in RAW 264.7 macrophage-
like cell cultures [31].  Other studies have reported decreased pro-inflammatory cytokines 
in infection systems with Echinacea extracts prepared in ethanol [10,32], and therefore it 
is not surprising that the same anti-inflammatory effects were observed.  The anti-
inflammatory properties of ethanol extracts could have benefits in an influenza infection 
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model by limiting immune-mediated tissue damage.  It will be important to identify the 
active components in future studies.  
Another consistent finding observed in these experiments was that H2O extracts 
obtained from E. purpurea, E. angustifolia, and E. paradoxa stimulated chemokine 
production by A549 cells.  However, the EtOH extracts had little impact on cytokine or 
chemokine production by A549 cells. The A549 model represents the type of cell that is 
first infected by influenza virus in the respiratory tract, and the possibility that Echinacea 
stimulates chemokine production would be expected to result in a more rapid recruitment 
of appropriate immune cells to the lungs.  It has been established that lung epithelial cells 
secrete a variety of chemotactic proteins in response to infections.   In the A549 culture, 
Echinacea water and ethanol extracts enhanced cytokines/chemokines responsible for 
cellular recruitment (Eotaxin, GM-CSF, IL-8, and MIP-1α/β).  These chemokines have 
effects on specific cell populations in contributing to host defense. Eotaxin recruits 
eosinophils, and also a recent study by Sever-Chroneos et al demonstrated that increased 
GM-CSF expression in the lung could provide protection from influenza infection [33].  
IL-8 is released from lung epithelial cells and induces neutrophil infiltration.  While 
neutrophils are not the cells responsible for viral clearance, neutrophils may be more 
involved in wound healing after the resolution of infection.  In one study, the removal of 
neutrophils had no deleterious effects on the outcome of influenza resolution [34].  
Another study suggests that neutrophils can act as antigen presenting cells to effector 
CD8 cytotoxic T-cells [35].  MIP-1α and MIP-1β are involved in the recruitment of 
macrophages and monocytes.   These chemokines may also enhance NK activity  [36].  
The increased chemokine production by lung epithelial cells could enhance the immune 
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response to influenza in the lung, and therefore H2O extracts of Echinacea may be useful 
during the first several days of infection when innate immunity is important. 
One limitation with respect to the use of Echinacea is the high degree of 
variability in findings that has been reported in the literature.  In this investigation, with a 
careful comparison of three different plant species using extracts prepared in an identical 
manner, it was possible to compare the effects of Echinacea on three relevant host 
defense responses important in influenza infection.  The findings revealed that even with 
carefully controlled conditions, variations between species, type of extract, and plant 
accession are apparent. Findings from other studies also suggest that variation in the 
preparation techniques can yield changes in the immunomodulatory ability of the extract 
[37,38].  Also, slight variations within the same plant species in the relative change of 
response to influenza infection may be due to growing conditions from season to season 
[39].  To limit the variability as much as possible, the plants used for these experiments 
were cultivated and extracted by the Iowa State Botanical Center to ensure the extracts 
were as comparable as possible.  In our study, Eang1 (accession PI631285) and Eang2 
did not demonstrate the same effects of Eang2 (accession A28187) and similarly with 
Epur1 (accession PI 631307) and Epur2 (accession PI633669).  Each of these extracts 
was prepared from plants grown in different seasons.  Also, Eang1 and Epur1 have been 
stored at -20°C for longer duration than Eang2 and Epur2 because of the different growth 
and cultivation year.  In spite of the variability, there were consistent patterns that 
emerged.  The H2O extracts from all species stimulated epithelial production of 
chemokines in response to influenza virus.  Also consistent were the results showing that 
EtOH extracts had largely anti-inflammatory effects when cultured with spleen immune 
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cells.  Of all three species studied, E. purpurea H2O extracts appeared to influence T 
helper cytokines to the greatest extent in influenza primed mice with an increase in IL-4, 
IL-5, possibly IL-17, but a reduction in anti-inflammatory cytokines.  In future studies, it 
will be important to determine if E. purpurea H2O extract administered in vivo results in 
greater antibody production (resulting from greater IL-4 and IL-5), and limited lung 
inflammation.   
To our knowledge, this is study is the first to evaluate Echinacea extracts in an 
anti-viral assay, lung model, and spleen immune cell populations.  We have demonstrated 
that Echinacea water extracts demonstrate modest anti-viral activity in vitro independent 
of dosage, whereas anti-viral activity in Echinacea ethanol extracts was observed in the 
high dose only.  Echinacea water and ethanol extracts enhanced cytokines/chemokines 
responsible for cellular recruitment in the lung, while the Echinacea ethanol extracts also 
provided some anti-inflammatory properties.  While in the spleen Echinacea H2O 
extracts enhanced cytokine/chemokines for cellular recruitment and differentiation, and 
an anti-inflammatory profile was observed with the Echinacea EtOH extracts with 
variability seen between the species utilized.  These data suggest that Echinacea may be 
beneficial in treating influenza infections.  In conclusion, Echinacea modulated the 
influenza infection through direct anti-viral activity, enhancement of the lung epithelial 
and immune cell responses and decreased inflammation. 
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Chapter II figures. 
Figure 1. 
 
 
 
 
Figure 1:  Anti-viral effect of extracts compared to vehicle controls using an anti-
viral assay in MDCK cells.  Extracts were applied to MDCK cells in low (300μg/ml) 
and high (1500μg/ml) dose concentrations.  A/PR/8/34 was added in 1:10 dilution to 10-
12
. Viral titers were calculated using Kirby-Spearmann calculations.  Student t-test was 
utilized to determine statistical significance for each extract compared to the appropriate 
vehicle control (ex. H2O, EtOH1, EtOH2).  Low dose water extracts Eang2, Epur2, and 
Epara demonstrated a trend towards decreased viral titer compared to the H2O control.  
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High dose water extracts Epur1 (trend) and Epur2 demonstrated a decrease in viral titer 
compared to the H2O control.  Both low and high doses of EtOH extract Epur1 showed a 
trend towards a decrease in viral titer compared to the EtOH1 control.  Low dose of 
EtOH Epara was significantly increased compared to the EtOH2.  Whereas, high doses 
of Epur2 was significantly decreased compared to EtOH2 with Eang2 and Epara 
demonstrating a trend towards a decrease in viral titer when applied in the high doses.  
n=4; *, p<0.05; + p=0.1. 
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Figure 2. 
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Figure 2. continued. 
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Figure 2:  Effect of extracts on lung epithelial cells without virus present. 
A549 cells treated with extracts and incubated without virus for 24 hours.  Supernatants 
from the cells were analyzed using Bio-plex® multiplex assay.   Student T-test was used 
to evaluate each extract and the appropriate vehicle control and the EtOH control against 
the water control.  H2O= water, EtOH = ethanol, Eang1 = E. angustifolia extract 1, 
Epur1 = E. purpurea extract 1, Eang2 = E. angustifolia extract 2, Epur2 = E. purpurea 
extract 2, Epara = E. paradoxa var. paradoxa extract.  H2O N=9; EtOH N=8; Eang1 and 
Epur1 EtOH N=5; Eang1 and Epur1 H2O N=4; *, p <0.05; +, p=0.1; & = p<0.05 for 
EtOH vs. H2O control.   
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Figure 3. 
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Figure 3. continued. 
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Figure 3. continued. 
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Figure 3. continued. 
 
 
Figure 3:  Effect of extracts on lung epithelial cells with influenza virus infection. 
A549 cells treated with extracts and infected with Influenza A H1N1 PR/8/34 HA=4092.  
Supernatants were collected and tested using Bio-plex® multiplex assay.  Student T-test 
was used to analyzed the extracts against the proper vehicle control (H2O extracts against 
H2O, EtOH extracts against EtOH).  No significant changes between the EtOH vehicle 
control and H2O vehicle control were observed. H2O= water, EtOH = ethanol, Eang1 = 
E. angustifolia extract 1, Epur1 = E. purpurea extract 1, Eang2 = E. angustifolia extract 
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2, Epur2 = E. purpurea extract 2, Epara = E. paradoxa var. paradoxa extract.  N=3 *, 
p<0.05; +, p<0.1.   
Figure 4. 
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Figure 4. continued. 
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Figure 4. continued. 
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Figure 4. continued. 
 
 
 
 
Figure 4:  Effect of extract on splenocytes collected from uninfected mice. 
Spleens were collected from uninfected mice, and splenocytes were cultured with each 
extract without virus.  Supernatants were collected and tested using Bio-plex® multiplex 
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assay.  Student t-test was used to compare the splenocytes receiving extract to vehicle 
control only (water extracts against water only; ethanol extracts against ethanol only). 
N=3, *, p<0.05; +, p=0.1.  EtOH vehicle was also compared to H2O vehicle control.  &, 
p<0.05; #, p=0.1. 
Figure 5. 
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Figure 5. continued.  
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Figure 5: Effect of water (H2O) extracts applied to splenocytes from mice infected 
with influenza A/PR/8/34 compared to splenocytes from uninfected mice.  
Cytokines/Chemokines were measured using Bio-plex® multiplex assay.  Student T-test 
was used to determine significance of each extract compared to the appropriate water 
control.  N=3; *, p<0.05; +, p=0.1.  The effect of infection in the mouse was evaluated 
with the student t-test (comparing uninfected H2O control to infected H2O control). &, 
p<0.05, #, p=0.1. 
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Figure 6. continued. 
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Figure 6. continued. 
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Figure 6: Effect of ethanol (EtOH) extracts applied to splenocytes from mice 
infected with influenza A/PR/8/34 compared to splenocytes from uninfected mice.  
Cytokines/Chemokines were measured using Bio-plex® multiplex assay. Student T-test 
was used to determine significance of each extract compared to the appropriate EtOH 
control.  Uninfected mice N=3; infected mice N=4; *, p<0.05; +, p=0.1.  The effect of 
infection in the mouse was evaluated with the student t-test (comparing uninfected EtOH 
control to infected EtOH control). &, p<0.05, #, p=0.1. 
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Figure 7. continued. 
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Figure 7:  Effect of water extracts on splenocytes from mice primed with A/PR/8/34 
and stimulated with UV inactivated H1N1 A/PR/8/34.  Cytokines/Chemokines were 
measured using Bio-plex® multiplex assay.  Student T-test was utilized to evaluate each 
extract against the appropriate vehicle control.  Primed mice no virus N=3; Primed mice 
virus N=4; *, p<0.05; +, p=0.1.  The effect of UV inactivated stimulation on primed 
splenocyte cultures was evaluated with the student t-test (comparing primed mice no 
virus H2O control to primed mice virus H2O control). &, p<0.05, #, p<0.1. 
Figure 8. 
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Figure 8. continued. 
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Figure 8. continued. 
 
 
Figure 8:  Effect of ethanol extracts on splenocytes from mice primed with 
A/PR/8/34 and stimulated with UV inactivated H1N1 A/PR/8/34.  
Cytokines/Chemokines were measured using Bio-plex® multiplex assay.  Student T-test 
was utilized to evaluate each extract against the appropriate vehicle control.  Primed mice 
no virus N=4; Primed mice virus N=5; *,p<0.05; +, p=0.1 The effect of UV inactivated 
stimulation on primed splenocyte cultures was evaluated with the student t-test 
(comparing primed mice no virus EtOH control to primed mice virus EtOH control). &, 
p<0.05, #, p<0.1. 
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Table 1.  Effect of virus infection on A549 cell cytokine/chemokine response. 
  H2O EtOH 
  no virus virus 
Virus 
vs no 
virus no virus virus 
Virus 
vs no 
virus 
n= 9 9   8 9 
 
  mean 
std. 
error mean 
std. 
error p-value mean 
std. 
error mean std. error 
p-
value 
IL-1b 0.08 0.04 0.16 0.08 0.40 0.07 0.03 0.54 0.3 0.15 
IL-1ra 0.58 0.38 0.58 0.38 1.00 0.18 0.12 1.36 0.84 0.20 
IL-2 0.37 0.22 0.91 0.63 0.43 0.1 0.1 0.54 0.44 0.37 
IL-4 0.01 0.01 0.61 0.14 0.00 0 0 0.7 0.15 0.00 
IL-5 0.05 0.03 0.05 0.02 0.98 0.05 0.02 0.04 0.02 0.87 
IL-6 2.88 0.53 350.75 21.39 0.00 1.43 0.24 415.43 34.74 0.00 
IL-7 0.13 0.05 0.72 0.12 0.00 0.18 0.08 1.05 0.19 0.00 
IL-8 266.55 13.74 1139.7 367.83 0.05 185.18 19.86 1007.5 289.77 0.02 
IL-9 5.77 0.42 9.36 1.08 0.01 5.21 0.85 10.04 0.88 0.00 
IL-10 0.2 0.1 0.3 0.15 0.56 0.23 0.12 0.27 0.12 0.79 
IL-12p70 7.63 0.44 9.7 0.36 0.00 8.19 0.97 11.22 1.23 0.08 
IL-13 0 0 0.13 0.07 0.11 0.18 0.18 0.38 0.23 0.51 
IL-15 0.46 0.15 0.94 0.26 0.13 0.44 0.15 1.46 0.28 0.01 
IL-17 0 0 0.33 0.18 0.11 0 0 1.81 0.54 0.01 
Eotaxin 1.28 0.6 4.32 0.7 0.01 1.7 0.9 3.96 0.65 0.06 
G-CSF 0.26 0.11 1.43 0.2 0.00 0.22 0.1 2.32 0.31 0.00 
GM-CSF 0.58 0.34 2.01 0.73 0.10 0.42 0.37 1.68 0.82 0.19 
IFN-γ 4.64 2.53 49.49 4.86 0.00 5.69 5.37 50.67 4.8 0.00 
IP-10 10.2 3.12 6276.5 342.19 0.00 10.35 2.69 8551.2 914.25 0.00 
MCP-1 375.77 20.23 2101.4 214.09 0.00 312.34 16.51 3251.9 808.87 0.01 
MIP-1α 0.49 0.27 6.42 0.5 0.00 0.42 0.28 8.13 0.59 0.00 
MIP-1β 0.58 0.19 214.15 6.51 0.00 0.31 0.18 254.97 8.62 0.00 
RANTES 2.93 0.45 7013.9 1480.36 0.00 1.68 0.34 8772.5 1619.96 0.00 
TNF-α 0.08 0.08 17.25 1.8 0.00 0.18 0.1 20.81 3.45 0.00 
PDGFbb 1.04 0.4 2.67 0.54 0.03 0.87 0.28 3.78 0.76 0.01 
FGFbasic 2.84 1.36 9.38 2.33 0.03 1.16 0.76 9.09 1.88 0.00 
VEGF 238.97 13.36 382.15 21.41 0.00 278.85 29.37 393.38 26.17 0.01 
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Table 2.  Ex vivo spleen effect of H2O extracts on Cytokine/Chemokine expression. 
Uninfected mice - no virus in culture 
  H2O Eang1 Epur1 Eang2 Epur2 Epara 
Cytokine Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
IL-1α 226.3 28.8 *108.17 7.6 178.6 12.1 *128.26 16.6 154.5 22.9 *137.82 3.9 
IL-1β 81.6 9.0 62.8 9.4 *29.82 5.2 *43.93 3.7 44.5 11.5 *35.38 5.2 
IL-2 12.1 4.4 7.3 1.7 14.9 2.9 16.8 5.1 7.2 0.7 17.6 3.9 
IL-4 2.1 0.3 1.4 0.3 *4.57 0.6 1.8 0.5 3.2 1.0 1.8 0.2 
IL-5 14.5 1.8 9.9 2.0 *36.96 0.8 10.4 1.4 *25.02 0.4 *7.02 2.1 
IL-6 1410.6 42.7 *533.36 27.4 *389.72 34.6 *698.01 120.3 1173.6 167.0 *660.56 154.9 
IL-10 667.6 50.8 *1656.33 71.2 494.0 150.8 1152.6 350.7 939.0 332.4 621.6 160.5 
IL-
12p40 
3.4 1.0 1.0 0.5 0.6 0.4 4.5 3.0 1.2 1.2 0.0 0.0 
IL-
12p70 
0.8 0.8 0.0 0.0 0.0 0.0 0.8 0.8 0.0 0.0 0.0 0.0 
IL-15 18.1 9.6 1.5 1.5 7.2 7.2 12.5 10.3 0.0 0.0 3.1 3.1 
IL-17 13.1 6.6 30.5 11.9 *136.56 17.8 35.1 20.3 *324.54 74.8 36.4 21.3 
IFN-γ 8531.8 1968.1 6878.1 871.2 *308.20 95.6 *1779.75 479.7 *131.76 57.2 1656.4 271.7 
TNF-α 219.8 54.2 163.2 21.9 151.0 13.4 140.3 26.8 256.9 2.2 125.4 28.0 
Eotaxin 0.6 0.6 0.2 0.2 0.0 0.0 0.3 0.3 0.0 0.0 0.0 0.0 
IP-10 522.4 125.0 526.4 65.2 212.9 86.3 506.0 86.1 232.3 107.1 376.2 61.6 
KC 1467.2 494.1 904.4 230.6 1320.7 345.7 1206.3 505.2 1690.6 190.1 1158.9 497.7 
MIP-1α 1019.1 266.3 897.7 68.3 *1988.61 53.5 1215.4 180.3 *1961.10 176.4 1170.8 186.3 
MIP-1β 969.6 312.3 1318.1 71.5 *2459.62 335.8 1639.0 290.3 2151.6 520.3 1164.3 63.9 
MCP-1 76.6 9.2 49.4 14.5 113.0 25.8 79.0 31.7 81.9 7.4 77.3 31.0 
Primed mice - no virus in culture 
  H2O Eang1 Epur1 Eang2 Epur2 Epara 
Cytokine Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
IL-1α 288.2 41.0 *103.38 5.1 187.4 47.4 *112.37 18.7 172.4 10.2 *115.07 27.9 
IL-1β 55.0 7.0 48.7 8.7 *20.72 3.3 36.5 7.5 *31.26 4.9 *20.37 4.5 
IL-2 5.0 0.6 5.2 0.6 *9.43 0.3 *10.90 0.3 5.6 0.7 *11.93 2.1 
IL-4 1.1 0.2 1.0 0.3 *2.48 0.4 2.1 0.9 2.4 0.5 2.1 0.8 
IL-5 6.4 3.4 5.5 0.9 13.2 3.2 5.6 1.1 14.6 0.7 0.0 0.0 
IL-6 3077.7 539.0 *689.85 91.0 *289.16 104.7 *922.77 117.0 *1197.11 176.3 *906.07 134.5 
IL-10 348.6 54.7 *1453.03 55.5 378.7 39.6 *984.02 77.0 *665.00 102.5 360.4 37.4 
IL-
12p40 
1.2 0.6 1.1 1.0 0.0 0.0 2.0 0.7 0.0 0.0 0.2 0.2 
IL-
12p70 
0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.4 0.0 0.0 0.0 0.0 
IL-15 0.0 0.0 0.0 0.0 0.0 0.0 12.1 8.8 0.0 0.0 0.0 0.0 
IL-17 15.4 9.4 22.9 4.4 39.2 1.5 26.5 12.9 108.4 25.9 47.8 27.3 
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Table 2. continued. 
Cytokine Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
IFN-γ 12109.6 322.0 *5666.29 1615.8 375.2 115.7 *3348.25 704.7 *148.02 1.7 *2388.17 502.2 
TNF-α 243.2 26.5 *162.92 5.0 154.9 13.1 165.6 18.3 290.6 18.1 *125.15 15.2 
Eotaxin 0.0 0.0 0.3 0.3 0.0 0.0 1.1 0.8 0.0 0.0 0.0 0.0 
IP-10 413.1 35.7 401.3 47.8 *116.07 66.3 457.3 73.6 *134.91 24.7 292.5 43.4 
KC 1701.9 265.8 *942.20 88.1 1266.8 214.1 1418.8 136.3 2081.6 237.6 1604.8 297.8 
MIP-1α 1167.6 87.6 *581.05 28.6 *1886.95 150.1 1104.6 35.4 *2074.65 20.8 1098.3 155.2 
MIP-1β 767.2 58.5 *977.59 23.8 2297.0 534.5 *1397.67 133.7 *1919.62 283.7 889.3 123.1 
MCP-1 158.7 28.0 *51.96 7.2 102.0 29.2 85.1 20.1 86.2 22.0 117.6 16.8 
Primed mice - stimulation with virus in culture 
  H2O Eang1 Epur1 Eang2 Epur2 Epara 
Cytokine Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
IL-1α 313.0 56.9 *144.61 23.9 166.0 18.6 *111.76 16.0 *137.70 16.9 145.9 5.2 
IL-1β 61.1 6.1 49.4 7.5 *27.24 7.0 *30.70 5.7 *31.80 3.4 *24.43 6.5 
IL-2 10.9 1.7 6.5 0.7 15.8 2.2 7.3 0.7 11.3 0.7 11.6 2.7 
IL-4 2.4 0.7 1.7 0.3 8.9 3.0 2.8 0.7 4.0 1.1 4.8 2.0 
IL-5 15.9 2.0 15.6 4.8 *65.65 15.1 25.9 6.0 43.5 16.7 22.2 5.9 
IL-6 1882.0 103.9 *882.92 141.1 *546.37 89.8 *759.54 93.1 *1275.90 152.6 *991.19 29.6 
IL-10 1272.5 236.5 1948.2 288.3 782.8 92.6 1291.4 175.7 966.9 51.6 1133.8 50.1 
IL-
12p40 
0.6 0.5 0.3 0.2 0.0 0.0 0.0 0.0 0.6 0.3 1.2 0.9 
IL-
12p70 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
IL-15 4.4 4.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.4 3.4 
IL-17 21.7 4.8 31.6 8.4 45.0 9.8 23.9 2.4 *83.16 19.5 38.8 13.7 
IFN-γ 12416.4 64.7 11420.2 529.7 *4628.22 833.3 10552.5 1001.4 *2497.28 385.4 10713.9 1647.9 
TNF-α 203.6 40.4 182.6 30.9 157.7 15.6 128.9 20.6 269.1 49.9 148.6 19.6 
Eotaxin 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.3 0.5 0.3 
IP-10 611.1 31.2 477.9 70.2 *308.55 52.3 497.3 47.2 *264.80 19.1 529.3 26.3 
KC 1108.0 139.3 1036.9 111.4 1107.5 61.3 832.3 74.1 *2041.58 258.7 1459.1 227.8 
MIP-1α 1009.8 119.6 688.7 101.0 *1896.17 65.6 873.8 56.5 *1830.45 83.9 1049.3 39.1 
MIP-1β 893.8 68.2 1065.9 161.8 2837.4 674.4 1052.6 66.9 *1675.26 144.9 *1238.38 92.2 
MCP-1 162.4 46.4 68.6 18.1 192.2 70.9 85.8 25.7 209.5 61.8 145.9 30.8 
SEM – standard error of the mean. *, p<0.05, + p<0.1 for treatment group compared to 
vehicle control. 
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Table 3.  Ex vivo spleen effect of EtOH extracts on Cytokine/Chemokine expression. 
Uninfected mice - no virus in culture 
  EtOH Epur1 Eang2 Epur2 Epara 
Cytokine Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
IL-1α 232.61 47.78 *11.62 4.58 *73.38 29.16 *3.63 3.63 *19.64 12.31 
IL-1β 117.27 18.39 *10.95 8.31 *24.97 16.12 *8.46 5.89 *15.68 8.13 
IL-2 16.13 2.37 *0.00 0.00 *37.78 3.54 *0.00 0.00 +5.43 5.06 
IL-4 1.85 0.74 4.28 3.85 2.01 0.50 2.72 0.11 +4.49 0.68 
IL-5 27.56 5.84 *0.00 0.00 *7.09 1.12 *0.00 0.00 *2.86 2.86 
IL-6 2127.21 523.09 +26.84 26.84 +286.29 67.33 +18.43 9.16 7+7.23 43.68 
IL-7 2.26 1.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
IL-9 0.00 0.00 14.84 13.13 *0.00 0.00 0.00 0.00 8.63 8.63 
IL-10 856.15 171.01 *3.91 2.38 *309.39 100.93 *6.70 3.88 *27.71 20.24 
IL-12p40 4.18 0.83 *0.00 0.00 *0.00 0.00 *0.00 0.00 *0.40 0.40 
IL-12p70 14.19 1.77 *1.14 0.31 *1.88 1.88 *0.00 0.00 *0.71 0.71 
IL-13 118.35 31.16 +7.58 7.58 +22.25 22.25 +0.00 0.00 +7.58 7.58 
IL-15 31.49 3.70 *5.43 5.43 33.94 12.30 *0.00 0.00 *8.29 4.30 
IL-17 18.16 5.67 +0.17 0.17 24.36 15.86 +0.00 0.00 +0.85 0.49 
IFN-γ 12069.78 320.93 *0.00 0.00 *447.52 358.50 *0.00 0.00 *1.66 1.66 
TNF-α 230.84 27.71 *2.78 2.78 *67.16 19.21 *0.70 0.70 *14.10 6.25 
IP-10 711.78 115.60 *3.22 2.17 *241.81 119.13 *3.46 0.77 *11.76 4.32 
KC 1298.53 479.98 +72.00 69.36 1961.13 496.20 +40.81 31.54 716.35 452.19 
G-CSF 2155.14 871.88 +14.16 14.16 916.41 180.49 +15.27 11.70 218.21 151.61 
GM-CSF 1161.24 128.49 *25.12 4.65 *167.27 86.96 *0.00 0.00 *22.09 5.36 
MCP-1 129.25 54.55 +3.75 3.75 +430.68 141.44 +0.00 0.00 123.34 123.34 
MIP-1α 1364.13 38.17 *13.90 10.73 1354.77 223.85 *43.39 8.71 *68.76 52.38 
MIP-1β 1401.34 239.21 *24.73 13.79 1102.87 268.39 *23.28 7.69 *93.15 51.50 
MIP-2 4954.18 1842.07 +322.75 235.41 4213.56 892.23 +510.70 92.94 +1326.91 768.02 
RANTES 216.36 9.86 *8.66 1.68 *88.18 21.34 *32.16 3.47 *11.30 3.95 
Primed mice - no virus in culture 
  EtOH Epur1 Eang2 Epur2 Epara 
Cytokine Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
IL-1α 527.47 112.97 *1.02 1.02 *21.32 12.41 *3.74 2.57 *4.25 4.25 
IL-1β 127.02 5.71 *4.95 4.95 *22.79 6.28 *7.74 4.23 *13.60 7.91 
IL-2 9.38 0.54 *0.00 0.00 *23.60 7.63 *0.00 0.00 *0.00 0.00 
IL-4 1.18 0.23 1.28 0.89 1.25 0.28 2.00 1.38 4.51 1.91 
IL-5 16.17 2.86 *0.00 0.00 *3.10 1.90 *0.00 0.00 *0.00 0.00 
IL-6 4922.90 591.06 *3.13 2.64 *103.57 35.54 1*0.41 5.01 3*4.32 15.87 
IL-7 4.06 1.33 +0.00 0.00 +0.00 0.00 +0.00 0.00 +0.00 0.00 
IL-9 0.00 0.00 12.81 12.81 0.00 0.00 0.00 0.00 +35.68 17.37 
IL-10 514.49 100.51 *1.37 1.37 *102.31 31.04 *3.65 2.23 *8.54 5.17 
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Table 3. continued. 
Cytokine Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
IL-12p40 5.59 1.46 *0.00 0.00 *0.82 0.50 *0.00 0.00 *0.00 0.00 
IL-12p70 24.75 1.58 *0.95 0.95 *0.58 0.33 *0.29 0.29 *0.44 0.28 
IL-13 119.18 33.59 *11.37 6.56 *0.00 0.00 *0.00 0.00 *11.38 11.38 
IL-15 40.06 8.03 *0.00 0.00 +18.18 6.99 *0.00 0.00 *6.91 3.93 
IL-17 25.63 6.66 *0.00 0.00 *4.97 4.08 *0.00 0.00 *0.13 0.13 
IFN-γ 13938.98 491.29 *0.00 0.00 *17.11 12.53 *0.00 0.00 *0.00 0.00 
TNF-α 361.78 63.11 *1.18 1.18 *35.62 13.22 *0.52 0.52 *11.60 6.92 
IP-10 663.11 43.27 *2.55 1.49 *38.40 16.22 *4.64 1.76 *5.92 2.36 
KC 2114.40 324.37 *2.99 2.58 1603.25 600.95 *15.39 8.54 *263.61 189.74 
G-CSF 3882.12 281.53 *0.00 0.00 *691.89 317.20 *6.87 4.27 *56.84 41.46 
GM-CSF 1483.57 174.57 *4.18 4.18 *37.55 15.21 *4.18 4.18 *10.64 6.42 
MCP-1 405.94 106.39 *0.00 0.00 732.41 287.93 *0.00 0.00 *11.90 11.90 
MIP-1α 1588.62 161.24 *3.29 2.10 +847.21 337.46 *31.03 13.43 *41.07 29.85 
MIP-1β 1099.67 57.63 *2.65 2.65 634.29 259.27 *16.80 8.11 *48.54 28.37 
MIP-2 13276.35 4017.53 *71.62 15.48 +3365.99 1275.45 *306.40 130.91 *740.09 452.58 
RANTES 234.82 23.80 *9.64 1.59 *48.71 8.50 *25.33 2.28 *8.28 2.49 
Primed mice - stimulation with virus in culture 
  EtOH Epur1 Eang2 Epur2 Epara 
Cytokine Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
IL-1α 441.85 96.81 *7.54 6.57 *148.49 55.12 *8.03 2.60 *12.55 2.75 
IL-1β 133.07 3.94 *7.74 5.05 *45.59 7.70 *9.28 4.28 *8.44 5.19 
IL-2 22.19 0.53 *0.28 0.28 *69.01 12.65 +7.01 7.01 *2.81 1.30 
IL-4 3.42 0.78 7.32 2.62 *10.44 1.93 4.41 1.81 7.02 2.37 
IL-5 41.43 6.65 *0.00 0.00 *23.39 3.67 *0.66 0.66 *0.00 0.00 
IL-6 2522.00 545.46 *29.77 14.77 +978.72 432.52 *34.20 17.77 *65.33 23.17 
IL-7 1.70 0.55 *0.00 0.00 0.86 0.86 *0.00 0.00 *0.00 0.00 
IL-9 0.00 0.00 +33.81 18.47 3.09 3.09 0.00 0.00 +20.16 10.16 
IL-10 1343.54 303.95 *4.42 2.19 964.84 108.89 *23.30 19.41 *15.41 7.04 
IL-12p40 3.67 1.01 *0.00 0.00 *0.82 0.38 *0.00 0.00 *0.00 0.00 
IL-12p70 16.98 2.50 *0.66 0.43 *7.80 2.01 *0.51 0.51 *0.00 0.00 
IL-13 145.45 24.49 *19.95 14.93 +254.38 47.17 *4.55 4.55 *9.10 9.10 
IL-15 27.82 3.68 *2.42 1.48 32.91 6.78 *8.63 5.40 *4.18 2.56 
IL-17 43.60 14.33 *0.08 0.08 +17.34 6.15 *0.44 0.44 *0.18 0.11 
IFN-γ 14016.33 406.58 *0.00 0.00 *5262.26 1778.16 *3.21 3.21 *0.89 0.46 
TNF-α 211.53 47.66 *4.33 3.00 +108.20 28.46 *5.01 4.19 *13.58 6.12 
IP-10 731.54 57.76 2.93 2.93 *505.88 62.53 *8.98 6.31 *7.95 2.84 
KC 1659.48 272.00 *68.53 57.48 +3120.73 822.51 *204.46 189.79 *316.14 127.85 
G-CSF 2808.01 247.00 *16.27 14.82 2707.40 932.06 *77.81 70.51 *67.90 26.77 
GM-CSF 1676.53 214.04 *19.60 6.35 *495.00 52.11 *14.24 6.37 *3.35 3.35 
MCP-1 295.19 101.56 *1.90 1.90 *1191.08 224.36 +77.85 77.85 *18.80 9.03 
MIP-1α 936.08 229.93 *17.58 13.19 *1859.98 135.32 *111.17 81.63 *60.10 28.20 
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Table 3. continued. 
Cytokine Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
MIP-1β 1006.72 190.93 *27.74 20.87 *1796.58 167.45 *70.69 51.50 *76.07 27.51 
MIP-2 5814.77 705.03 *313.11 213.48 7998.15 3401.07 *666.06 415.43 *806.57 332.08 
RANTES 149.56 14.81 *10.16 2.92 *89.92 10.39 *24.15 2.95 *10.06 3.49 
SEM – standard error of the mean. *, p<0.05, + p<0.1 for treatment group compared to 
vehicle control 
 
References: 
1. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K: 
Mortality associated with influenza and respiratory syncytial virus in the 
United States. JAMA 2003, 289:179-186. 
 
2. Noah DL, Noah JW: Adapting global influenza management strategies to address 
emerging viruses. Am J Physiol Lung Cell Mol Physiol 2013, 305:L108-117. 
 
3. Treanor J: Weathering the influenza vaccine crisis. N Engl J Med 2004, 351:2037-
2040. 
 
4. Boivin G: Detection and management of antiviral resistance for influenza viruses. 
Influenza Other Respir Viruses 2013, 7 Suppl 3:18-23. 
 
5. Samson M, Pizzorno A, Abed Y, Boivin G: Influenza virus resistance to 
neuraminidase inhibitors. Antiviral Res 2013, 98:174-185. 
 
6. Roussy JF, Abed Y, Bouhy X, Boivin G: Emergence of an Oseltamivir-Resistant 
Influenza A/H3N2 Virus in an Elderly Patient Receiving a Suboptimal Dose 
of Antiviral Prophylaxis. J Clin Microbiol 2013, 51:4234-4236. 
 
7. Hudson J, Vimalanathan S, Kang L, Amiguet VT, Livesey J, Arnason JT: 
Characterization of antiviral activities in Echinacea root preparations. 
Pharmaceutical Biology 2005, 43:790-796. 
 
8. Vimalanathan S, Kang L, Amiguet VT, Livesey J, Arnason JT, Hudson J: Echinacea 
purpurea aerial parts contain multiple antiviral compounds. Pharmaceutical 
Biology 2005, 43:740-745. 
 
9. Goel V, Chang C, Slama JV, Barton R, Bauer R, Gahler R, Basu TK: Alkylamides of 
Echinacea purpurea stimulate alveolar macrophage function in normal rats. 
Int Immunopharmacol 2002, 2:381-387. 
 
98 
 
10. Matthias A, Banbury L, Stevenson LM, Bone KM, Leach DN, Lehmann RP: 
Alkylamides from Echinacea modulate induced immune responses in 
macrophages. Immunol Invest 2007, 36:117-130. 
 
11. Sullivan AM, Laba JG, Moore JA, Lee TD: Echinacea-induced macrophage 
activation. Immunopharmacol Immunotoxicol 2008, 30:553-574. 
 
12. Wang CY, Staniforth V, Chiao MT, Hou CC, Wu HM, Yeh KC, Chen CH, Hwang 
PI, Wen TN, Shyur LF, et al.: Genomics and proteomics of immune 
modulatory effects of a butanol fraction of Echinacea purpurea in human 
dendritic cells. BMC Genomics 2008, 9:479. 
 
13. Spelman K, Iiams-Hauser K, Cech NB, Taylor EW, Smirnoff N, Wenner CA: Role 
for PPARgamma in IL-2 inhibition in T cells by Echinacea-derived undeca-
2E-ene-8,10-diynoic acid isobutylamide. Int Immunopharmacol 2009, 9:1260-
1264. 
 
14. Zhai Z, Liu Y, Wu L, Senchina DS, Wurtele ES, Murphy PA, Kohut ML, Cunnick 
JE: Enhancement of innate and adaptive immune functions by multiple 
Echinacea species. J Med Food 2007, 10:423-434. 
 
15. Goel V, Chang C, Slama J, Barton R, Bauer R, Gahler R, Basu T: Echinacea 
stimulates macrophage function in the lung and spleen of normal rats. J Nutr 
Biochem 2002, 13:487. 
 
16. Hwang SA, Dasgupta A, Actor JK: Cytokine production by non-adherent mouse 
splenocyte cultures to Echinacea extracts. Clin Chim Acta 2004, 343:161-166. 
 
17. Bauer R: Echinacea: biological Effects and Active Principles. In Phytomedicines of 
Europe. Edited by: ACS Symposium Series; 1998:140-157. vol 691.] 
 
18. Woelkart K, Bauer R: The role of alkamides as an active principle of Echinacea. 
Planta Med 2007, 73:615-623. 
 
19. Zhai Z, Solco A, Wu L, Wurtele ES, Kohut ML, Murphy PA, Cunnick JE: Echinacea 
increases arginase activity and has anti-inflammatory properties in RAW 
264.7 macrophage cells, indicative of alternative macrophage activation. J 
Ethnopharmacol 2009, 122:76-85. 
 
20. Senchina DS, Wu L, Flinn GN, Konopka del N, McCoy JA, Widrlechner MP, 
Wurtele ES, Kohut ML: Year-and-a-half old, dried Echinacea roots retain 
cytokine-modulating capabilities in an in vitro human older adult model of 
influenza vaccination. Planta Med 2006, 72:1207-1215. 
 
99 
 
21. Binns SE, Hudson J, Merali S, Arnason JT: Antiviral activity of characterized 
extracts from Echinacea spp. (Heliantheae: Asteraceae) against herpes 
simplex virus (HSV-I). Planta Med 2002, 68:780-783. 
 
22. Reinke RA, Lee DJ, McDougall BR, King PJ, Victoria J, Mao Y, Lei X, Reinecke 
MG, Robinson WE, Jr.: L-chicoric acid inhibits human immunodeficiency 
virus type 1 integration in vivo and is a noncompetitive but reversible 
inhibitor of HIV-1 integrase in vitro. Virology 2004, 326:203-219. 
 
23. Or R, Renz H, Terada N, Gelfand EW: IL-4 and IL-2 promote human T-cell 
proliferation through symmetrical but independent pathways. Clin Immunol 
Immunopathol 1992, 64:210-217. 
24. Bot A, Holz A, Christen U, Wolfe T, Temann A, Flavell R, von Herrath M: Local IL-
4 expression in the lung reduces pulmonary influenza-virus-specific 
secondary cytotoxic T cell responses. Virology 2000, 269:66-77. 
 
25. Abbas AK, Murphy KM, Sher A: Functional diversity of helper T lymphocytes. 
Nature 1996, 383:787-793. 
 
26. Herring AC, Hernandez Y, Huffnagle GB, Toews GB: Role and development of 
TH1/TH2 immune responses in the lungs. Semin Respir Crit Care Med 2004, 
25:3-10. 
 
27. Neurath MF, Finotto S, Glimcher LH: The role of Th1/Th2 polarization in mucosal 
immunity. Nat Med 2002, 8:567-573. 
 
28. Bot A, Rodrigo E, Wolfe T, Bot S, Von Herrath MG: Infection-triggered regulatory 
mechanisms override the role of STAT 4 in control of the immune response 
to influenza virus antigens. J Virol 2003, 77:5794-5800. 
 
29. Almansa R, Socias L, Ramirez P, Martin-Loeches I, Valles J, Loza A, Rello J, Kelvin 
DJ, Leon C, Blanco J, et al.: Imbalanced pro- and anti-Th17 responses (IL-
17/granulocyte colony-stimulating factor) predict fatal outcome in 2009 
pandemic influenza. Crit Care 2011, 15:448. 
 
30. Kumar P, Chen K, Kolls JK: Th17 cell based vaccines in mucosal immunity. Curr 
Opin Immunol 2013. 
 
31. Cech NB, Kandhi V, Davis JM, Hamilton A, Eads D, Laster SM: Echinacea and its 
alkylamides: effects on the influenza A-induced secretion of cytokines, 
chemokines, and PGE(2) from RAW 264.7 macrophage-like cells. Int 
Immunopharmacol 2010, 10:1268-1278. 
 
32. Sharma M, Schoop R, Hudson JB: Echinacea as an Antiinflammatory Agent: The 
Influence of Physiologically Relevant Parameters. Phytotherapy Research 
2009, 23:863-867. 
100 
 
 
33. Sever-Chroneos Z, Murthy A, Davis J, Florence JM, Kurdowska A, Krupa A, 
Tichelaar JW, White MR, Hartshorn KL, Kobzik L, et al.: GM-CSF modulates 
pulmonary resistance to influenza A infection. Antiviral Res 2011, 92:319-328. 
 
34. Wareing MD, Lyon AB, Lu B, Gerard C, Sarawar SR: Chemokine expression 
during the development and resolution of a pulmonary leukocyte response to 
influenza A virus infection in mice. J Leukoc Biol 2004, 76:886-895. 
 
35. Hufford MM, Richardson G, Zhou H, Manicassamy B, Garcia-Sastre A, Enelow RI, 
Braciale TJ: Influenza-infected neutrophils within the infected lungs act as 
antigen presenting cells for anti-viral CD8(+) T cells. PLoS One 2012, 
7:e46581. 
 
36. Vareille M, Kieninger E, Edwards MR, Regamey N: The airway epithelium: soldier 
in the fight against respiratory viruses. Clin Microbiol Rev 2011, 24:210-229. 
 
37. Senchina DS, McCann DA, Asp JM, Johnson JA, Cunnick JE, Kaiser MS, Kohut 
ML: Changes in immunomodulatory properties of Echinacea spp. root 
infusions and tinctures stored at 4 degrees C for four days. Clin Chim Acta 
2005, 355:67-82. 
 
38. Spelman K, Wetschler MH, Cech NB: Comparison of alkylamide yield in ethanolic 
extracts prepared from fresh versus dry Echinacea purpurea utilizing 
HPLC-ESI-MS. J Pharm Biomed Anal 2009, 49:1141-1149. 
 
39. Binns SE, Livesey JF, Arnason JT, Baum BR: Phytochemical variation in 
Echinacea from roots and flowerheads of wild and cultivated populations. J 
Agric Food Chem 2002, 50:3673-3687. 
 
 
 
 
 
 
 
101 
 
CHAPTER III. EFFECTS OF ALTERNATING WATER AND ETHANOL 
ECHINACEA SPP. EXTRACTS DURING DIFFERENT PHASES OF 
INFLUENZA INFECTION IN MICE 
 
 
Susan Hodgkins 
1
, Young-Je Sim
2
, Kristi Warren
1
, Shibani Naik
1
, Kristina Feye
1
, 
Christina Loiacono
3
, Cathy Hauk
4
, Patricia Murphy
4
, K.J. Yoon
5
, Marian Kohut 
1, 6
 
 
1
Program of Immunobiology, Iowa State University, Ames, Iowa 50011 
2
College of Physical Education, Hanyang University, Seoul, Korea 
3
Pathobiology Laboratory- Pathology Section, National Veterinary Services Laboratories, 
Ames, Iowa 50010 
4
Food Science and Human Nutrition, Iowa State University, Ames, Iowa 50011 
5
Veterinary Diagnostic Laboratory, Iowa State University, Ames, Iowa 50011 
6
Department of Kinesiology, College of Human Sciences, Iowa State University, Ames, 
Iowa 50011 
 
 
Abstract: 
Background:  In influenza infection, the balance between activation of inflammatory and 
antiviral pathways and the appropriate down-regulation of immune response as virus is 
cleared is important in optimal recovery from infection.  Early in infection, a delayed or 
compromised immune response to the virus can result in longer duration of infection or 
greater severity of infection. In the later days of infection, an overactive immune 
response to the virus can cause damage to the lung tissue.  Echinacea is a dietary 
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supplement used to treat upper respiratory infections.  Data suggests that Echinacea 
preparation in water results in immune-stimulatory effects, whereas ethanol preparations 
may result in anti-inflammatory effects.  It was hypothesized that an “immune-
stimulatory” water extract preparation of Echinacea during the early phase of influenza 
infection may promote appropriate antiviral immune activation, and that the 
administration of an ethanol extract preparation during the later phase of infection may 
minimize immunopathology.  
Methods:  In the first set of experiments, BALB/c mice were gavaged with E. 
angustifolia water extract (Eang H2O) days 1-5 of influenza virus infection, followed by 
daily gavage with E. angustifolia ethanol extract (Eang EtOH) until day 9 post-infection 
(p.i.). Inflammation was assessed using cytokine/chemokine analysis of the 
bronchoalveolar lavage fluid (BAL) and serum anti-influenza antibody was measured. In 
a second set of experiments, five different combinations of Echinacea extracts were used 
to identify optimal treatment strategies. Mice were gavaged with either Eang H2O water 
extract or a water vehicle (H2O) until day 5 p.i., followed by treatment with either Eang 
EtOH ethanol extract, E. paradoxa var. paradoxa ethanol extract (Epara EtOH), or EtOH 
vehicle control on day 6 until day 8 p.i.: 1) H2O/EtOH, 2) Eang H2O/EtOH, 3) Eang 
H2O/Eang EtOH, 4) Eang H2O/Eang EtOH, and 5) Eang H2O/Epara EtOH).  The 
pattern of lung gene expression was analyzed using the Database for Annotation, 
Visualization, and Integrated Discovery (DAVID).   
Results:  In the first set of experiments, there was a trend towards a decrease in the viral 
titer of the Eang H2O/Eang EtOH treatment group in the BAL and lung. In BAL fluid, 
the pro-inflammatory cytokines IFN-γ, IL-6, TNF-α, and multiple chemokines (eotaxin, 
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MCP-1, RANTES, LIX, M-CSF, MIP-2) were significantly decreased (p<0.05) in the 
Eang H2O/Eang -treated mice compared to the H2O/EtOH control mice. Serum anti-
influenza IgG was also increased in mice receiving Eang H2O/Eang EtOH treatment. 
In the second set of experiments, five different treatment groups were used to compare 
different combinations of extracts on illness severity and gene expression with a control 
treatment group. No significant change in lesion scores or weight loss was observed in 
any of the treatment groups.  However, the gene expression results demonstrated that the 
Eang H2O/EtOH vehicle treatment group up regulated a greater number of genes 
associated with lymphocyte activation and differentiation, whereas the Eang H2O/Eang 
EtOH and Eang H2O/Epara EtOH groups down-regulated expression of IL-8-like 
chemokines and several genes involved in wound healing. 
Conclusions:  Although the Echinacea treatments did not impact illness severity or lung 
lesion score, a reduction of inflammatory BAL cytokines and chemokines and enhanced 
anti-influenza serum antibody was observed, suggesting that the combination of Eang 
H20 followed by the Eang EtOH may have beneficial immunomodulatory effects that 
could be further optimized. Gene expression revealed different profiles for each 
combination analyzed also suggesting that the combination selected could impact the 
anti-inflammatory effects in the lung, an effect that could potentially reduce 
immunopathology if assessed at a subsequent time point.  
Introduction: 
Influenza is a seasonal infection that impacts the millions of people worldwide 
every year [1].  The ability of this virus to recombine with other strains adds to the high 
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variability in the strains present in circulation in a process termed antigenic shift.  In 
addition, influenza is an RNA virus that has no proofreading mechanism to correct 
transcription errors.  This adds to the mutations and antigenic drift seen in influenza 
seasons.  Because mutations and re-combinations can lead to new viral strains of 
influenza, there is a high rate of treatment resistant strains of influenza.  Currently, the 
seasonal vaccination for influenza is the best strategy for influenza treatment [2,3].  In 
some years, the match between influenza strains in the vaccine is not an optimal match 
with the strains of the virus that are circulating in the population. Anti-viral medications 
are effective in treating influenza; however, several anti-viral medications have already 
been discontinued due to emergence of resistant strains [2,4,5].  Ion channel targeted 
therapies, such as amantadine and rimantadine, are currently no longer effective against 
circulating strains of influenza. [6,7].  Also, influenza viruses have developed resistance 
to neuraminidase, a viral structure protein, inhibitors (oseltamivir) [4].   To combat the 
influenza resistance to these antivirals, one proposed treatment has been to use all three 
antivirals in combination.  Although this approach has shown increased antiviral activity 
compared to each antiviral alone, it is not appropriate for all age groups and physical 
condition of the patients that would benefit the most from antiviral therapy, such as the 
older and immunosuppressed populations [8,9]. 
With decreased anti-viral treatments available and a trend towards more 
alternative medicine approaches, Echinacea has become a popular nutritional supplement 
in the U.S.  Echinacea is a flowering plant that is native to North America, commonly 
harvested for its therapeutic value.  There are nine known species of Echinacea [10].  
Three of these species are used medicinally: E. purpurea, E. angustifolia, and E. pallida.  
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Echinacea can be used as a whole plant, aerial parts, or the roots.  The plant part can be 
then combined with either water or ethanol (tincture).  The solution the plant is prepared 
in dictates the active components present for immune activity due to solubility of the 
compounds.  Water preparations may contain polysaccharides (hydrophilic compounds) 
and caffeic acid derivatives.  Ethanolic preparations consist largely of alkamides 
(lipophilic compounds) and caffeic acid derivatives.  Echinacea extracts have been 
shown to enhance the immune system, promote wound healing, and may have some anti-
viral properties when administered as a water extract.  In addition, some findings suggest 
that Echinacea extracts promotes an anti-inflammatory response when administered as an 
ethanol extract.  Polysaccharides isolated from Echinacea preparations have been shown 
to be immunostimulatory, enhancing innate immunity and cellular adaptive immune 
responses, whereas alkamides have an anti-inflammatory effect decreasing inflammatory 
cytokines [11-15].  With respect to plant species, extracts prepared from E. angustifolia 
or E. purpurea are more widely used and have been evaluated in other studies.   Although 
the E. paradoxa var. paradoxa species has not been traditionally used for medicinal 
purposes, one recent study showed that ketones isolated from E. paradoxa var. paradoxa 
extracts had anti-inflammatory effects on macrophages [16,17].  E. paradoxa ethanol 
extract has also been shown to inhibit the nitric oxide production in macrophages 
stimulated with LPS in vitro [17].  Therefore, although the potential effects of extracts 
prepared from E. paradoxa var. paradoxa species in influenza virus infection remain to 
be determined, findings from other studies demonstrating immunomodulatory effect 
support the possibility that this species may also have some benefits.  
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In influenza, an appropriate balance between the development of a potent immune 
response to clear the virus, and yet limit tissue damage is necessary for optimal recovery 
from the infection.  An insufficient cellular and cytokine response lead to an insufficient 
immune response that results in prolonged recovery time and diminished challenge 
response; whereas, an overactive immune response adds to the immunopathology 
associated with fatal infections through cellular infiltration, inflammation, and fibrosis 
[18,19].  Increased cellular infiltration and hypercytokinemia (in highly pathogenic 
strains) are thought to contribute to lung injury during influenza infection [18]. Given that 
Echinacea appears to have different immunomodulatory properties, it may be possible to 
take advantage of the immunostimulatory properties during the first few days of viral 
infection by administering water extracts, and follow this with ethanol-based extracts that 
may limit inflammation associated tissue damage.  Although extracts derived from E. 
paradoxa have never been tested in an in vivo influenza infection model, previous 
findings have shown E. paradoxa ethanol extract reduced production of inflammatory 
factors including nitric oxide, and it is possible that extracts derived from this species 
may also have some benefit, as decreased nitric oxide production may limit acute lung 
injury [20].  To address these balance issues with influenza, we propose to utilize a 
combination of Echinacea extracts administered at different time points during the 
infection.  
Echinacea has been shown to be immunostimulatory when prepared as a water 
extract and anti-inflammatory when prepared in as an ethanolic extract.  According to the 
hypotheses proposed for these studies, it was predicted that administration of Echinacea 
water extracts during the first several days of infection would results in enhanced innate 
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immune activation including dendritic cell priming and T helper activation culminating in 
increased antibody response.  It was also hypothesized that administration of ethanol 
extracts during the later phase of infection would limit inflammation-associated tissue 
damage by decreasing pro-inflammatory cytokines.  Finally, it was expected that extract 
administration would potentiate gene expression of genes important in stimulating 
adaptive immunity, and would decrease inflammatory-associated gene expression. The 
Echinacea combination treatment is a novel approach to modulating the immune 
response to influenza infection.  
Material and Methods:  
Overall experiment design 
Two sets of experiments were performed.  In the first experiment, the commonly 
used E. angustifolia extract was evaluated.  Mice were gavaged with either an E. 
angustifolia water extract or a water vehicle until day 5 post-infection (p.i.), and then 
with E. angustifolia ethanol extract or ethanol vehicle until termination of the experiment 
at day 9 p.i.  This design allowed us to test whether the combination treatment would 
provide immunostimulatory effects resulting in enhanced T or B cell immunity, and also 
limit the inflammatory-associated tissue damage.  In a second experiment, the same E. 
angustifolia treatment was tested, but this time was compared with extracts obtained from 
E. paradoxa given the recent finding that this species may also have anti-inflammatory 
effects.  Again in these experiments, water extract or vehicle was administered until day 5 
post-infection, followed by ethanol extract or vehicle from day 6 until the termination of 
the experiment at day 8 p.i.  The purpose of the first experiment was to assess 
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“traditional” immune measures: weight loss, viral titer, lung cell populations, and 
cytokine/chemokine expression.  The second experiment was designed to determine the 
effect of different combinations of Echinacea species and extracts on basic illness 
measures and gene expression in response to influenza infection.   
Mice. 
Male BALB/c mice (2 months of age) were purchased from Charles River 
laboratory and allowed to acclimate for several weeks prior to the start of the experiment 
(Experiment 1, n=27; Experiment 2, n=90).  Iowa State University Committee on Animal 
Care approval was obtained for all procedures that were utilized in the care and 
experiments involved with the mice.  The mice were housed separately to accurately 
evaluate illness severity measures.  
Plant and extracts. 
Echinacea angustifolia (Eang) (accessions PI631285, A28187) and Echinacea 
paradoxa var. paradoxa (accession PI633663) plants were grown and extracts at Iowa 
State University.  E. angustifolia (PI631285, A28187) and E. paradoxa (PI633663) were 
harvested in USDA North central regional plant introduction station at Ames, IA (USA).  
Water extracts were prepared by boiling 6 grams of dried root in 100 milliliters (ml) of 
endotoxin free water in an endotoxin free flask, and stirred for 1 hour at room 
temperature.  Extracts were filtered using endotoxin free glass filter paper, centrifuged for 
15 minutes at 10,000 rpm and pellets discarded before freeze drying.  The ethanol 
extracts were prepared from the dried ground root powder which was placed into a 
Whatman 43 × 123-mm cellulose extraction thimble (Whatman International Ltd., 
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Maidstone, UK) with glass wool.  The roots were refluxed with 250 ml of ethanol as an 
organic solvent for 6 hours using a Soxhlet extraction device [12].  The extract was dried 
using an R-114 rotary evaporator (Brinkman Instruments, Westbury, NY) at <30°C under 
reduced pressure and re-suspended in 43% ethanol.  These extracts were stored in 
concentration solution at -20°C until aliquots were made for testing.  Water and ethanol 
extracts were diluted to 14.67 mg/ml of extract for the experiments. 
Gavage treatment and infection.  
Animal feeding needles (20 gauge x 1-1/2, Cadence Science, Staunton, VA) were 
used to gavage the mice.  In the first experiment, there were two treatment groups, 1) E. 
angustifolia (Eang) H2O extract+ Eang EtOH extract, and 2) H2O vehicle+EtOH 
vehicle.  In this first experiment, mice were gavaged either with E. angustifolia (Eang) 
water or vehicle (H2O) solutions starting one day prior to infection and for the first 5 
days following infection.  This treatment was then followed by gavage with either Eang 
EtOH extract or EtOH vehicle for days 6-9 of infection.  Mice were euthanized day 9 
post-infection.  Echinacea extracts were administered at a concentration of 110 mg/kg.  
In the second experiment, there were 6 treatment groups: 1) H2O/EtOH; 2) Eang 
H2O/EtOH; 3) Eang H2O/Eang EtOH; 4) Eang H2O/Epara EtOH; 5) H2O/Eang EtOH; 
6) H2O/Epara EtOH.  Similar to experiment one, mice were gavaged with Eang water 
extract or H2O vehicle one day before infection and during the first 5 days of infection.  
Then, on days 6-8 of infection, mice were gavaged with one of the following solutions:  
Eang EtOH, E. paradoxa var. paradoxa (Epara) ethanol extract, or EtOH only control.  
In experiment two, all mice were euthanized day 8 post-infection (p.i.).  In both 
experiment one and experiment two, mice were infected with 30µl of influenza virus, 
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A/PR/8/34, H1N1 (HA=8192, at 10
10.45
 EID50/ml) via an intranasal route given under 
isoflurane anesthesia.   
Disease severity and viral load. 
Body weight was measured daily as a measure of illness severity post-infection.  
Viral titer in lungs and BAL fluid from mice in the first experiment was assessed by the 
Iowa State University Veterinary Diagnostic Laboratory using primers to detect influenza 
virus by fluorogenic reverse transcription polymerase chain reaction (real-time reverse 
transcription PCR) in the lung tissue samples.  The apical, azygous, cardiac, and 
diaphragmatic lobes were submitted for viral titers from the first experiment only.  
Primers specific to the virus conserved region of the SIV NP gene were used with 
TaqMan® chemistry.  Sequences from GenBank 
(www.ncbi.nlm.nih.gov/Genbank/index.html) and Influenza Sequence database 
(www.flu.lanl.gov) were utilized.  A commercial vendor synthesized the forward primer 
(SIVRTF: 5’-CGGACGAAAAGGCAACGA-3’), reverse primer (SIVRTR: 5’-
CTGCATTGTCTCCGAAGAAATAAG-3’) and a TaqMan® MGB reporter probe FAM 
(6-carboxyfluorescein) and a non-fluorescent quencher (SIVRTP: 5’-6FAM-
CCGATCGTGCCYTC).  Primers were synthesized by Integrated DNA Technologies 
(Coralville, IA), and the probes were synthesized by Applied Biosystems (Foster City, 
CA).  Viral RNA was extracted from 50µl of lung tissue using the Ambion® 
MagMAX™ Viral RNA Isolation kit (Applied Biosystems) and a KingFisher® 96 
magnetic particle processor (Thermo Scientific, Waltham, MA).  H1N1 and H3N2 swine 
influenza viruses and elution buffer were used as positive and negative controls, 
respectively.  The QuantiTect® Probe RT-PCR Kit by Qiagen (Valencia, CA) was used 
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to perform the real time reverse transcription-PCR.  Each reaction consists of 4µl of lung 
sample with 0.4µM (final concentration) of each primer and 0.2µM (final concentration) 
of the probe for a total volume of 20µl for each reaction.  Using a 384 well format and 
the ABI 7900HT Sequence Detection System (Applied Biosystems), reverse transcription 
occurred for 30 minutes at 50°C.  Immediately following reverse transcription, the RT-
PCR was activated with 15 minutes at 95°C.  Activation was followed by 40 cycles of 15 
seconds at 94°C and 60 seconds at 60°C.  To generate a standard curve, a set of influenza 
preparations with known concentrations of viral titers (EID50/ml) were used.  Each 
sample then could be extrapolated by using the standard curve to convert the threshold 
cycle (Ct) value to a viral titer [21].      
Lung pathology. 
Lung tissue from left cranial lobe from mice in the second set of experiments was 
submitted to the ISU Veterinary Diagnostic Laboratory for lesion scoring.  Lungs were 
immersion-fixed in 10% buffered formalin, processed, sectioned, and stained with 
hematoxylin and eosin for histopathological examination.  The remaining lung lobes were 
utilized for RNA extraction.  The tissues were embedded in paraffin wax and sectioned at 
5-µm thickness.  These sections were then stained with hematoxylin and eosin (H&E), 
and examined by light microscopy.  Lungs were examined for bronchiolar epithelial 
changes.  These changes included attenuation, proliferation, degeneration, and necrosis.  
Severity of peribronchiolar and alveolar inflammation were also evaluated.  Lungs were 
scored from 0 to 3 to reflect an estimate of the percentage of lung tissue containing lesion 
and the severity of lesions.  The lung sections were scored according to the following 
criteria: 0, no significant lesions or minimal epithelial cells change in <25% of the lung 
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tissue; 1, mild to moderate epithelial cell changes and interstitial pneumonia in ~25%–
50% of the tissue; 2, moderate epithelial cell changes and moderate interstitial pneumonia 
in ~50%–75% of the tissue; and 3, significant epithelial cell changes and moderate to 
severe interstitial to bronchointerstitial pneumonia in ~75%–100% of the tissue [21].  
One pathologist performed the scoring and remained blinded to the treatment groups 
during analysis.   
qRT-PCR. 
The lung (for experiment 1 the left lobe and in experiment two the remainder of 
the lung) was homogenized with a glass grinder, and RNA was extracted using a TRIzol® 
extraction method utilizing 1 ml of TRIzol® per 100 mg of lung tissue.  Grinders were 
washed with 1 ml of TRIzol® after each lung.  Samples were kept on ice until all lungs 
were processed and allowed to come to room temperature before proceeding to phase 
separation.  Phase separation was conducted using 200 μl of chloroform per 1 ml of 
TRIzol®.  Samples were vortexed for at least 30 seconds and centrifuged for 15 minutes 
at 4°C at 12,000 x g.  The colorless aqueous phase was removed and used for RNA 
isolation.  One ml of the aqueous phase was combined with 400 μl of COLD isopropanol 
in a 1.5 ml Eppendorf tube.  After vortexing, the samples were centrifuged at room temp 
for 15 minutes at 12,000 x g.  The RNA pellet was washed using 200 μl of 75% ethanol 
and centrifuged at room temp for 15 minutes.  Ethanol was removed without disrupting 
the pellet and allowed to air dry.  Pellets were re-suspended in 100 μl of RNAse free 
water.  Using the Qiagen® RNeasy® Mini prep kit, following the protocol provided by 
the company for animal tissues, and the on-column DNase digestion optional step, the 
RNA was prepared and then converted to complimentary DNA (cDNA) using the RT2 
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first strand kit by Qiagen®.  The cDNA was then analyzed in the Qiagen® qRT-PCR 
microarray for inflammatory cytokines/chemokines and T and B cell activation pathways.   
The T and B cell activation array kit was used for the first set of experiments and 
included mice from the following treatment groups: 1) H2O/EtOH (n=3), and 2) Eang 
H2O/Eang EtOH (n=3).  In the second set of experiments, both the T and B cell 
activation array and  the Inflammatory cytokine and chemokine array kits were used with 
the following treatment groups: 1) H2O/EtOH ( n= 6), 2) Eang H2O/EtOH( n=5),  3) 
Eang H2O/Eang EtOH (n= 7), 4) Eang H2O/Epara EtOH  (n=6) , 5) uninfected (n=3). 
The H2O/Eang EtOH and H2O/Epara EtOH groups were not analyzed for gene 
expression.     
Flow cytometry. 
BAL cells were harvested by centrifugation at 1200 revolutions per minute (rpm) 
for 10 minutes and re-suspended in 250 µl of BD stain buffer (PBS- azide+0.1%BSA, 
BD Biosciences).  Samples were treated with 2 mls of ice cold 0.015M ammonium 
chloride red blood cell lysing agent for 10 minutes, washed in BSA and re-suspended in 
250 µl BSA.  Cell counts were obtained using the Z™ series Coulter Counter® 
(Beckman-Coulter, Inc., Brea, CA).  Cell count for each sample was determined and 
adjusted to a range from 1x10
5
 and 1x10
6 
per ml.  Samples less than 1x10
5
 cells per ml 
were combined with another sample from the same treatment group.  For flow cytometry, 
each sample was treated with 10 µl of Fc block 1:10 dilution (0.5mg/ml, BD Biosciences) 
for 10 minutes.  Cells were stained with PE anti-mouse GR-1, FITC anti-mouse CD11b, 
and PE-Cy7 anti-mouse CD45.  Cell populations were defined as follows: neutrophils 
(PMNs) defined as CD45+CD11b+Gr1+, high side scatter SSC+; inflammatory 
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monocytes (i-Monos) defined as CD45+, CD11b+, Gr1+;  constitutive monocytes 
(cMonos) defined as CD45+, CD11b+, Gr1-, low side scatter;  and lymphocytes defined 
as CD45+, CD11b-, Gr1-, low side scatter).  Samples were mixed and incubated for 30 
minutes at 4°C protected from light.  After incubation, 1 ml of BD stain buffer was added 
to each sample.  The samples were centrifuged at 1200 rpm for 5 minutes at 2-4°C.  
Supernatant was removed by vacuum suction and 2 more wash steps were performed 
using 1 ml of BD stain buffer for each wash.  After the final wash step, supernatants were 
removed, cells were gently mixed by placing the plate on a vortex, and 150 µl of diluted 
BD™ stabilizing fixative (BD Biosciences) was added to each sample.  Samples were 
then transferred to 5 ml BD Falcon™ tubes and stored at 4°C until analyzed on a BD 
FACSCanto™ Flow Cytometer (BD, Franklin Lakes, New Jersey) by Iowa State 
University Flow Cytometry Facility.             
Multiplex Assay.  
Bronchoalveolar lavage fluid (BAL) was collected to measure 
cytokine/chemokine concentration.  The BAL was separated into supernatant and cellular 
portions by centrifugation at 1200 rpm for 10 minutes.  The Milliplex® microsphere 
(EMD Millipore Corporation, Billerica, MA) assay was used to analyze BAL supernatant 
for expression of different cytokines and chemokines that could be present in the lung of 
the infected mice.  The preparation of the plate was performed according to 
manufacturer’s instructions.  The plate was read using Bio-plex® Suspension Array 
System (Bio-Rad laboratories, Inc., Hercules, CA) instrumentation.  Data was exported 
from Bio-plex® Manager to Microsoft® Excel (Microsoft, Redmond, WA) for further 
analysis.   
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Serum antibody. 
Blood was collected by cardiac puncture and centrifuged at 600 x g for 15 
minutes.  Sera were stored at -80 °C until tested by indirect ELISA for anti-influenza IgG 
(H&L).  ELISA plates (Immulon, Alexandria, VA) were coated with influenza virus 
A/PR/8/34 diluted in carbonate coating buffer (pH = 9.6) at a concentration of 200 
HAU/ml for anti-influenza-IgG (H&L) and incubated overnight at 4 °C.  After blocking 
with 0.1% BSA in saline solution at 37°C for one hour, plates were washed three times 
with PBS/0.05% Tween 20.  Three washes with PBS/0.05% Tween 20 were utilized 
between each step.  Samples were tested in duplicate.  After 3 hours of incubation at 
37°C, alkaline phosphatase-conjugated goat anti-mouse IgG (H&L) was added.  After 
overnight incubation at 4°C, phosphatase substrate (Sigma-Aldrich, St. Louis, MO) was 
added and incubated at room temperature for 20 minutes. Optical density (OD) of each 
well was measured using a microtitration plate reader (BMG FLUOstar Galaxy) at a 405 
nm wavelength.   
Analysis. 
Statistical analysis was performed with an analysis of variance (ANOVA) with 
post hoc least significant difference (LSD), and independent student t-test using SPSS® 
software version 20 (IBM Corporation, Armonk, New York).  For body weight analysis, 
a repeated measures ANOVA was used.  The independent student t-test was used to 
evaluate the outcome measures: BAL cytokines and chemokines, BAL immune cell 
subpopulations, as well as viral load in the lungs.  SABiosciences™ microarrays were 
analyzed: T and B cell activation array, House-keeping gene (HSK) Hsp90ab1, 
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Inflammatory Cytokines and Chemokines, HKG-Hsp90ab1.  Results were obtained using 
SABiosciences™ Web-based analysis software, RT2 Profiler PCR Array Data Analysis 
version 3.5.  Housekeeping gene selection was based on the automatic selection in the 
Web-based software analysis.  This gene was selected because it was consistently <1 Ct 
change between all the groups analyzed.  The Database for Annotation, Visualization, 
and Integrated Discovery (DAVID) was utilized for data-mining and functional 
annotation and analysis of SABiosciences™ Array data.  Extracts were evaluated for 
gene fold changes compared to uninfected mice and then again to mice treated with 
vehicle control in separate analysis.  The fold change data exported from SABiosciences 
Web based software analysis was imported into DAVID and analyzed against a murine 
background with classification stringency (default setting).  Statistical threshold for 
selection of fold changes was x>1.5 for up regulation and <0.667 for down regulation. 
Enrichment score for each cluster reported was selected as > 1.3 which is equal to a 
geometric mean of all the enrichment p-values <0.05 in the cluster (EASE score).  EASE 
score (p-value) is used to evaluate the significant of a gene-term enrichment for each 
gene annotation.   For a gene functional classification cluster, the enrichment score is a 
geometric mean of all the EASE scores in the cluster.  Enrichment score for each cluster 
was selected as > 1.3 which is equal to a geometric mean of all the enrichment p-values 
and represents a p-value<0.05.   Bonefferoni values corrected for multiple testing effects 
which is a conservative approach to data mining which is utilized to prevent false 
discovery rates in large gene backgrounds that return lower EASE scores and can result 
in false interpretation of the data.  In this study, a Bonferroni value of <0.10 was 
considered significant because of the size of the gene input list.  This study submitted a 
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pool of roughly 170 genes.  DAVID gene input lists range from 1-10 genes to much 
larger gene lists and whole genomic sequences [22].     
Results: 
Daily body weight was used to assess illness severity, and in the first experiment, 
there were no significant differences in weight loss between the  H2O/EtOH control 
treatment and Eang H2O/Eang EtOH extract treatment (Figure 1), although the daily 
weight loss did differ from uninfected mice as expected (significant interaction, p < 0.05).  
In the second experiment, the six treatment groups including a vehicle control were 
compared to an uninfected control, (Figure 2).  With respect to Experiment two, the 
results from a repeated-measures-ANOVA showed a significant treatment by time 
interaction such that the daily weight loss for the infection period was not the same across 
groups (p< 0.05).  However, in follow-up post hoc analyses, only weight loss in the 
uninfected mice was significantly different than all other groups (as expected) with no 
significant differences observed between treatments.  However, there were no differences 
in the daily weight loss between any of the Echinacea treatment groups and vehicle 
treatment suggesting that Echinacea treatment did not alter the severity of infection as 
measured by weight loss during the eight day infection period.  If weight loss was 
examined only during the early phase combining the same treatment groups together (all 
Eang treated mice compared to all vehicle treated mice), no significant effects of extract 
were found.  
In experiment 1, viral titer was evaluated as another measure of illness severity.  
Although at day 9 p.i., viral clearance has already begun and may not reflect peak viral 
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loads observed earlier during the infection.  All infected mice had detectable virus in the 
lungs and BAL at this time point.  Mice treated with Eang H2O/Eang EtOH showed a 
trend towards reduced viral load present in the BAL fluid (p=0.08) compared to the mice 
treated with the vehicle control.  The lung titer results were in the same direction as the 
BAL results, with a trend towards a decrease in viral titer with mice that received the 
Echinacea combination (p=0.08) (Figure 3).  
In the second set of experiments, lung tissue was used to examine the extent of 
histopathology and to examine gene expression, and therefore tissue was not available to 
assess viral load. In this second set of experiments, lesion scores were determined by the 
size and extent of the pathology (Figure 4a).  A lung index was determined by 
multiplying the lesion score by the percent of the lung involved (Figure 4b).   No 
significant differences in lesion scoring or lung index were observed between any of the 
Echinacea treated groups compared to the mice treated with vehicle control (H2O/EtOH).  
The BAL cell populations were compared between Eang H2O/Eang EtOH treated 
mice and H2O/EtOH on day 9 p.i. (experiment 1).  The total number of cells was not 
significantly different between groups (Figure 5a).  Cell populations were analyzed for 
overall cell count (Figure 5b) and percent of total cell count (Figure 5c).  The total 
number of each cell population and the percentage of each population were not different 
between the Eang H2O/Eang EtOH treated mice and the H2O/EtOH treated mice, 
suggesting that at the time point measured, Echinacea combination treatment of the mice 
did not affect cell infiltration.  It is possible that Eang H2O/Eang EtOH treatment alters 
cellular populations at an early phase of treatment and/or alters a population that was not 
isolated in this study.   
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To further analyze the impact of Eang H2O/Eang EtOH treatment, cytokine and 
chemokine concentration in the BAL fluid was analyzed from mice euthanized on day 9 
p.i. (experiment 1) (Figure 6a-f).  To establish the effect of infection on the concentration 
of cytokines and chemokines, infected mice from either treatment group are compared 
with uninfected mice in Table 1.  It is apparent that infection results in significant 
increases in multiple cytokines and chemokines. To evaluate the effect of the extract 
combination on the cytokine/chemokine levels present in the lung at day 9, the Eang 
H2O/Eang EtOH treatment group was compared with the vehicle control.   The cytokines 
IFN-γ, IL-6, and TNF-α were significantly decreased (p<0.05), with a trend towards a 
decrease in leukemia inhibitory factor (LIF) (p=0.06) and IL-12p70 (p=0.10) in the BAL 
of treated mice compared to the BAL of H2O/EtOH control mice.  In addition, the 
concentration of multiple chemokines was significantly decreased (p<0.05) in Eang 
H2O/Eang EtOH treated mice including eotaxin, MCP-1, RANTES, LIX, M-CSF, and 
MIP-2.  VEGF, a protein involved in angiogenesis and cell migration, was also decreased 
(p<0.05) in the BAL of mice treated with the Eang H2O/Eang EtOH combination.   
To determine the effect of Eang H2O/Eang EtOH on the adaptive immunity, 
serum from the mice was analyzed for anti-influenza specific IgG levels.  Eang 
H2O/Eang EtOH treated mice demonstrated a trend towards greater anti-influenza 
specific IgG level (Figure 7) compared to the H2O/EtOH treated mice (p=0.06).   
To further analyze the effects of the Echinacea combination treatments on the 
immune response to influenza, lung gene expression data was evaluated using 
SuperArray Biosciences analysis.  Genes associated with cytokines, chemokines, and T 
and B cell activation were both up-regulated and down regulated with infection at day 8.  
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Relative to vehicle control, the Echinacea combination in general increased genes related 
to T and B cell activation and decreased the cytokine/chemokine gene fold regulation 
(Figures 8 and 9).   
To further understand the gene regulation in the lungs of mice treated with 
Echinacea combinations, the data-mining tool DAVID was used to determine the effect 
of treatment with Echinacea combination treatments compared to the H2O/EtOH control 
(Appendix).  DAVID imports functional data from a variety of databases.  The gene 
ontology (GO) was reported for the cluster unless otherwise specified in the cluster.  
Genes lists for up regulated and down regulated genes relative to infection are shown in 
Table 2 and 3; gene lists relative to vehicle control are shown in Table 4 and Table 5. 
For experiment 1 (day 9 p.i), DAVID analysis returned only 2 genes with 
regulation changes in the Eang H2O/Eang EtOH group compared to H2O/EtOH control 
(Table 3 and Table 5).  Gene clustering is not performed in groups less than 6.  However, 
the Ccr8 (Chemokine (C-C) receptor 8 gene) was up regulated (p<0.05) and the CD3g 
(CD3 antigen, gamma polypeptide gene) was down regulated (p<0.05).   
In experiment 2 (day 8 p.i.), the gene regulation fold change results varied by 
species of Echinacea used for treatment.  Interestingly, the Eang H2O/EtOH treatment 
altered expression of more genes than the other Echinacea combinations (Figure 10 and 
11).  DAVID analysis returned 25 gene that were up regulated (Figure 10b and Table 3) 
and 7 genes that were down regulated with Eang H2O/EtOH  (Figure 11b and Table 5) 
treatment compared to H2O/EtOH controls.  For Eang H2O/EtOH up regulation, DAVID 
returned 10 annotations clusters with enrichment scores >1.3.  Gene ontology (GO term) 
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evaluation suggested that Eang H2O/EtOH treatment enhanced cellular proliferation, 
differentiation of T cells, activation of the T cell receptor (TCR) through molecules Lck 
and Fyn, cell to cell communication and expression of adhesion molecules through 
external cell stimulation and enhanced phosphorylation.     
For Eang H2O/EtOH down regulation, DAVID analysis returned 4 gene 
annotation clusters >1.3 (Appendix).  Genes that were down regulated with fold 
enrichment were CRP (C-reactive protein), CCL4 (MIP-1β), CCL9 (chemokine ligand 9), 
CCL19 (MIP-3β), CCL20 (MIP-3a), TNF (tumor necrosis factor), and IL1f8 (IL-1 family 
8).   GO terms data suggested that Eang H2O/EtOH down regulated the 
cytokine/chemokine activity, signaling, and IL-8-like chemokines, and decreased the 
inflammatory response to damage or infection. 
When Eang H2O treatment was instead followed by Eang EtOH treatment, a 
different set of genes were altered.  Eang H2O/Eang EtOH treatment up regulated 3 
genes compared to H2O/EtOH controls (Figure 9b and Table 4): PRLR (Prolactin 
receptor), IL11 (Interleukin 11), and Impdh1 (nosine 5'-phosphate dehydrogenase 1).  Six 
genes were down regulated with Eang H2O/Eang EtOH compared to H2O/EtOH controls 
(Figure 9b and Table 5): CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES), CCL8 
(MCP-2), TNF (tumor necrosis factor), and Tnfsf14 (tumor necrosis factor superfamily 
member 14).  DAVID analysis returned 2 annotation clusters >1.3 (Appendix).  
Evaluation of the GO term data suggest that Eang H2O/Eang EtOH treatment down-
regulated genes involved with the inflammatory response, defense response, response to 
wounding , chemotaxis, and IL-8-like chemokines.     
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The results also suggested that administering an ethanol extract from a different 
species (E. paradoxa rather than E. angustifolia) during day 6-8 post-infection again 
altered the pattern of gene expression.  Eang H2O/Epara EtOH treatment up regulated 10 
genes (Figure 10b and Table 3) and down regulated no genes compared to H2O/EtOH 
controls (Figure 11b and Table 5): PRLR (Prolactin receptor), Clcf1 (cardiotropin-like 
cytokine factor 1), Dock2 (Dedicator of cyto-kinesis 2), Ptprc (B220, Protein tyrosine 
phosphatase, receptor type, C), Vav1 (Vav1 Oncogene), IL5ra (IL-5 receptor alpha), 
Pik3cd (Phosphatidylinositol 3-kinase catalytic delta polypeptide), IL-27, Hdac5 (Histone 
deacetylase 5), and IL-11. DAVID analysis returned 2 annotation clusters >1.3 
(Appendix).  The evaluation of the GO terms data suggest that treatment with Eang 
H2O/Epara EtOH up regulated genes involved in the activation, differentiation of 
lymphocytes, leukocytes, and B-cells and up regulated genes involved Fcγ receptor- 
mediated phagocytosis.      
The effect of day of post-infection on the gene expression is shown in figure 12.  
Genes up-regulated on day 8 were not identical to those up regulated on day 9 as 
expected with 63 genes up-regulated (Table 2) in both day 8 and day 9 groups treated 
with Eang H2O/Eang EtOH (Figure 12a).  Similarly, on both day 8 and day9, both 
groups had 7 genes down regulated compared to uninfected mice (Figure 12b and Table 
4); however, only 4 of these genes were shared between the days: Cr2, CXCR5, Ms4a1, 
and Wwp1.  On day 8, CCL17, CD81, and Hdac5 were down regulated, and on day 9, the 
genes Jag2, IL4, and Hdac7 were down-regulated with Eang H2O/Eang EtOH treatment 
compared to the uninfected controls.  Mice treated with Eang H2O/Eang EtOH to day 8 
and day 9 compared to H2O/EtOH vehicle control demonstrated different genes up 
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regulated and down regulated with no gene regulation shared between the days when 
compared to the vehicle control (Table 3 and Table 5).   
Discussion:  
We have shown that although Echinacea combination treatment does not decrease 
the illness severity measures analyzed (weight loss and lesion scores),  Eang H2O extract 
administered day 1-5 of influenza infection  followed by Eang EtOH extract on days 6-9 
of infection resulted in  decreased BAL concentrations of cytokines that may have 
inflammatory effects (IL-6, IFN-γ and TNF-α).  It was interesting to observe that anti-
influenza IgG tended to be greater in the Echinacea treated mice, and this may reflect a 
shift away from a Th1 driven cell mediated immunity response (reduced IFN-γ and 
TNFα).  The BAL concentration of several chemokines also tended to be decreased with 
Echinacea treatment compared to vehicle treatment, although this did not translate to 
altered numbers of specific cell subpopulations in the BAL.  However, an analysis of cell 
populations at multiple time points would better detect changes in time that may have 
occurred with Echinacea extracts. In addition to these immunomodulatory changes,  
Eang H2O/Eang EtOH treatment resulted in up regulation of genes associated with 
cellular differentiation, activation, and proliferation of lymphocytes, monocytes, T cells 
and B cells, and down regulation of inflammatory cytokine/chemokine genes, and 
enhanced anti-influenza specific IgG production.   
While it was hypothesized that treatment with a combination of Echinacea water 
and Echinacea ethanol extracts would decrease lung lesions seen in influenza mice at day 
8 p.i., no significant difference was observed.  In the Eang H2O/EtOH and Eang 
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H2O/Eang EtOH treatment, down regulation of genes associated with response to wound 
healing could explain the lack of change in lesion score and lung index; however, no 
change was also seen in the Eang H2O/Epara EtOH lesion score which did not have 
down-regulation in the wound healing associated genes.  A possible explanation for this 
is the time point of this experiment being too early to detect visual changes between Eang 
H2O/Epara EtOH.  With the down regulated wound healing response genes in Eang 
H2O/EtOH and Eang H2O/Eang EtOH, it is possible that no changes in lesion scores 
would be evident if down regulation of wound healing genes translates into a downstream 
effect of delayed wound healing.   Other studies have shown that Echinacea pallida 
ethanol extract enhanced stress related wound healing in mice [16].  This punctuates the 
interspecies functional variability of Echinacea supplements.   
Increased neutrophils present in the lung after injury or infection has been shown 
to promote acute lung injury and acute respiratory distress syndrome [20].  In severe 
cases of influenza infection, acute lung injury and secondary bacterial infections increase 
mortality.  The down regulation of the IL-8-like chemokines genes (CCL3, CCL4, CCL5, 
CCL8) that are encoded for the chemokines involved in neutrophil recruitment to the 
lung at day 8, and the decrease in KC, LIX, RANTES, and MCP-1 in the BAL at day 9 
could promote the decrease in acute lung injury in a severe influenza infection.  The 
chemokines could be decreased in the lung at day 9 p.i. due to decreased gene expression 
of IL-8-like chemokine genes and down regulated wound healing response seen in the 
PCR data at day 8 during infection.  A decrease in MCP-1 has been associated with 
delayed wound healing with decreased re-epithelialization [23].  However, increased 
MCP-1 has been shown to increase pulmonary fibrosis [24].  This suggests a role for 
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Echinacea in balancing the protective wound healing mechanisms in the lung.  Lung 
injury resolution requires a balance of inflammation and fibroproliferation [25].  In the 
first experiment, LIX, MIP-2 and VEGF were decreased in the lung at day 9 in the mice 
treated with the Echinacea combination.  LIX (CXCL5) and MIP-2 are neutrophil 
chemoattractants and VEGF is involved in wound healing.  CXCL5 has been shown to be 
involved in lung inflammation in mice [26].  While it was hypothesized that the 
Echinacea extract combination would decrease the severity in lung lesions, the data 
presented in this study suggest the decrease in wound healing (based on gene expression, 
not actual histopathological differences).  However, the down regulation in IL-8-like 
chemokine genes at day 8 could decrease the KC, RANTES, LIX, and MIP-2 thereby 
decreasing neutrophil recruitment, and prevent acute lung injury in a severe infection 
ultimately leading to decreased lesion scores and decreased neutrophil recruitment at a 
later time point.   
Decreased production of IFN-γ, IL-6, TNFα, MCP-1 and RANTES in the lung 
detected in the BAL of Echinacea combination treated mice at day 9 could provide 
protection against lung inflammation.  MCP-1 and RANTES have been shown to be 
involved in inflammation and the cellular infiltration of leukocytes into the lung in 
asthma [27].  The decrease in inflammation seen in both the BAL cytokine/chemokine 
data and lung gene regulation did not translate into decreased lung lesions at day 8 p.i.  
The time point selected in this study may have been too early to detect significant 
changes in the lung lesion scores.   
The Eang H2O/Epara EtOH extract up regulated genes associated with 
lymphocyte/leukocyte activation and differentiation, B cell activation and FcγR-mediated 
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phagocytosis.  Antigen-specific cytotoxic CD8 cells are important in influenza clearance, 
and gene expression of CD8 was observed.   Increased T helper cell activation would 
provide enhancement to the humoral immunity and enhance influenza specific antibody 
production.  The prolactin receptor (PRLR) signaling occurs through mechanisms similar 
to TCR signaling pathways by utilizing Fyn and Vav1 [28].  PRLR has been shown to be 
constitutively expressed on Treg populations [29] and prolactin signaling increases CD4 
T-bet and Th1 response [30].  Echinacea has been shown to inhibit prolactin levels in 
serum [31].  However, it is possible that a compound in the extract modulates immune 
function through the PRLR.  Future studies could investigate the role of PRLR immune 
signaling with Echinacea.   
Antibodies in influenza both aid in the antibody-mediated neutralization and 
increased macrophage phagocytosis.  In the Eang H2O/Epara EtOH treatment group, 
DAVID analysis suggested an up-regulation in the genes associated with FcγR-mediated 
phagocytosis.  Although FcγR-mediated phagocytosis is associated with bacterial and 
fungal infections, a study utilizing FcγR knockout mice demonstrated that FcγR mediated 
phagocytosis was important for influenza viral clearance in vaccinated mice with 
increased mortality in the FcγR-/-mice upon secondary challenge with influenza [32].  
Increased antibody mediated alveolar macrophage phagocytosis of influenza virus was 
also observed in a phagocytic assay [32].  Another study demonstrated that the 
impairment of macrophage at late phase of infection resulted in greater susceptibility to 
secondary bacterial infections [33].  Enhanced macrophage phagocytosis has been shown 
with Echinacea.  Polysaccharides isolated from botanical extracts have demonstrated a 
variety of effects on macrophage activation with enhanced phagocytosis and NO 
127 
 
production and decreased inflammatory cytokine production [34,35].  Alveolar 
macrophage enhanced phagocytosis was also shown in chicoric acid, polysaccharides, 
and alkamide fractions of Echinacea purpurea [36].  Although in our study macrophage 
cellular counts were not changed between the Eang H2O/Epara EtOH compared to and 
H2O/EtOH treatment, it is still feasible that the overall activation of the macrophages 
could potentially be enhanced.  The Eang H2O/Epara EtOH combination treatment could 
potentially promote clearance of virus and cellular debris through enhanced FcγR 
mediated phagocytosis in macrophages.     
Echinacea water extracts have an immunostimulatory property that is conferred 
largely through hydrophilic polysaccharides that are present in the water based 
preparations.  These polysaccharides have been shown to stimulate the innate immune 
system.   In one study human white blood cells were harvested and stimulated using 
several water Echinacea polysaccharide preparations and were found to be stimulated in 
the presence of the extract compared to media treatment [15].  Echinacea water-based 
extracts have been shown to increase number and functions of NK cells and activation 
and maturation of DCs [13,14].   Activation of NK cells and maturation of DCs are 
necessary for viral clearance and the recovery from influenza infection.  Echinacea 
extracts have been shown to have anti-viral properties in vitro, but have not been 
demonstrated to have clearly anti-viral effect in an in vivo model.  Polysaccharides and 
chicoric acid are potential compounds present in Echinacea extracts that have been 
identified as demonstrating an anti-viral effect.  It is possible that the early treatment with 
Eang H2O based extract polysaccharides or chicoric acid could be responsible for the 
trend in viral titer reduction that was observed in the Eang H2O/Eang EtOH treated mice 
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compared to the H2O/EtOH treated mice.  Arabinogalactan is one of the polysaccharides 
that have been isolated from Echinacea water preparations.  In a study with 
arabinogalactan isolated from Larch tree and not Echinacea, increased levels of IgG 
antibodies to Streptococcus pneumonia were demonstrated in the serum of humans [37].  
Arabinogalactan in the Eang H2O preparation used in this study could be responsible for 
the trend towards an increase in anti-influenza specific antibody seen in the Eang 
H2O/Eang EtOH treated mice compared to the H2O/EtOH control mice.  Further study 
with arabinogalactan isolated from Eang would be required to confirm this hypothesis.   
Another possible explanation for the decrease in viral titer is the modulation of 
the cellular adaptive immune pathways.  An increase in the plasmacytoid dendritic cells 
(pDC) population and enhancement through cellular adaptive immune pathways would 
be another possible explanation for the trend towards an increase in anti-influenza 
antibody production by the Eang H2O/Eang EtOH treated mice through pDC dependent 
B cell activation.  Mucosal pDCs produce type I IFN and have been shown to aid in viral 
clearance through pDC-dependent antibody production [38].  Further study of the pDC 
production of type I IFN from mice treated with Echinacea would be needed to determine 
if this mechanism would be responsible for the reduction in viral titer.              
Alkamides from Echinacea plants have been shown to be responsible for the anti-
inflammatory properties associated with Echinacea extracts.  Alkamides are the primary 
active constituent in ethanol-based extracts of Echinacea.  A decrease in inflammatory 
cytokines in this study was shown in both the BAL of mice treated with Eang H2O/Eang 
EtOH and in the gene expression profiles reflecting down-regulation in several 
inflammatory cytokine/chemokines.  This gene down regulation and decrease in 
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inflammatory cytokines did not translate into decreased lesion scores or in decreases in 
BAL cell populations.  One possible explanation for this observation is that the cell 
populations that are decreasing in the lung were not specifically analyzed, such as NK 
cells or T cell subtypes.  NK cells and cytotoxic T-cells are essential for viral clearance 
but can also add to the immunopathology of influenza infection, particularly NK cells 
that have been shown to enhance lung inflammation [39].  Echinacea alkamides have 
been shown to inhibit inflammatory cytokine production in RAW264.7 murine 
macrophages in response to LPS and influenza A/PR/8/34 [40,41].  TNF-α was shown to 
be decreased in a dose dependent manner [41].  IL-10 and KC were decreased in the 
lungs and IFN-γ was decreased in the serum of C57BL/6 mice infected with influenza 
A/WSN/33 when treated with polysaccharide extracts from E. purpurea [42].  Similar 
decreases in cytokines and chemokines were observed in E. angustifolia and E. pallida 
ethanolic extracts administered in vivo to BALB/c mice which demonstrated decreased 
TNF-α and IL-1β with increased IL-10 in splenocytes stimulated in vitro after 7 days of 
treatment [12].  Caffeic acid derivatives have also been shown to have anti-inflammatory 
effects, but the effects are dampened compared to the anti-inflammatory effects seen with 
the alkamide fractions [40].  Caffeic acid derivatives were shown to increase activation of 
iDCs through increased CD83 expression in an E. purpurea butanol extract applied to 
DCs cultured in vitro [43].  The decrease in anti-inflammatory cytokines is not surprising 
in this study; however, the lack of change in the cellular populations was unexpected.  
Based on the cellular populations tested, we expected a decrease in neutrophils and 
macrophages.  However, with decreased RANTES and eotaxin the cell populations 
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decreased in response to the cytokine profile may be NKs, DCs, eosinophils, and 
subtypes of T-cells.   
There have been some questions surrounding the bioavailability of the active 
constituents in Echinacea extract preparations.  Alkamides and caffeic acid have been 
demonstrated to be readily absorbed and bioavailable through CACO-2 monolayers and 
human studies evaluating the absorption in serum samples and through excretion [44,45].  
Other questions surrounding Echinacea preparations include the anti-inflammatory effect 
due to the ethanol and immune-stimulatory effect due to endotoxins [46].  In this study, 
we used extracts prepared in water free of endotoxins and controlled for ethanol effect by 
utilizing the H2O/EtOH control treatment group which included the same concentration 
of ethanol that was present in the Echinacea extracts.  Invariably, endotoxin is present in 
Echinacea root preparations, particularly those prepared in water, such as a tea 
preparation [46,47].  Typical endotoxin mediated immune responses include, increases in 
toll-like receptors, production of inflammatory factors, and macrophage activation.  
These hallmarks were not observed at the time point measured in this study.  However, it 
will be essential determine whether endotoxin was present in the extracts, and if so, at 
what concentration.  While this study did not evaluate the effect of the combination of 
extracts on the immune response uninfected mice, other studies have reported a general 
immunostimulatory response.  Several studies have analyzed the components found in 
Echinacea extracts; however, the mechanisms behind the complex complete extract and 
interaction of constituents remains elusive.  Studies utilizing fractions of extracts could 
be beneficial in extrapolating these mechanisms.   
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This study is the first to explore the utilization of combinations of Echinacea 
treatments to enhance the immune response and resolve influenza infections.  To our 
knowledge, it is also the first Echinacea study to utilize DAVID analysis of immune gene 
regulation in influenza infection.  The different expression profiles from the Echinacea 
treatment groups revealed suggest that the combination selected could greatly impact the 
anti-inflammatory effects in the lung.  No significant treatment effects were observed 
with respect to the disease severity measures, body weight, or lesion scores.  However, 
there was a trend towards reduced viral load in the mice treated with the Echinacea 
combination at day 9.  Although, the immunomodulatory effect is determined by 
Echinacea species utilized, the data in this study suggest the possibility of enhancing the 
innate and cellular immune response particularly macrophage phagocytosis, lymphocyte 
activation and differentiation, along with increased antibody production by utilizing an 
Echinacea water extract at the early phase of infection.  Also, the data in this study 
support a decrease in pro-inflammatory cytokines, chemokines responsible for neutrophil 
recruitment, and down-regulation of genes associated with the wound response and 
neutrophil recruitment during later phases of infection using an anti-inflammatory 
Echinacea ethanol extract during the late phase of influenza infection.    
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Figures for Chapter III. 
Figure 1. 
 
 
Figure 1.  Experiment 1 Illness Severity Measure: Daily weights post infection with 
A/PR/8/34.  Mice were gavaged with either Echinacea angustifolia (Eang) water extract 
or H2O control for one day prior to intranasal infection with 0.001 HAU A/PR/8/34 
through day 5p.i.  Mice were then gavaged with either Eang ethanol extract (instead of 
Eang water) or EtOH control (instead of H2O) until day 9p.i.  There was no significant 
difference between the Eang H2O/Eang EtOH treatment mice compared to the 
H2O/EtOH control mice.  Measures are given as means +/- standard error of the mean 
(SEM).  n=3 uninfected; n=6 H2O/EtOH; n=9 Eang H2O/Eang EtOH. 
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Figure 2. 
 
Figure 2.  Experiment 2 Illness Severity Measure: Daily weights post infection with 
A/PR/8/34.  Mice were gavaged with either Echinacea angustifolia (Eang) water extract 
or H2O control for one day prior to intranasal infection with A/PR/8/34 through day 5 p.i.  
Mice were then gavaged with one of the Echinacea ethanol extracts (Eang-E. 
angustifolia or Epara-E. paradoxa var. paradoxa) or EtOH control until day 8 p.i.  
Measures are given as means +/-SEM.  n=4 uninfected; n=10 H2O/EtOH; n=10 
H2O/Eang EtOH; n=12 H2O/Epara EtOH; n=8 Eang H2O/EtOH; n=9 Eang H2O/Eang 
EtOH; n=8 Eang H2O/Epara EtOH. 
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Figure 3. 
  
Figure 3.  Lung Viral titers of influenza assessed by polymerase chain reaction in 
mice infected with A/PR/8/34 at 9 days p.i. and treated with a combination of Eang 
extracts or control.  BALB/c mice were infected with A/PR/8/34 intranasal and treated 
with either H2O/EtOH or Eang H2O/Eang EtOH.  Mice treated with Eang water for 5 
days p.i. followed by Eang EtOH from day 6-9p.i. had a trend towards decreased virus in 
the BAL and in the lung (p=0.08) as indicated by +. Measures are given in Log 10 of the 
mean viral titer as determined by PCR +/- SEM.  .  n=6 H2O/EtOH; n=9 Eang H2O/Eang 
EtOH) 
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Figure 4a. 
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Figure 4b. 
 
Figure 4a, b.  Lung lesion evaluation 8d p.i. with Echinacea combination treatments 
or control.  Mice were treated with a combination of water (day 1-5 p.i.) and ethanol 
extracts (day 6-8 p.i.).  Lungs were collected on day 8 p.i.  Tissue sections were analyzed 
by a pathologist, and influenza induced pathology was assessed.  Lesion scores were 
determined by the size and extent of the pathology.  A.) Lesion scores.  Results are given 
as mean lesion score for each treatment group +/- SEM.  There was no statistical 
difference observed in the lesion scores in the lungs of mice treated with the Echinacea 
combination compared to H2O/EtOH control.   B.) Lung index was determined by 
multiplying the lesion score by the percent of the lung involved.  There was no statistical 
difference between the lung index scores of combination treated mice compared to 
H2O/EtOH.  n=4 uninfected; n=10 H2O/EtOH; n=10 H2O/Eang EtOH; n=12 
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H2O/Epara EtOH; n=8 Eang H2O/EtOH; n=9 Eang H2O/Eang EtOH; n=8 Eang 
H2O/Epara EtOH. 
Figure 5a. 
 
 
Figure 5b. 
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Figure 5c. 
 
Figure 5a, b, c.  Effect of Eang H2O/Eang EtOH treatment of mice on cellular 
infiltration of the lung compared to vehicle control treatment.  Mice were treated 
with Eang H2O for 5 days p.i. then with Eang EtOH for day 6-9 p.i.  Cells were isolated 
from BAL at 9 days p.i. from Eang H2O/Eang EtOH or H2O/EtOH treated mice infected 
with influenza and analyzed by flow cytometry for cell populations.  A.) Cell counts are 
given for total live cells and CD45+ cells.  Measures given as mean +/-SEM.  B.) Cell 
counts for populations analyzed, measured as mean +/-SEM.  C.) Populations in B given 
as % total live cells in BAL +/- SEM.   No statistical difference was observed in the BAL 
cell populations comparing Eang H2O/Eang EtOH to the vehicle control.  Cell 
populations were significantly different between the mice treated with H2O/EtOH 
compared to the uninfected control as indicated by  *, p<0.05, or +, p=0.1 by student t-
test.  n=3 uninfected; n=6 H2O/EtOH; n=9 Eang H2O/Eang EtOH. 
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Figure 6a. 
 
 
Figure 6b. 
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Figure 6c. 
 
Figure 6d. 
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Figure 6e. 
 
Figure 6f. 
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Figure 6a-f.  Cytokines/Chemokines in BAL day 9 p.i. from mice infected with 
influenza.  BAL fluid was collected and analyzed using Bio-plex® multiplex testing for 
cytokines and chemokines at day 9 p.i.  Cytokines/Chemokines figures are shown in 
order based on concentration with highest concentration shown first. Decreases in 
Eotaxin (p<0.05), IFN-γ (p<0.05), IL-6 (p<0.05), IL-12p70 (p=0.1), LIF (p=0.06), LIX 
(p<0.05), MCP-1 (p<0.05), M-CSF (p<0.05), MIP-2 (p<0.05), RANTES (p<0.05), TNF-
α (p<0.05), and VEGF (p<0.05) were observed in the Eang H2O/Eang EtOH treatment 
group compared to the H2O/EtOH vehicle control.  Measures are mean +/-SEM.  Student 
t-test was used to evaluate the Eang H2O/Eang EtOH treatment against the vehicle 
control.  *, p<0.05; +, p<0.1 n=6 H2O/EtOH; n=9 Eang H2O/Eang EtOH. 
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Figure 7. 
 
Figure 7.  Effect of Echinacea combination treatment on Anti-influenza IgG 
production at day 9 p.i.  Mice were gavaged for 1 day prior to infection with influenza 
A/PR/8/34 and 5 days post-infection (p.i.) with Eang water extract or H2O control 
followed by Eang EtOH or EtOH control until day 9 p.i.  Serum was collected on day 9 
p.i. and tested for Anti-influenza IgG by enzyme linked immunoassay (ELISA).  Optical 
density (O.D.) demonstrated by the uninfected mice represents the background in the 
assay.  Both H2O/EtOH and Eang H2O/Eang EtOH had O.D. values greater than the 
background (p<0.05).  H2O/EtOH treated mice demonstrated a lower O.D. reading than 
the Eang H2O/Eang EtOH (p=0.06) indicating that H2O/EtOH had lower anti-influenza 
IgG present in their serum compared to the Eang H2O/Eang EtOH treated mice.  Results 
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are given as average O.D. +/-SEM. +, p=0.06 (n=6 for H2O/EtOH; n=9 for Eang 
H2O/Eang EtOH). 
Figure 8. 
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Figure 8. continued. 
 
 
Figure 8.  Effect of Echinacea combination treatments on gene expression in lungs at 
day 8 p.i.  T and B cell array gene fold regulation combination treatment relative to 
vehicle treatment measured by q-rtPCR microarray from cDNA isolated from lungs of 
mice treated with a combination of extracts and infected with influenza A/PR/8/34.  
Genes shown were significantly changed with extract combination treatment p<0.1.  Day 
8 only.  H2O/EtOH n= 6; Eang H2O/EtOH n=5; Eang H2O/Eang EtOH n= 7; Eang 
H2O/Epara EtOH n=6.  Genes that were selected by DAVID analysis to be >1.5 fold 
change (#) or <0.667 (&) with fold enrichment. 
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Figure 9.  
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Figure 9. continued. 
 
Figure 9.  Effect of Echinacea combination treatments on gene expression in lungs at 
day 8 p.i.  Cytokine and Chemokine array gene fold regulation combination treatment 
relative to vehicle treatment measured by PCR microarray from cDNA isolated from 
lungs of mice treated with a combination of extracts and infected with influenza 
A/PR/8/34. Day 8 only. H2O/EtOH n= 6; Eang H2O/EtOH n=5; Eang H2O/Eang EtOH 
n= 7; Eang H2O/Epara EtOH n=6. Genes that were selected by DAVID analysis to be 
>1.5 fold change (#) or <0.667 (&) with fold enrichment. 
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Figure 10a. – Day 8 p.i., number of genes up regulated relative to uninfected 
 
Figure 10b. –Day 8 p.i., number of genes up regulated relative to H2O/EtOH 
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Figure 10a-b. Venn diagrams illustrating the Echinacea combination treatment gene 
up-regulation profiles for Day 8 treatment groups. Venn diagrams were created to 
illustrate the gene up regulation in the DAVID fold enrichment.  These diagrams magnify 
the different gene regulation profiles demonstrated by each treatment group.  A.) 
Echinacea combination groups compared to uninfected mice (effect of infection with the 
treatment).  Eang H2O/EtOH up-regulated a total of 98 genes, Eang H2O/Eang EtOH 
up-regulated 70, Eang H2O/Epara EtOH up-regulated 68 genes. 56 genes were up 
regulated similarly in all three treatment groups.  19 genes were up-regulated only by 
Eang H2O/EtOH treatment; whereas, Eang H2O/Eang EtOH up regulated 1 gene 
differently than the other treatments and Eang H2O/Epara EtOH up regulated 2 genes 
differently than the other treatment groups.  B.) Echinacea combination groups compared 
to H2O/EtOH controls (effect of combination treatment).   Eang H2O/EtOH up-regulated 
a total of 25 genes, Eang H2O/Eang EtOH up-regulated 3, Eang H2O/Epara EtOH up-
regulated 10 genes. 14 of these genes were not up regulated by the other two treatment 
groups.  2 genes were shared with both Eang H2O/Eang EtOH and Eang H2O/Epara 
EtOH.  8 genes were up regulated in both Eang H2O/EtOH and Eang H2O/Eang EtOH; 
whereas 1 gene was up regulated in both Eang H2O/EtOH and Eang H2O/Epara EtOH.  
Neither Eang H2O/Eang EtOH nor Eang H2O/Epara EtOH up-regulated genes that was 
not also up-regulated with one of the other treatment groups. 
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Figure 11a. – Day 8 p.i., number of genes down regulated relative to uninfected 
 
Figure 11b. – Day 8 p.i., number of genes down regulated relative to H2O/EtOH 
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Figure 11a-b. Venn diagrams illustrating the Echinacea combination treatment gene 
down-regulation profiles for Day 8 treatment groups.  Venn diagrams were created to 
illustrate the gene down regulation in the DAVID fold enrichment.  A.) Echinacea 
combination groups compared to uninfected mice (effect of infection).  Eang H2O/EtOH 
down regulated a total of 8, Eang H2O/Eang EtOH down regulated 7, and Eang 
H2O/Epara EtOH down regulated 4 in respect to infection.  2 of these genes were down 
regulated in all 3 treatment groups. 4 were exclusively down regulated in Eang 
H2O/EtOH, 2 exclusively down regulated in Eang H2O/Eang EtOH treatment and only 1 
exclusively in Eang H2O/Epara EtOH. B.) Echinacea combination groups compared to 
vehicle control (H2O/EtOH) to illustrate effect of extract combination.  Eang H2O/EtOH 
down regulated a total of 7, Eang H2O/Eang EtOH down regulated 4, and Eang 
H2O/Epara EtOH down regulated 0 genes in respect to H2O/EtOH controls.  Eang 
H2O/EtOH and Eang H2O/Eang EtOH both down regulated 2 of the same genes 
compared to H2O/EtOH controls.     
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Figure 12a.- comparison of infection effect on day 8 and day 9 p.i. with the same 
extract treatment, up regulated relative to uninfected 
 
Figure 12b.- comparison of infection effect on day 8 and day 9 p.i. with the same 
extract treatment, down regulated relative to uninfected
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Figure 12a-b.  Effect of day post infection on gene regulation. Venn diagrams 
comparing gene regulation between the Eang H2O/Eang EtOH day 8 and Eang 
H2O/Eang EtOH day 9. Venn diagrams were created to illustrate the gene up regulation 
in the DAVID fold enrichment between day 8 and day 9.  A.) Eang H2O/ Eang EtOH 
day 8 and day 9 up-regulated compared to uninfected mice (effect of infection).  On day 
8, 70 genes were up regulated by treatment compared to uninfected mice.  On day 9, 89 
genes were up-regulated.  63 of these genes were up regulated on day 8 and day 9.  B.) 
Echinacea day 8 and day 9 down-regulated genes compared to uninfected mice to 
demonstrate the Echinacea treatment specific changes between day 8 and day 9.  Both 
day 8 and day 9 Eang H2O/ Eang EtOH treatment down regulated 7 genes; however the 
same 7 genes were not down regulated.  4 genes were down regulated similarly in both 
day 8 and day 9; whereas, 3 genes were exclusive to each day.   
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Table 1.  Effect of infection and extract treatment on lung cytokine/chemokines  
  Uninfected H2O/EtOH Eang H2O/Eang EtOH 
N= 3 6 
vs. 
Uninfected 9 
vs. 
Vehicle 
  Mean SEM Mean SEM P-value Mean SEM P-value 
Eotaxin 3.13 0.98 
a289.30 18.55 0.00 *198.73 22.14 0.01 
G-CSF 0.59 0.59 
a1058.06 227.05 0.01 742.94 84.16 0.16 
GM-CSF 0.00 0.00 
a9.17 2.26 0.01 5.20 1.75 0.18 
IFN-γ 7.08 0.89 
a535.39 117.01 0.02 *220.16 27.73 0.04 
IL-1α 34.86 2.01 35.63 2.47 0.85 30.22 2.55 0.17 
IL-1β 12.30 2.59 8.71 1.49 0.23 8.10 1.18 0.75 
IL-2 10.46 0.81 
a0.66 0.66 0.00 0.54 0.54 0.89 
IL-3 0.00 0.00 0.25 0.25 0.52 0.00 0.00 0.23 
IL-4 0.00 0.00 0.00 0.00 NA 0.00 0.00 NA 
IL-5 0.00 0.00 
a1.13 0.38 0.03 4.44 2.93 0.29 
IL-6 0.33 0.33 
a1100.89 253.30 0.01 *551.93 61.39 0.03 
IL-9 71.66 9.38 
a0.00 0.00 0.02 0.10 0.10 0.44 
IL-10 10.28 1.00 
a76.05 18.70 0.05 50.86 9.90 0.22 
IL-12p40 13.95 1.04 
a2.60 1.42 0.00 2.05 0.93 0.74 
IL-12p70 0.43 0.43 4.40 1.64 0.15 +1.90 0.65 0.13 
IL-13 26.36 9.35 
b1.10 1.10 0.11 1.46 1.46 0.86 
IL-15 25.39 2.31 17.46 3.42 0.17 13.84 2.08 0.35 
IL-17 0.00 0.00 0.00 0.00 NA 0.13 0.13 0.44 
IP-10 7.79 0.94 
a8914.48 1988.21 0.01 6484.41 1667.73 0.37 
KC 62.22 16.06 
a189.71 23.66 0.01 154.54 21.81 0.31 
LIF 0.00 0.00 
a146.67 24.76 0.00 +98.20 10.55 0.06 
LIX 0.00 0.00 
a5.88 2.98 0.11 *0.61 0.55 0.05 
MCP-1 0.00 0.00 
a4542.32 789.31 0.00 *2059.69 445.21 0.01 
M-CSF 0.00 0.00 
a20.98 3.78 0.00 *9.42 1.87 0.01 
MIG 12.61 2.70 
a11497.90 645.99 0.00 22764.99 15895.91 0.58 
MIP-1α 9.06 1.66 
a70.56 7.58 0.00 55.60 6.27 0.15 
MIP-1β 10.23 1.00 
a124.30 16.73 0.00 110.07 17.77 0.59 
MIP-2 50.02 4.31 
a148.68 32.50 0.03 *62.62 5.85 0.05 
RANTES 0.94 0.13 
a12.83 1.32 0.00 *9.39 0.99 0.05 
TNF-α 0.23 0.23 
a12.14 0.53 0.00 *7.75 0.66 0.00 
VEGF 16.01 1.70 
a52.84 14.66 0.05 *22.23 2.55 0.03 
SEM – standard error of the mean.  NA- not applicable, *, p<0.05 relative to vehicle 
control, +, p<0.1 relative to vehicle control (Eang H2O/Eang EtOH compared to 
H2O/EtOH).  
a
, p<0.05 relative to uninfected; 
b
, p<0.1 relative to uninfected (H2O/EtOH 
compared to Uninfected). 
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Table 2.  Genes upregulated by infection DAVID output. 
Up Regulation Fold Change from DAVID 
Relative to Uninfected 
H2O/EtOH Eang/EtOH Eang/Eang Eang/Epara Eang/Eang 
Day 8 Day 8 Day 8 Day 8 Day 9 
 
Abcf1 
  
Abcf1 
    
Aimp1 
 
Ap3b1 
  
Ap3b1 
 
C3 
 
C3 C3 
Casp1 Casp1 Casp1 Casp1 Casp1 
 
Cblb 
 
Cblb Cblb 
 
Ccl1 Ccl1 Ccl1 Ccl1 
Ccl12 Ccl12 Ccl12 Ccl12 Ccl12 
Ccl19 Ccl19 Ccl19 Ccl19 Ccl19 
Ccl20 Ccl20 Ccl20 
 
Ccl20 
Ccl2 Ccl2 Ccl2 Ccl2 
 
 
Ccl3 Ccl3 
 
Ccl3 
Ccl4 Ccl4 Ccl4 Ccl4 Ccl4 
Ccl5 Ccl5 Ccl5 Ccl5 Ccl5 
Ccl6 Ccl6 Ccl6 Ccl6 
 Ccl7 Ccl7 Ccl7 Ccl7 
 
 
Ccl8 Ccl8 Ccl8 Ccl8 
Ccl9 Ccl9 Ccl9 Ccl9 Ccl9 
 
Ccnd3 
   
 
Ccr1 Ccr1 Ccr1 Ccr1 
 
Ccr2 
  
Ccr2 
 
Ccr3 Ccr3 Ccr3 Ccr3 
Ccr5 Ccr5 Ccr5 
 
Ccr5 
 
Ccr8 
  
Ccr8 
 
Ccr9 
   Cd1d1 Cd1d1 Cd1d1 Cd1d1 Cd1d1 
Cd2 Cd2 Cd2 Cd2 Cd2 
 
Cd28 Cd28 Cd28 Cd28 
Cd3d Cd3d Cd3d Cd3d Cd3d 
Cd3e Cd3e Cd3e Cd3e Cd3e 
Cd3g Cd3g Cd3g Cd3g Cd3g 
 
Cd4 Cd4 
  Cd40 Cd40 Cd40 Cd40 Cd40 
 
Cd40lg 
  
Cd40lg 
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Table 2. continued. 
H2O/EtOH Eang/EtOH Eang/Eang Eang/Epara Eang/Eang 
 
Cd40lg 
  
Cd40lg 
  
Cd74 
  Cd8a Cd8a Cd8a Cd8a Cd8a 
Cd8b1 Cd8b1 Cd8b1 Cd8b1 Cd8b1 
Cdkn1a Cdkn1a Cdkn1a Cdkn1a Cdkn1a 
 
Clcf1 
  
Clcf1 
 
Cxcl1 Cxcl1 
 
Cxcl1 
 
Cxcl10 Cxcl10 Cxcl10 Cxcl10 
Cxcl11 Cxcl11 Cxcl11 Cxcl11 Cxcl11 
Cxcl12 Cxcl12 
 
Cxcl12 Cxcl12 
Cxcl13 Cxcl13 Cxcl13 Cxcl13 Cxcl13 
Cxcl9 Cxcl9 Cxcl9 Cxcl9 Cxcl9 
Cxcr2 Cxcr2 Cxcr2 
  Dock2 Cxcr3 Cxcr3 Cxcr3 Cxcr3 
 
Dock2 Dock2 Dock2 Dock2 
 
Egr1 Egr1 Egr1 Egr1 
Gadd45g Gadd45g Gadd45g Gadd45g Gadd45g 
Glmn Glmn 
 
Glmn Glmn 
Gusb Gusb Gusb Gusb Gusb 
 
H2-Aa 
 
H2-Aa 
 H60a H60a H60a H60a H60a 
Hells Hells Hells Hells Hells 
Hprt Hprt Hprt 
 
Hprt 
 
Icosl 
  
Icosl 
Ifng Ifng Ifng Ifng Ifng 
Igbp1 
  
Igbp1 Igbp1 
Il10 Il10 Il10 Il10 Il10 
 
Il10ra Il10ra 
 
Il10ra 
Il11 Il11 Il11 Il11 Il11 
Il12b Il12b Il12b Il12b Il12b 
 
Il13ra1 Il1b 
 
Il13ra1 
 
Il15 
 
Il17b Il15 
 
Il1b 
  
Il1b 
 
Il1r2 
   Il27 Il27 Il27 Il27 Il27 
Il2ra Il2ra Il2ra Il2ra Il2ra 
 
Il2rb 
 
Il2rb Il2rb 
 
Il2rg 
 
Il2rg Il2rg 
 
Impdh2 
 
Impdh2 Impdh2 
 
Inha 
  
Inha 
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     Table 2. continued. 
H2O/EtOH Eang/EtOH Eang/Eang Eang/Epara Eang/Eang 
 
Itgam Itgam 
 
Itgam 
 
Itgb2 Itgb2 Itgb2 Itgb2 
    
Ltb 
Mif Mif Mif Mif Mif 
 
Nos2 
  
Nos2 
 
Pdcd1lg2 Pdcd1lg2 
 
Pdcd1lg2 
Pik3cd Pik3cd Pik3cd Pik3cd Pik3cd 
 
Prkcd 
  
Prkcd 
 
Prkcq 
   
 
Prlr 
   Ptprc Ptprc Ptprc Ptprc Ptprc 
Relb Relb Relb Relb Relb 
 
Rgs1 Rgs1 Rgs1 Rgs1 
Sit1 Sit1 Sit1 Sit1 Sit1 
Sla2 Sla2 Sla2 Sla2 Sla2 
Spp1 Spp1 Spp1 Spp1 Spp1 
    
Tgfb1 
Tlr1 Tlr1 Tlr1 Tlr1 Tlr1 
Tlr4 Tlr4 Tlr4 Tlr4 
 Tlr6 Tlr6 
 
Tlr6 Tlr6 
Tnf Tnf Tnf 
 
Tnf 
Tnfrsf13b Tnfrsf13b Tnfrsf13b Tnfrsf13b Tnfrsf13b 
Tnfrsf1a Tnfrsf1a Tnfrsf1a Tnfrsf1a Tnfrsf1a 
 
Tnfrsf1b Tnfrsf1b 
 
Tnfrsf1b 
 
Tnfsf13b 
 
Tnfsf13b Tnfsf13b 
Tnfsf14 Tnfsf14 Tnfsf14 Tnfsf14 Tnfsf14 
 
Traf6 
  
Traf6 
Vav1 Vav1 Vav1 Vav1 Vav1 
Was Was Was Was Was 
 
Wwp1 
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Table 3.  Genes up regulated relative to vehicle control (H2O/EtOH) DAVID output. 
Up regulated fold change from DAVID 
relative to H2O/EtOH Vehicle control 
Eang/EtOH Eang/Eang Eang/Epara Eang/Eang 
Day 8 Day 8 Day 8 day 9 
   
Ccr8 
Ccnd3 
   Cd3e 
   Cd4 
   Cd8a 
   Cd8b1 
   Cd93 
   Clcf1 
 
Clcf1 
 Cr2 
   Cxcr5 
   Dock2 
 
Dock2 
 Gadd45g 
   Hdac5 
 
Hdac5 
 Hells 
   Icosl 
   Il11 Il11 Il11 
 Il27 
 
Il27 
 Il5ra 
 
Il5ra 
 Impdh1 Impdh1 
  Inha 
   Pik3cd 
 
Pik3cd 
 Prlr Prlr Prlr 
 Ptprc 
 
Ptprc 
 Socs5 
   Tlr4 
   Vav1 
 
Vav1 
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Table 4.  Genes down regulated by infection DAVID output. 
Down Regulation Fold Change from DAVID 
Relative to Uninfected 
H2O/EtOH Eang/EtOH Eang/Eang Eang/Epara Eang/Eang 
Day 8 Day 8 Day 8 Day 8 Day 9 
 Ccl17 Ccl17 Ccl17  
Cd81  Cd81   
 Ccr6    
Cr2 Cr2 Cr2 Cr2 Cr2 
 Cxcl15    
 Cxcr5 Cxcr5  Cxcr5 
Hdac5 Hdac5 Hdac5   
    Hdac7 
 Il1f8    
    Il4 
Il5ra Il5ra    
Impdh1   Impdh1  
    Jag2 
Ms4a1  Ms4a1  Ms4a1 
Wwp1  Wwp1 Wwp1 Wwp1 
 
Table 5.  Genes down regulated relative to vehicle control (H2O/EtOH) DAVID 
output. 
Down regulated fold change from DAVID 
relative to H2O/EtOH Vehicle control 
Eang/EtOH Eang/Eang Eang/Epara Eang/Eang 
Day 8 Day 8 Day 8 day 9 
   
Cd3g 
Ccl19 
   Ccl20 
   
 
Ccl3 
  Ccl4 Ccl4 
  
 
Ccl5 
  
 
Ccl8 
  Ccl9 
   Crp 
   Il1f8 
   Tnf Tnf 
  
 
Tnfsf14 
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Abstract: 
Background:  Obesity is associated with increased morbidity and mortality to influenza 
infections.  Evidence suggests that dysfunction in the innate and adaptive immune 
responses to influenza in the obese condition may contribute to the higher rates of 
morbidity/mortality.  Echinacea purpurea has been demonstrated as an 
immunostimulatory herbal remedy often used to treat respiratory infections.  The purpose 
of this study was to determine the extent to which treatment with E. purpurea may 
improve immune response to influenza infection in the obese.  
Methods:  C57BL/6 mice were fed either a high fat diet at 60% kcal from fat (diet-
induced obese mice) or a normal mouse diet for 8 weeks.  One day prior to infection with 
Influenza A/PR/8/34 virus, mice were gavaged with either Echinacea purpurea water 
extract (ECH) treatment or water vehicle control treatment for a total of 4 groups: H2O 
lean, ECH lean, H2O Obese, and ECH Obese.  Body weight was assessed daily (through 
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day 4) as a measure of illness severity.  On day 3 post-infection (p.i.), bronchoalveolar 
lavage (BAL) and lungs were collected for analysis of viral titer, cytokines/chemokines, 
and cell populations.  Similarly, on day 8 p.i., BAL, lungs, and spleens were collected for 
analysis of viral titer, cytokines/chemokines, intracellular IFN-γ production, and cell 
populations.   
Results:  In this study, there was an effect of obesity at day 3 p.i.  Infected obese mice 
had increased IL-5, IP-10 and IFN-γ in the BAL, but decreased plasmacytoid dendritic 
cells (pDCs), alveolar macrophages, and CD8+ cells.  The effect of ECH treatment at day 
3 p.i. was a decrease in the number of conventional dendritic cells (cDC) and CD3+ cells, 
and reduced CD3+ cell percentage.  At day 8 p.i., obese mice had greater concentrations 
of IL-5, but fewer alveolar macrophages, CD8+ cells, and fewer CD4+ IFNγ+ cells 
responding to Influenza NP peptide.  The effect of ECH treatment at day 8 p.i. was 
increased IFN-γ by lung CD4+ and CD8+ cells in response to PMA-ionomycin and NP 
peptide and increased IFN-γ by spleen cells.  However, the total number of BAL CD8+ 
cells was affected by ECH treatment differently in lean and obese mice, with a greater 
number of CD8+ cells in ECH treated lean mice, but a reduced number of CD8+ cells in 
ECH treated obese mice.  
Conclusions:  Overall, the obesity related effects are similar to those observed in previous 
studies.  Although ECH did have immunomodulatory effects, ECH treatment did not 
reverse the obesity-associated alterations of immune response.  
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Introduction: 
Obesity has a negative impact on immune function particularly during influenza 
infection. In the 2009 H1N1 pandemic, obesity emerged as a major risk factor that was 
associated with increased morbidity and mortality [1].  Decreased function in the cellular 
innate and cellular adaptive immune responses has been observed in both human and 
mice models of obesity [2,3].  In influenza infection of obese mice, decreases in NK 
cells, T cells and DC have been observed [3,4].  A therapy that could reverse the obesity-
associated impairments of immunity might improve disease outcome.   
There has been an increase in the use of over the counter supplements as a means 
to limit the severity or duration of respiratory infections including influenza.  Influenza is 
prone to mutations and has been shown to become resistant to several anti-viral therapies, 
prompting some individuals to look for alternative medicine approaches [5].  Echinacea 
spp. has emerged as one of the most commonly used plant remedies for influenza 
infections.  Echinacea has both immune-stimulatory and anti-inflammatory properties.  
Variations in preparation techniques, namely water and ethanol extractions lead to the 
immunomodulatory characteristics of each extract by altering the chemical profile found 
in each extract [6].  Water preparations are rich in polysaccharides, whereas ethanolic 
preparations are rich in alkamides.   Caffeic acid derivatives and phenolic compounds 
have been shown to be in both water and ethanolic preparations [7].  Echinacea extracts 
have been shown to increase the number and function of dendritic cells (DC’s), 
macrophages, and NK cells, while also providing anti-inflammatory effects [8-10].  The 
water preparations of Echinacea purpurea used in this study have been previously shown 
to exhibit immunostimulatory activity, by activating cytokine/chemokine expression in 
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lung epithelial cells and in murine splenocytes in vitro (unpublished findings).  The 
efficacy of Echinacea spp. in an obese model of immune response to influenza infection 
has not been evaluated.  With over 30% of Americans categorized as obese [11], it has 
become exceedingly important to evaluate the impact of obesity on the efficacy of over 
the counter treatments for influenza, such as Echinacea spp.     
A murine diet induced obesity model was used to evaluate the efficacy of a water 
preparation of Echinacea purpurea.  While a genetic based obesity model on C57BL/6J 
Ob/Ob is commercially available, these mice lack leptin signaling.  Leptin signaling is 
important in immune function in the lung [12-14].  Also, leptin mutation is not a common 
cause of obesity in humans.  Therefore, the diet induced obesity model may provide a 
more accurate modeling of human immune function in obesity.  It was hypothesized that 
the Echinacea purpurea water extract (ECH) would correct the diet induced obesity 
immune dysfunction during influenza infection in mice.  Using a high fat diet and 
C57BL/6J mice that are susceptible to diet induced obesity, mice were treated daily with 
ECH or vehicle (H2O) starting one day before intranasal infection with the mouse 
adapted Influenza A/PR/8/34 virus and continuing through day four post infection.  
Lungs, spleens, and BAL were obtained at day three and day eight post infection.  These 
tissues were evaluated for cytokine/chemokines, cellular content or both.  It was 
hypothesized that ECH treatment would overcome the immune dysfunction associated 
with diet induced obesity; however, our findings suggest that ECH does not restore the 
immune dysfunction associated with obesity. 
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Materials and Methods: 
Plant & Extract.  
E. purpurea (PI633669) was harvested in USDA North central regional plant 
introduction station at Ames, IA (USA).  Water extracts were prepared by boiling 6 
grams of dried root in 100 milliliters (ml) of endotoxin free water in an endotoxin free 
flask, and stirred for 1 hour at room temperature.  Extracts were filtered using endotoxin 
free glass filter paper, centrifuged for 15 minutes at 10,000 revolutions per minute (rpm) 
and pellets discarded before freeze drying.  Extracts were prepared and provided by the 
Hauk and Murphy labs.   
Mice. 
C57BL/6 mice were purchased (n=110) from The Jackson Laboratory (Bar 
Harbor, ME). After three days of acclimation, mice were randomly selected to receive 
either a high fat or low fat diet.  Mice were fed either a high fat diet (Research diets 60% 
kcal from fat) (n=56) or normal rodent diet for 8 weeks (Research diets 10 kcal% fat) 
(n=54).  The nutritional contents of the diet are detailed in Table 1.  Iowa State 
University Committee on Animal Care approval was obtained for all procedures that 
were utilized in the care and experiments involved with the mice.   
Gavage treatment and infection.  
Animal feeding needles 20G x 1-1/2 (Cadence Science, Staunton, VA) were used 
to gavage the mice with either Echinacea purpurea (ECH) or vehicle (H2O) solutions.  
Extracts were diluted to 14.67 mg/ml of extract and administered at a concentration of 
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110 mg/kg.  Mice were gavaged with ECH or H2O one day before infection and during 
the first 4 days of infection for a total of 6 groups: 1) n=3 untreated uninfected lean, 2) 
n=25 H2O lean 3) n=26 ECH lean 4) n=4 untreated uninfected obese 5.) n=26 H2O obese 
6.) n=26 ECH obese.  Mice were infected with 30 µl of influenza virus, A/PR/8/34, 
H1N1 (HA=1024, EID50 = 10
9.5
) diluted 1:15,000 (HAU = 0.002/mouse) via an intranasal 
route given under isoflurane anesthesia.   
Disease severity and viral load. 
Mice were weighed weekly for the 8 weeks prior to infection.  Mice were housed 
separately after infection to allow monitoring of body weight and food consumption. 
Viral RNA levels were assessed by the Iowa State University Veterinary 
Diagnostic Laboratory using primers to detect influenza virus by fluorogenic reverse 
transcription polymerase chain reaction (real-time reverse transcription PCR) in the lung 
tissue samples submitted for titer.  Primers specific to the virus conserved region of the 
SIV NP gene were used with TaqMan® chemistry.  Sequences from GenBank 
(www.ncbi.nlm.nih.gov/Genbank/index.html) and Influenza Sequence database 
(www.flu.lanl.gov) were utilized.  A commercial vendor synthesized the forward primer 
(SIVRTF: 5’-CGGACGAAAAGGCAACGA-3’), reverse primer (SIVRTR: 5’-
CTGCATTGTCTCCGAAGAAATAAG-3’) and a TaqMan® MGB reporter probe FAM 
(6-carboxyfluorescein) and a non-fluorescent quencher (SIVRTP: 5’-6FAM-
CCGATCGTGCCYTC).   Primers were synthesized by Integrated DNA Technologies 
(Coralville, IA), and the probes were synthesized by Applied Biosystems (Foster City, 
CA).  Viral RNA was extracted from 50µl of lung tissue using the Ambion® 
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MagMAX™ Viral RNA Isolation kit (Applied Biosystems) and a KingFisher® 96 
magnetic particle processor (Thermo Scientific, Waltham, MA).  H1N1 and H3N2 swine 
influenza viruses and elution buffer were used as positive and negative controls, 
respectively.  The QuantiTect® Probe RT-PCR Kit by Qiagen (Valencia, CA) was used 
to perform the real time reverse transcription-PCR.  Each reaction consists of 4 µl of lung 
sample with 0.4 µM (final concentration) of each primer and 0.2 µM (final concentration) 
of the probe for a total volume of 20 µl for each reaction.  Using a 384 well format and 
the ABI 7900HT Sequence Detection System (Applied Biosystems), reverse transcription 
occurred for 30 minutes at 50°C.  Immediately following reverse transcription, the RT-
PCR was activated with 15 minutes at 95°C.  Activation was followed by 40 cycles of 15 
seconds at 94°C and 60 seconds at 60°C.  To generate a standard curve, a set of influenza 
preparations with known concentrations of viral titers (EID50/ml) were used.  Each 
sample then could be extrapolated by using the standard curve to convert the threshold 
cycle (Ct) value to a viral titer [15].      
Tissue Processing. 
Lung and spleen were harvested in stomacher bags containing 5 ml of digestion 
media (RPMI with 2% fetal bovine serum (FBS) with collagenase D at a concentration of 
1 mg/ml).  Lung and spleen tissues were subjected to Seward Stomacher® (Port St. 
Lucie, FL) paddle blender.  Lung and spleen were processed through 0.4µ cell filters with 
digestion media.  The plunger of a syringe was used to break up the remaining tissue 
through the filter, and the filtrate was suspended in 10 ml of digestion media.  Samples 
were centrifuged for 10 minutes at 1200 RPM, washed twice with complete RPMI 
(cRPMI), and re-suspended in 5 ml of cRPMI (RPMI with Hepes, glutamate, sodium 
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pyruvate, penicillin/streptomycin, fungizone, 2-mercaptoethanol and 10% FBS) without 
collagenase D.  BAL cells were harvested by centrifugation at 1200 RPM for 10 minutes 
and re-suspended in 250 µl of, BD stain buffer (PBS- azide+0.1%BSA)(BD Biosciences).  
All samples were treated with 2 mls of ice cold 0.015M ammonium chloride red blood 
cell lysing agent for 10 minutes, washed in cRPMI  (lungs, spleen, lymph nodes) or BSA 
(BAL cells) and re-suspended in 5 ml of cRPMI or 250µl BD stain buffer .  Cell counts 
were obtained using the Z™ series Coulter Counter® (Beckman-Coulter, Inc., Brea, CA).   
Flow Cytometry.    
Cell count for each sample was determined and adjusted to a range from 1x10
5
 
and 1x10
6 
per ml.  Samples less than 1x10
5
 cells per ml were combined with another 
sample from the same treatment group (BAL group only).  Adjusted cell samples (250 µl) 
were transferred to a 96 well round bottom plate for testing.  Intracellular cytokine 
assessment was performed on the lung cells only, not on cells from the BAL.  For flow 
cytometry, each well was treated with 10 µl of Fc block 1:10 dilution (0.5 mg/ml) (BD 
Biosciences) for 10 minutes.  Day 3 BAL cells were incubated with the following 
antibodies: PE-anti-mouse Ly6G, APC-anti-mouse mPDCA, PE-Cy7 anti-mouse CD11c, 
PerCp-Cy5.5-anti-mouse CD3e, AF647 anti-mouse CD11b, FITC- anti-mouse Ly6C, and 
APC-Cy7- anti-mouse CD8a.  Cell populations were defined by the following markers 
(Table 2):  Total live cells (live gate), conventional dendritic cells (cDC) (Autofluor-, 
CD11b+CD11c+LyC+LyG+), plasmacytoid dendritic cells (pDC) (Autofluor-, CD11c+, 
LyC+, LyG-, mPDCA+), alveolar macrophages (CD11b
lo
, CD11c+, Ly6C-, Ly6G-, 
Autofluor+), polymorphonuclear cells (PMN)- neutrophil, Autofluor-, CD11b+, CD11c-, 
LyC+, LyG+, SSC+), monocytes (Mono) (Autofluor-, CD11b+, CD11c-, LyC+, LyG+, 
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SSA-), CD8a (Autofluor-, CD11b-, CD11c-, CD3e+, CD8a+), and CD3e+ (Autofluor-, 
CD11b-, CD11c-, CD3e+, CD8a-).  Day 8 BAL cells were treated with PE- anti-mouse 
Gr1, APC-Cy7-anti-mouse CD8a, PE-Cy7-anti-mouse CD11c, AF 647 anti-mouse 
CD11b, AF700 anti-mouse MHCII, PE-Cy5 anti-mouse CD4, and PerCp-Cy5.5-anti-
mouse CD3e.  Cell populations were defined by the following: alveolar macrophages 
(CD11b+CD11c+Gr1-Autofluor+), conventional dendritic cells (cDC) (Autofluor-, 
CD11b
lo
, CD11c
int
, MHCII
int
), inflammatory monocytes (iMono) (Autofluor-, CD11b+, 
CD11c-,Gr1+, SSC-), PMN (neutrophil) (Autofluor-, CD11b+, CD11c-,Gr1+, SSC+), 
CD8a+ (Autofluor-, CD11c-,Gr1-, CD3e+, CD8a+), CD4+ (Autofluor-, CD11c-, Gr1-, 
CD3e+, CD8a-, CD4+), cross-presenting CD8+ dendritic cells (xDC) (Autofluor-, 
CD11b
lo
, CD11c
int
, CD3e-,CD8a+).  Day 8 spleen cells were treated AF488 anti-mouse 
CD8b, PE-Cy7 anti-mouse CD11c, APC-Cy7 anti-mouse CD19, and Pe-Cy5 anti-mouse 
CD4.  Cell populations were defined by the following: CD4 T-cells (CD11c-, CD4+, 
CD8b-), CD8b T-cells (CD11c-, CD4-, CD8b+), B cells (CD11c-, CD4-, CD8b-, 
CD19+).  Samples were mixed and incubated for 30 min. at 4°C protected from light 
(wrapped in aluminum foil).  After incubation, ~150 µl of BSA was added to each 
sample. The plates were centrifuged at 1200 RPM for 5 minutes at 2-4°C.  Supernatant 
was removed by pipetting and 2 more wash steps were performed using 250 µl of BD 
Stain buffer for each wash.  After the final wash step, supernatants were removed, cells 
were gently mixed by placing the plate on a vortex, and 150 µl of diluted BD™ 
stabilizing fixative was added to each sample.  Samples were then transferred to 5 ml BD 
Falcon™ tubes and stored at 2-4°C covered in foil (protected from light) until analyzed 
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on a BD FACSCanto™ Flow Cytometer (BD, Franklin Lakes, New Jersey) by Iowa State 
Flow Cytometry Facility.             
Intracellular flow cytometry staining for intracellular cytokines. 
Using a 96-well V bottom plate, 200 µl of lung cells (1x10
6
/ml) were added to 
four wells for each sample.  Controls for intracellular flow were plated by combining 
several samples and plating four wells for each color to be used.  Samples were 
stimulated with one of the following in one well for each sample: 10 µl of 1 µM of NP 
peptide, NP366-374 (ASNEMNDAM),), 5 µl of 1:10 diluted Leukocyte Activation 
Cocktail, with BD GolgiPlug™ (LAC) (BD Biosciences) in cRPMI (positive control 
containing PMA/Ionomycin), or 10 µl of cRPMI (unstimulated control). The protein 
transport inhibitor, BD GolgiPlug™ (containing Brefeldin), was added 2.5 µl of 1:10 
dilution to each well except the LAC which already contained the BD GolgiPlug™.  
Samples were placed in a humidified incubator at 37°C with 5% CO2 for 6 hours.   
Samples were centrifuged at 1600 RPM for 10 minutes at 4°C.  Supernatants were 
removed by gentle pipetting, and 100 µl of BSA was added to each well.  Each well was 
treated with 10 µl of Fc block 1:10 dilution (0.5 mg/ml) for 10 minutes.  Extracellular 
antibodies were added, 5 µl of 1:100 dilution of PE Cy-5 anti-mouse CD4 (0.25 µg/test) 
and 12.5µl of 1:100 dilution of AF-488 anti-mouse CD8b (0.25 µg/test).   Plates were 
incubated for 30 minutes at 4°C and protected from light with foil.  Samples were 
centrifuged at 1600 RPM for 5 minutes at 4°C and washed twice with 200 µl of BD Stain 
Buffer.  After the last wash, samples were re-suspended in 100 µl of 
Fixation/Permeabilization solution (BD Cytofix/Cytoperm™ Fixation/Permeabilization 
Solution Kit, BD Biosciences, San Jose, California).  After incubation with Fix/Perm for 
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20 minutes at 4°C protected from light, samples were washed with 1X BD Perm/Wash™ 
Buffer BD (250 µl/wash/well) and re-suspended in 100 µl of BD Perm/Wash™ Buffer 
(BD Perm/Wash™ BD Cytofix/Cytoperm™ Fixation/Permeabilization Solution Kit, San 
Jose, California).  Intracellular antibodies were added: 5 µl of 1:100 dilution PE anti-
mouse IFN-γ (0.25 µg/test) and 5 µl of 1:100 dilution Alexa Fluor 700 anti-mouse TNF-α 
(0.25 µg/test).  Samples were incubated at 4°C for 30 minutes protected from light.  After 
incubation, samples were washed twice with 1X BD Perm/Wash™ Buffer BD (250 
µl/wash/well) and re-suspended in 150 µl of 1X BD™ stabilizing fixative.  Samples were 
transferred to 5 ml BD Falcon™ tubes and stored at 2-4°C covered protected from light 
until analyzed on a BD FACSCanto™ Flow Cytometer (BD, Franklin Lakes, New Jersey) 
by Iowa State Flow Cytometry Facility.             
Spleen Culture. 
Spleens were processed as described above.  Cells were re-suspended in cRPMI at 
1x10
6
cells/ml, and cultured into 96 well plates (200 µl per well, 6 wells per spleen).  
Three wells for each spleen were stimulated with 10 µl of A/PR/8/34, H1N1 (HA=1024, 
EID50 = 10
9.5
) diluted to 100 HAU/1x10
6
 cells (UV inactivated for 30 minutes), while the 
other three wells received 10 µl of media alone for control.  Final volume for each well 
was 300 µl.   Samples were incubated at 37°C in a 5%CO2 humidified incubator, and 
supernatants were collected at 48, 72, and 96 hours post stimulation.  Supernatants were 
frozen at -20°C until further analysis.  
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ELISA. 
BD OptEIA™ Mouse IFN-γ (BD Biosciences, San Diego, CA) was used to 
analyze the supernatants from the spleen culture for IFN-γ.  A 96-well plate was coated 
with 100 µl per well of diluted Capture Antibody (1:250 in Coating Buffer prepared per 
package instructions).  The plate was incubated overnight at 4°C.  Using wash buffer 
(PBS plus 0.05% Tween-20), the plate was washed 5 times with 300 µl and blotted.  
Plates were blocked with 200 µl Assay Diluent for 1 hour at room temp and washed 
again 5 times with 300 µl of wash buffer.  Standards were diluted using a 2-fold serial 
dilution from 2000 pg/ml to 31.3 pg/ml. Samples were tested in undiluted state.  Each 
standard or sample tested was added to each well (100 µl) and incubated at room temp 
for 2 hours.  After washing 5 times with 300 µl of wash buffer, 100 µl of working 
detector was added (Detection antibody, diluted 1:250 in assay diluent plus SAv-HRP 
reagent diluted 1:250 in detection antibody).  Samples were incubated for 1 hour at room 
temp with working detector before washing the plate 10 times with 300 µl of wash buffer 
(allowing the wash to sit for 1 minute before removing).  Substrate solution (equal 
amounts of Tetramethylbenzidine [TMB] and Hydrogen Peroxide, BD 
Pharmingen™TMB Substrate Reagent Set) was added to each well (100µl each) and 
incubated in the dark for 30 minutes at room temperature.  After which, stop solution (2N 
H2SO4) was added to each well (50 µl).  Plate was read at 450 nm on BMG FLUOstar 
Galaxy.  
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Multiplex Assay.  
Bronchoalveolar lavage fluid (BAL) was collected to measure 
cytokine/chemokine concentration.   The BAL was separated into supernatant and 
cellular portions by centrifugation at 1200 RPM for 10 minutes.  The Milliplex® 
microsphere (EMD Millipore Corporation, Billerica, MA) assay was used to analyze 
BAL supernatant for expression of 19 different cytokines and chemokines that could be 
present in the lung of the infected mice.  The preparation of the assay was performed as 
package instructions indicated utilizing the overnight incubation of 18 hours.  The assay 
data was collected using Bio-plex® Suspension Array System (Bio-Rad laboratories, Inc, 
Hercules, CA) instrumentation.  Data was exported from Bio-plex® Manager to 
Microsoft® Excel (Microsoft, Redmond, WA) for further analysis.   
Analysis. 
Statistical analysis was performed with a 2-way ANOVA (obesity * Echinacea 
treatment) using SPSS® software version 20 (IBM Corporation, Armonk, New York).  
For body weight analysis, a repeated measures ANOVA was used.  If a treatment by time 
interaction was observed, follow-up analyses evaluated the effect of Echinacea separately 
for lean and obese mice.  If an interaction of obesity and ECH was observed follow up 
analysis were performed using one-way ANOVA.  One-way ANOVA analysis was also 
used to evaluate the uninfected control mice to the ECH and H2O treatment groups for 
each diet.  
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Results: 
It was hypothesized that ECH treatment of obese mice would stimulate the 
immune system and overcome the obesity associated immune dysfunctions.  The first 
measure to test this hypothesis was to evaluate clinical evidence of illness severity.  This 
was measured using daily weights and lung viral titer.  With respect to the mice that were 
euthanized on day 3 post-infection, a significant interaction between time and obesity 
status was observed (p<0.05).  In follow up analyses, the daily weight loss in grams was 
not statistically different in the ECH treatment in obese or lean mice compared to mice 
treated with H2O (Figure 1a). In the mice euthanized at day 8 post-infection, there was a 
trend (p=0.06) for a time by obesity by ECH treatment interaction, such that obese mice 
treated with ECH tended to lose less weight (Figure 1b). However, when weight loss was 
expressed as percent of original body weight, there was not an effect of ECH treatment 
on weight loss in either the obese or lean mice.   Food consumption was also monitored 
over the infection period (Figure 2).   Infected mice consumed less total kcal over the 
infection period as expected, although there were no significant differences between the 
ECH and VEH control groups.   
 In this particular study, there was a higher mortality than expected due to the 
stress sensitivity of the C57/BL6 not directly a result of the infection.  There appeared to 
be mortality associated with the stress of gavage treatment.  ECH dosing was 
discontinued on day 4, after which the mortality returned to normal levels.  Viral RNA 
level analysis was conducted using whole lung lobes.  Although there was no statistically 
significant difference in viral RNA levels at day 3 p.i. or day 8 p.i., there was a trend 
towards reduced viral load in ECH-treated obese mice by day 8 (Figure 3).  
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To further investigate the effect of ECH treatment on immune response in lean 
and obese mice, we analyzed cytokines and chemokines in BAL fluid collected from the 
mice on day 3 p.i. and day 8 p.i. (Figure 4 and Table 3).  On day 3 p.i., there was a main 
effect of obesity for IL-5, IP-10, and IFN-γ such that obese mice had significantly greater 
levels present in the BAL compared to the BAL from lean mice.  Cytokines and 
chemokines that were analyzed for each treatment group with are shown in Table 3.  
Cellular response in the lung BAL fluid was also evaluated at day 3 p.i.  Although 
diet induced obese mice receiving ECH treatment did not have altered total cell number 
in the BAL compared to the lean mice, there were changes in cell subpopulations (Figure 
6 and Table 4).  Obese mice had significantly fewer plasmacytoid dendritic cells (pDC) 
(both counts and percentages).   ECH treatment resulted in fewer CD3+ cells, both total 
number and percentage.  ECH also tended to be associated with decreased numbers of 
conventional dendritic cells (cDC) count and percentage.  These effects of ECH treatment 
were demonstrated in both lean and obese mice.  
On day 8 p.i., BAL fluid was also analyzed for cytokines/chemokines (Table 3), 
total lung cell count (Figure 5) and cell populations (Figure 7 and Table 5).  Similar to 
day 3, obese mice tended to have higher concentrations of IL-5 in the BAL.  There were 
no significant effects of ECH treatment on cytokines or chemokines in the BAL at day 8.  
At day 8 p.i., cell populations were altered in the obese condition and as a result of ECH 
treatment.  With respect to obesity, there were reduced percentages of alveolar 
macrophages, CD8+ cells, and a trend toward fewer CD4+ cells in obese mice relative to 
non-obese mice.  The effect of ECH treatment was different in lean mice compared to 
obese mice.  In lean mice, ECH treated mice had a greater percentage of CD8+ cells 
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whereas in obese mice, ECH treated mice had reduced percentage of CD8+ cells 
(significant interaction for CD8 at p <0.05; with a trend towards a similar effect in CD3+ 
cells at p = 0.09).   
The lung tissue from mice was used to assess total cell count, alveolar 
macrophages, CD4+ cells, and CD8+ cells.  Overall, ECH tended to reduce the total 
number of cells in the lung, although this effect only approached statistical significance 
(Figure 8). There were no significant effects of ECH treatment on alveolar macrophages, 
although a trend was observed such that the total number of macrophages declined in lean 
mice, but the actual percentage of alveolar macrophages tended to increase only in obese 
ECH-treated mice  (diet * ECH interaction, p < 0.10).  ECH treatment also reduced 
overall lung CD8%, and tended to decrease CD8 cell number.  Mice in the obese 
condition had reduced overall cell count, reduced alveolar macrophage, as well as a 
decrease in the percentage of CD8+ cells (Figure 8).    
Also, the number and percentage of CD4+ IFN-γ+ and CD8+IFNγ+ cells were 
determined under each in vitro condition (Figure 9).  Obese mice treated with ECH had a 
greater percentage of CD4+ IFN-γ+ cells responding to influenza NP peptide, but this 
effect was not observed in lean mice (d * e interaction).  However, both obese and lean 
mice treated with ECH had an increase in the percentage of CD8+ IFN-γ+ NP-responding 
cells. When PMA-ionomycin was used to activate IFN-γ as a non-specific stimulator, 
ECH treated mice had a greater percentage of CD8+ cells producing IFN-γ (p < 0.05).  
These results suggest that ECH may act as a non-specific activator, and obesity may be 
associated with a reduced influenza-specific response (Figure 9).  
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Lastly, the spleen cell populations were evaluated by flow cytometry for cell 
populations and by ELISA for IFN-γ production at day 8 p.i.  Total spleen cell counts 
(Figure 10), total spleen CD8 cell, CD4+ cell and CD19+ B cell counts (data not shown) 
were not different between lean and obese mice and did not change in response to 
treatment with ECH.  With respect to cell percentages, the actual percentage of CD8+ 
cells was higher in ECH obese mice compared to obese mice treated with vehicle, but the 
percentage of CD8+ cells in lean mice did not change with ECH treatment (significant 
interaction, p < 0.05) (Figure 10).  IFN-γ production was analyzed in spleen cultures 
stimulated with UV inactivated A/PR/8/34 at 48, 72, and 96 hours post-stimulation 
(Figure 11).  There were significant interactions between time and obesity as well as 
between ECH treatment and time (p < 0.05) at 72 and 96 hours.   A significant diet * 
ECH interaction was observed in the 48 and 96 hour IFN-γ production.  At 48 hours, 
treatment with ECH tended to decrease IFN-γ production in lean mice (p=0.08), while no 
change was observed in the obese treatment group.  ECH treatment increased IFN-γ 
production at 72 hours post stimulation but declined by 96 hours.  It is therefore possible 
that ECH treatment altered the kinetics of cytokine production.  At the 96 hour time 
point, the IFN-γ level in obese was lower than lean mice (p < 0.05).  It is possible that the 
peak levels of IFN-γ peak at an earlier time point in obese mice.   A main effect of diet 
was observed at 48 hours and 96 hours (p<0.05).  At both 48 and 96 hours obese mice 
had less IFN-γ production in the spleen cells relative to the lean mice.   
Discussion:      
Diet induced obesity results in dysfunction of both the innate and adaptive 
immune responses to influenza.  Echinacea spp. has been shown to enhance the innate 
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and adaptive immune responses in mice feed normal mouse diet, but the effect on diet 
induced obesity is unknown.  It was hypothesized that ECH treatment of obese mice 
would restore the obesity associated immune dysfunctions.  The only immune parameters 
measured in which ECH treatment appeared to improve response among obese mice was 
an increase in alveolar macrophage percentage, CD4+IFN γ+% and CD8+IFNγ+% cells 
in the whole lung when stimulated with NP-peptide and PMA-ionomycin.  There were 
decreased numbers of total lung cells and CD8 cells and percentage in the whole lung of 
diet induced obese mice treated with ECH.  This decrease in cellular infiltration could be 
a result of infection resolution with the decrease in viral titer in ECH treated mice at day 
8.  There was also an effect of ECH on the kinetics of IFN-γ production in stimulated 
spleen cells.  It was hypothesized that ECH would correct the obesity associated cellular 
immune function.  While there were no significant changes in the obese mice CD8 count 
when treated with ECH, there were increases in CD4+IFN-γ+% and CD8+IFN-γ+% cells 
in ECH treated mice.  ECH also appears to be a non-specific stimulator of the immune 
response that could provide benefit in preventing influenza associated secondary 
infections.  Echinacea has been shown to enhance the innate and adaptive immune 
responses in mice feed normal mouse diet.  It has been shown to be both stimulatory and 
anti-inflammatory through modulation of the expression of cytokines and chemokines 
and increases cellular immune activity [9,10,16].  There was also an effect of ECH on 
day 3 BAL with decreases in cDCs and CD3e+ counts and percentages.  Circulating CD8 
and CD4 T cells are decreased in obese patients [17].  With decreased numbers in 
circulation, decreased cells in circulation could translate into delay in the response to 
infection.   
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Obesity related changes at day 3 post-infection were increased of IL-5 and IP-10, 
and a tendency towards increased IFN-γ in the BAL, along with decreased pDCs.  By day 
8 p.i., the BAL fluid of obese mice still had a higher concentration of IL-5, but there were 
decreases in the percentage of alveolar macrophages and CD8+ cells in the BAL.  In the 
cells from BAL at day 3, there was an obesity effect on pDC cell count and percentage, 
and day 8 there were decreases in alveolar macrophage percentage and CD8.  Decreased 
numbers of pDC would be associated with an impaired immune response to influenza.  
These cells produce the anti-viral type I IFN.  Decreases in alveolar macrophages have 
been shown to regulate in cytotoxic CD8 function [18].  Reductions in all three of these 
cell types at day 3 may correlate with the delayed response to influenza that has been 
associated with the obese [2].  Another study demonstrated a decrease in IFN-α/β, TNFα, 
IL-6, and IL-10 the lungs of mice at day 3 p.i. [3].  This correlates with the decreased cell 
populations in our study with decreased pDC, alveolar macrophages, and CD8 which 
would be involved in producing those cytokines.  It has also been shown that the obesity 
condition alters the antigen presentation function of DCs and results in reduced antigen 
specific CD8 cells recruited to the lung [4].  These findings would lead to decreased 
CD8+ and CD4 cells in the lungs of diet induced obese mice, a finding we observed in 
this study with decreased CD8+ in the BAL at day at as well as decreased whole lung cell 
totals, CD8 cell number, alveolar macrophage percentages, and CD4+IFNγ+% cells. 
With the NP stimulation of the lung cells from obese mice, there was a decrease 
in both the CD8+IFNγ+ and CD4+IFNγ+ cells compared to the lean mice suggesting an 
influenza-specific immune impairment.  It has been shown that CD8+ cells from obese 
mice do not adequately produce IFN-γ in response to secondary challenge with influenza 
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[19].   CD4+IFNγ+ cells in the lung have been associated with improved clearance and 
protection from lethal influenza infection, with these CD4+ cells having an effecter 
function in the lung, producing IL-10 and IFN-γ [20].  While decreased CD4 response in 
primary infection has associated with a decrease in the CD8 response on secondary 
challenge [21].  In this study, our findings correlate with the influenza-specific immune 
impairment with CD8+ cells producing less IFN-γ compared to lean mice when 
stimulated with influenza NP peptide.  ECH treatment could possibly provide 
improvement to the obesity impairment as seen with the ECH treated groups 
demonstrating an increase in CD8+IFNγ+ cells and CD4+IFNγ+% when stimulated with 
PMA-ionomycin.  This suggests that ECH is a non-specific activator of CD4 and CD8 in 
the lung.       
In this study there were several interactions with ECH treatment and diet such that 
the ECH treatment resulted in different outcomes depending on the obesity condition.  
There was an interaction with respect to the percentage of macrophages in the lungs.  
ECH treated lean mice had fewer macrophages compared to the obese ECH treated mice.  
Both lean and obese mice had lower total lung cell counts with ECH treatment with a 
higher percentage of alveolar macrophages present in the obese ECH treated mice.  This 
could provide a benefit to the obese mice by promoting viral clearance.   
In the spleen, the percent CD8+ cells was increased with ECH treated obese mice 
compared with the ECH treated lean mice.  This could be a result in the increased viral 
clearance and correlated with the trend in the decreased viral titer seen in the ECH treated 
obese mice.  IFN-γ production in the stimulated spleen immune cells was increased with 
ECH treatment at 48 and 72 hours and obese mice had decreased IFN-γ production 
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compared to the lean at 96 hours suggesting that ECH treatment altered the kinetics of 
cytokine production in the obese mice.  This could also be a result of increased CD8+ 
cells in the spleen.     
Endotoxin activity in botanical treatments remains in question.  One limitation of 
this study is the presence of endotoxin in root preparations of Echinacea.  It has been 
suggested that the macrophage activation seen in the in vitro studies with Echinacea 
treatment is a direct response from the endotoxin levels in the extract [22,23].  Although 
this remains unconfirmed in vivo, the non-specific activation of IFN-γ production in the 
CD4 and CD8 cells in response to LAC treatment in the intracellular staining experiment 
in this study could be a result of presence of endotoxin.  Follow up analysis of endotoxin 
concentration would be necessary to confirm presence of endotoxin.  
In this study, we utilized a short-term diet induced obesity model with the mice 
consuming a high fat diet for 8 weeks.  DEXA analysis was performed previously in our 
lab to establish the adiposity of mice after this duration of high fat diet (unpublished 
data).  The DEXA analysis was not re-evaluated in this study, but the results from the 
previous study was used to determine a proper duration of the diet for DIO conditions.  
Because of the short duration of the obesity condition of the mice in this study, the results 
from this experiment would not necessarily reflect the leptin insensitivity observed in the 
long term obese condition.  Leptin insensitivity could potentially be investigated with 
Echinacea using a high fat diet given over a longer duration [24].  This study also does 
not address the impact of genetic (leptin deficiency) development of obesity as mentioned 
with the design and selection of the DIO model of obesity, nor does it address the 
prospect of insulin resistance.   In addition, further studies should evaluate the potential 
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of enhanced immunological memory response with ECH treatment in diet induced obese 
mice as well as susceptibility of ECH treated, influenza infected mice to secondary 
bacterial infections, a common cause of influenza associated mortality in both lean and 
obese humans.     
Taken together, the obesity effects seen in the diet induced obesity mice used in 
this study correlated with the findings of previous studies.  To the best of our knowledge, 
no previous studies have evaluated the effect of ECH treatment in a diet induced obesity 
model of influenza infection.  ECH treatment increased percentage of alveolar 
macrophages while decreasing CD8 counts in the lungs of obese mice, and also altered 
the IFN-γ production in spleen cells.  Overall, ECH treatment did not correct the obesity 
associated immune changes seen in diet induced obesity, but could provide a benefit in 
increased viral clearance and faster recovery through increased alveolar macrophages and 
CD8+IFNγ+%, and CD4+IFNγ+% cells in the lung.   
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Figures for Chapter IV. 
Figure 1a. 
Illness Severity - Body Weight Loss
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Figure 1b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1a, b.  Daily weights of mice infected with A/PR/8/34.  a.) Day 3 b.) Day 8.  No 
significant changes weight loss rates were observed in the treatment at day 3 or day 8.  
Each day represents the mean +/- SEM.  Time*obesity*extract interaction.  Obese mice 
treated with ECH tended to lose less weight over time.  +, t*d*e, p=0.06 
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Figure 2. 
 
 
 
 
Figure 2.  Total food consumption post infection in kilocalories (kcal). 
Total food consumption of each group of mice over either the 3 day or 8 day experiment 
post infection.  Values are given in mean +/-SEM.  Grams were converted to energy 
relevant to each diet consumed in total kcal.  Infected mice consumed less food during 
the infection period compared to the uninfected mice during the same time frame.  *, 
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p<0.05 +, p=0.06.  Uninfected Lean (day 3: n=3; day 8: n=3), Uninfected obese (day 3: 
n=4; day 8: n=4), H2O lean (day 3: n=4; day 8: n=4), ECH lean (day3: n=6; day 8: n=5).  
Figure 3. 
 
 
 
Figure 3.  Lung Viral titer in mice Day 3 and Day 8 post infection (p.i.) with 
influenza A/PR/8/34 virus and treatment with Echinacea or vehicle control.  Log 10 
of the mean viral load +/- SEM from lungs obtained on day 3 p.i. and day 8 p.i.  There 
was no difference in viral load between treatment groups at day 3 p.i.  However, at day 8 
p.i., treatment with ECH tended to decrease viral load in the lungs of obese mice on day 8 
p.i. Uninfected n=3; day 3: H2O lean, n=3 ECH Lean n=4; H2O obese n=3; ECH obese 
n=3; day 8: H2O lean, n=4; ECH Lean n=5; H2O obese n=7; ECH obese n=3.  +, 
p=0.10. 
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Figure 4. 
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Figure 4. continued. 
 
 
Figure 4.  Day 3 Main effect of the obesity condition on BAL cytokines and 
chemokines.  BAL collected from mice infected with influenza and treated with ECH or 
H2O at day 3 p.i.  BAL supernatants were collect and analyzed for cytokines/chemokines 
by Bio-Plex multiplex array.  The main effect of obesity showed an increase in IL-5 
(p<0.05), IP-10 (p<0.05), and had a trend towards an increase in TNF-α and IFN-γ 
(p=0.07) compared to lean mice.  Each graph represents the mean +/- standard error.  
Uninfected n=3; H2O Lean n=3; ECH Lean n=4; H2O Obese n=3; ECH Obese n=3. *, d 
p<0.05 main effect of obesity; +, d p=0.1 main effect of obesity using an ANOVA 
analysis.  
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Figure 5. 
 
 
Figure 5.  BAL total cell counts from Day 3 and Day 8 post infection with A/PR/8/34 
and treatment with either Echinacea or Vehicle Control.   BAL was collected day 3 
p.i. and day 8 p.i. and analyzed using flow cytometry.  Total cell counts were not 
statistically significant due to the high variation in counts.  Day 8 counts were 
significantly different from uninfected mice by ANOVA.  *, p<0.05.  Data shown are 
mean values +/- SEM.   Uninfected n=3; day 3: H2O lean, n=3 ECH Lean n=4; H2O 
obese n=3; ECH obese n=3; day 8: H2O lean, n=4; ECH Lean n=5; H2O obese n=7; 
ECH obese n=3.   
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Figure 6. 
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Figure 6. BAL Cell populations from Day 3 post infection.  Mice were infected with 
A/PR/8/34 and treated with either ECH or H2O control.  BAL was collected 3 days p.i. 
and analyzed for cell populations using flow cytometry.  Mean cell counts for each 
population+/- SEM and % of live cells +/- SEM.  A main effect of obesity was observed 
with decreased pDC count (p<0.05).  There was a main effect of ECH treatment with 
decreased cDC cell count (p=0.07) and percent (0.06); decreased CD3+CD8- cells count 
and percent (p<0.05).   *, p<0.05; +, p=0.10, *, e ECH effect <0.05; *, d Obesity effect 
p<0.05. +, e ECH p<0.10 H2O lean, n=3 ECH Lean n=4; H2O obese n=3; ECH obese 
n=3.  
 
 
Figure 7. 
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Figure 7. continued. 
 
 
Figure 7.  BAL cell populations from day 8 post infection.  Mice were infected with 
A/PR/8/34 and treated with either ECH or H2O control.  BAL was collected day 8 p.i. 
and analyzed for cell populations using flow cytometry.  Percent of total cell counts are 
shown for each population +/-SEM.  Effect of obesity was seen with decreases in alveolar 
macrophages % and CD8+ T cells % (p<0.05).  Diet by Extract interaction was observed 
in the CD8% (p=0.05) with obese mice treated with ECH showing a decrease in CD8% 
whereas lean mice had an increase.  A similar pattern was observed with respect to CD3+ 
cells, although this was only a trend (p=0.09). *, d p<0.05 obesity effect; +d p<0.10; 
obesity*extract interaction, d*e <0.05; +d*e, p<0.10. Uninfected n=3; H2O lean, n=4; 
ECH Lean n=5; H2O obese n=7; ECH obese n=3.   
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Figure 8. 
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Figure 8. continued. 
 
 
    
Figure 8.  Whole lung cell populations.  Mice were infected with A/PR/8/34 and treated 
with either ECH or H2O.  Whole lungs were collected on day 8 p.i.  Lung cells were 
isolated, cultured, and then identified using appropriate antibodies and flow cytometry. 
There was a trend towards a main effect of ECH with decreased total lung cell counts in 
mice receiving ECH treatment (e+) (p=0.07).   In the whole lung, there was a diet by 
ECH interaction (d * e)for the alveolar macrophage count (p=0.09) and percent (p=0.10) 
such that lean mice treated with ECH tended to have a reduced number of macrophages 
whereas obese mice treated with ECH tended to have a greater percentage of alveolar 
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macrophages.  There was a main effect of obesity with decreased alveolar macrophages 
count (d*, p<0.05). ECH treatment reduced CD8% in both lean and obese mice (e*, p 
<0.05) and tended to decrease total CD8 number (e+, p=0.07). Obese mice had decreased 
total lung cell count (d*, p<0.05), and trend towards fewer CD8% (d+, p=0.10) *, e 
p<0.05; +, e p<0.10; obesity effects d* p <0.05, d+ p=0.10; d, diet; e, extract; d*e, 
interaction p<0.05. Uninfected n=3, H2O lean, n=4; ECH Lean n=5; H2O obese n=7; 
ECH obese n=3.   
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Figure 9.  Day 8 Intracellular flow cytometry NP, Med, and LAC stimulated lung 
cells.  Mice were infected with influenza A/PR/8/34 virus and treated with either ECH or 
vehicle control (H2O).  Whole lungs were collected on day 8 p.i., cultured, and 
stimulated media only, leukocyte activation cocktail, or NP peptide from influenza virus.  
Cell populations and IFN-γ producing cells were analyzed using flow cytometry.   Lean 
mice and obese mice %CD4 and %CD8 populations producing IFN-γ are shown.  There 
was a diet*extract (d*e) interaction (p<0.05) with obese mice having increased 
CD4%IFN-γ+ cells when stimulated with media only.  There was also a main effect of 
ECH in the media stimulation with ECH treated obese mice having increased CD8% cells 
producing IFN-γ (p=0.08).  With the PMA-ionomycin (LAC) stimulation, the percent 
CD4+IFNγ+ (p=0.07) increased in obese mice treated with ECH (d*e p=0.06) and also 
had an increase production of CD8+IFNγ (p<0.05).  There was a d*e interaction (p<0.05) 
with the NP stimulation.  The main effect of obesity shows decreases in the CD4 T cells 
producing IFN-γ in obese mice (p=0.05) in response to NP stimulation.  A main effect of 
extract (p=0.07) was also observed with ECH treated mice demonstrating an increase in 
CD4%IFNγ+. d*e (p<0.05 diet *ECH interaction) *, e (p <0.05 ECH effect); *e, (+ 
p<0.10 ECH effect).  +, d (obesity effect p<0.10).  np = NP peptide stimulated condition, 
lac = PMA-ionomycin stimulated condition.  Uninfected n=3, H2O lean, n=4; ECH Lean 
n=5; H2O obese n=7; ECH obese n=3.   
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Figure 10. 
 
 
 
Figure 10.  Day 8 p.i. Spleen cell populations.  Mice were infected with A/PR/8/34 and 
treated with either ECH or H2O control.  Spleens were collected day 8 p.i. and analyzed 
for cell populations using flow cytometry.  Mean total spleen cell count +/- SEM, and 
CD8b as percent of total spleen cells.  Total spleen counts were not different between the 
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2 groups.  Significant interaction of obesity and ECH: %CD8+ in ECH obese mice was 
increased compared to lean mice that did not change with controls. d*e, p<0.05 
Uninfected n=3, H2O lean, n=4; ECH Lean n=5; H2O obese n=7; ECH obese n=3.   
 
Figure 11. 
 
Figure 11. IFN-γ production by spleen cells stimulated with UV inactivated virus.  
Spleens were collected from mice infected with A/PR/8/34 on day 8 p.i.  Spleen cells 
were isolated, cultured, and stimulated with UV inactivated A/PR/8/34.  Supernatants 
were collected from the samples 48, 72, and 96 hours post-stimulation and analyzed for 
IFN-γ production by ELISA.  A diet * ECH interaction was observed in the 48 (p=0.07) 
and 96 hour (p=0.08) IFN-γ production.  At 48 hours, treatment with ECH tended to 
decrease IFN-γ production in lean mice (p=0.08), while no change was observed in the 
obese treatment group.  ECH treatment increased IFN-γ production at 72 hours post but 
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resulted in a decline by 96 hours.  A main effect of diet was observed at 48 hours and 96 
hours.  At both 48 and 96 hours obese mice had less IFN-γ production in the spleen cells 
(p<0.05); d*e, p<0.05, interaction of diet and ECH; *, d; main effect of diet p<0.05; +, e; 
main effect of ECH p=0.08. Uninfected n=3, H2O lean, n=4; ECH Lean n=5; H2O obese 
n=7; ECH obese n=3.   
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Table 1.  Mouse diet nutritional information. 
Diet   High fat  Low fat  
 Mouse group   DIO Lean 
 protein % 23.1   17.3   
 fat % 34.9   4.3   
 fiber % 6.5   4.7   
 carbohydrates % 25.9   67.4   
 Minerals 
 calcium % 0.79   0.57   
 phosphorus % 0.59   0.43   
 potassium % 0.77   0.57   
 magnesium % 0.07   0.05   
 sodium % 0.15   0.12   
 chlorine % 0.25   0.21   
 iron, ppm ppm 64   44   
 zinc, ppm ppm 46   34   
 manganese, ppm ppm 76   55   
 copper, ppm ppm 7.8   5.7   
 iodine, ppm ppm 0.27   0.2   
 Vitamins 
 vitamin A IU/g 5.2   3.8   
 vitamin D IU/g 1.3   0.9   
 vitamin E IU/g 67.2   49.3   
 vitamin K ppm 0.65   0.48   
 thiamin ppm 7.8   5.75   
 riboflavin ppm 8.7   28   
 niacin ppm 39   14   
 folic acid ppm 2.8   1.9   
 biotin ppm 0.3   0.2   
 vitamin B12 mcg/kg 18   9   
 ascorbic acid ppm 0   0   
 choline chloride ppm 1290   950   
 energy (kcal/g)   kcal % kcal % 
 from: 
  
      
 protein 
 
0.924 18.1 0.692 18.3 
 fat 
 
3.14 61.6 0.384 10.2 
 carbohydrates   1.035 20.3 2.697 71.5 
 DIO- diet induced obesity; ppm- parts per million; IU/g – international unit per gram; 
mcg/kg – microgram per kilogram; kcal/g – kilocalorie per gram. 
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Table 2. Flow cytometry cell populations 
Day 3 BAL Flow marker 
Cell CD11b CD11c LyC LyG mPDCA CD3 CD8a SSC AF 
PMN + - + + 
   
+ - 
Mono + - + + 
   
- - 
cDC 
 
+ + + 
    
- 
pDC + + + + + 
   
- 
alveolar 
macrophage 
+ + - - 
    
+ 
CD8a T cell - - 
   
+ + 
 
- 
CD3e+CD8a- - - 
   
+ - 
 
- 
Day 8 BAL 
  CD11b CD11c Gr1 MHCII CD3 CD8a CD4 SSC AF 
PMN + - + 
    
+ - 
Mono + - + 
    
- - 
DC +
lo
 +
int
 
 
+
int
 
    
- 
xDC +
lo
 +
int 
  
- + 
  
- 
alveolar 
macrophage 
+ + - 
     
+ 
CD8a T cell 
 
- - 
 
+ + 
  
- 
CD4 T cell 
 
- - 
 
+ - + 
 
- 
  
        
  
  
        
  
Day 8 Spleen 
  CD11c CD19 CD8b CD4           
CD4 T cell - - - + 
    
  
CD8 T cell - - + - 
    
  
B cell - + - -           
BAL – Bronchoalveolar lavage; PMN- polymorphonuclear cell (neutrophil) cDC- 
conventional dendritic cell; pDC – plasmacytoid dendritic cell; xDC – cross presenting 
dendritic cell; int – intermediate; +, Antigen positive expression; -, no antigen expression. 
AF- autofluorescence. 
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Table 3.  BAL cytokine and chemokine levels in Lean and Obese mice treated with 
H2O or ECH analyzed on day 3 and day 8 post-infection. 
  
Lean 
    Day 3 Day 8 
  Uninfected H2O ECH H2O ECH 
n= 3 3 4 4 5 
cytokines MEAN SEM MEAN SEM MEAN SEM MEAN SEM MEAN SEM 
IL-1a 31.35 9.53 52.17 30.07 48.81 23.61 *6.12 2.31 49.20 40.44 
IL-1b 2.58 2.58 0.00 0.00 103.17 103.17 0.00 0.00 0.00 0.00 
IL-2 14.98 2.51 8.12 5.75 *4.17 0.30 *2.84 0.92 11.05 7.83 
IL-4 0.00 0.00 0.00 0.00 0.00 0.00 4.01 4.01 0.00 0.00 
IL-5D 0.00 0.00 D0.17 0.17 D0.00 0.00 +70.71 36.15 *69.31 23.47 
IL-6 0.00 0.00 *52.41 13.83 4636.59 3624.35 1661.27 966.53 +1724.18 641.08 
IL-10 16.18 4.64 7.49 2.92 27.13 18.25 52.25 23.33 +62.39 17.30 
IL-
12p40 
13.47 1.01 7.87 6.59 *0.15 0.15 *1.88 1.28 *3.05 2.31 
IL-
12p70 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
IL-15 6.13 2.39 2.41 1.77 +0.76 0.76 +2.29 0.76 +2.17 0.61 
IL-17 0.00 0.00 0.00 0.00 3.22 3.22 5.66 5.66 +2.76 1.15 
IFN-γd 0.75 0.75 d2.39 1.81 d3.01 3.01 +4792.33 2243.45 +3937.46 1451.76 
TNF-αd 0.00 0.00 d0.00 0.00 d12.41 12.41 15.03 7.77 +20.46 8.12 
IP-10D 7.04 1.17 D*232.62 37.03 D+365.58 163.39 *1143.51 256.83 *1430.96 460.83 
Eotaxin 4.87 2.75 5.77 3.22 55.12 33.60 90.41 50.70 +132.18 47.99 
KC  16.72 1.85 *65.07 12.20 5569.80 4938.99 189.25 106.79 +113.78 33.98 
MCP-1 0.00 0.00 +25.88 8.59 2218.75 2171.74 706.61 477.34 +592.32 256.75 
MIP-1α 0.00 0.00 15.76 7.92 167.58 155.60 *54.16 16.02 *55.74 18.25 
MIP-1β 0.00 0.00 *42.01 14.09 836.81 799.46 *104.62 35.10 +134.85 45.38 
  Obese 
      Day 3 Day 8 
  Uninfected H2O ECH H2O ECH 
n= 3 3 3 7 3 
cytokines MEAN SEM MEAN SEM MEAN SEM MEAN SEM MEAN SEM 
IL-1a 33.67 11.88 26.56 4.65 30.84 15.01 +5.59 0.88 +5.88 3.32 
IL-1b 0.00 0.00 2.58 2.58 8.27 8.27 1.11 1.11 0.00 0.00 
IL-2 8.58 2.96 5.02 1.42 8.95 4.92 +0.82 0.38 3.01 2.35 
IL-4 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 12.32 12.32 
IL-5D 0.00 0.00 D+4.17 2.09 D+3.46 1.84 *139.99 34.64 176.21 128.97 
IL-6 1.37 1.13 469.52 375.07 5196.10 5095.36 *4460.34 1401.15 2628.83 1624.29 
IL-10 10.81 2.99 7.35 2.08 13.40 9.16 +81.94 31.31 38.77 28.26 
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SEM – standard error of the mean.  *, p<0.05 relative to uninfected, +, p=0.1 relative to 
uninfected.  Effect of obesity, D, p<0.05; d, p=0.1 (day 3 only). 
 
Table 4. Day 3 BAL cell count and cell subpopulations. 
  DAY 3 BAL  
  Lean Obese 
  H2O  ECH  H2O  ECH  
  MEAN  SEM MEAN  SEM MEAN  SEM MEAN  SEM 
Total Cells 16644.25 9310.05 19743.83 4942.19 16346.33 9449.64 21700.00 9951.05 
iMono% 4.52 2.90 2.30 1.69 1.96 0.62 1.87 1.72 
PMN% 0.08 0.07 0.04 0.01 0.19 0.14 0.13 0.12 
cDC%
e
 0.37 0.13 0.18 0.12 0.59 0.27 0.14 0.07 
pDC%
D
 3.53 0.55 3.23 1.23 1.36 0.32 2.00 0.90 
CD3e%
E
 4.47 1.07 1.32 0.22 3.97 1.02 1.03 0.40 
CD8% 8.52 0.96 7.73 3.06 6.81 1.88 3.95 0.54 
SEM – standard error of the mean.  Effect of obesity, D, p<0.05 Effect of extract, E, 
p<0.05; e, p=0.1 
 
 
 
 
 
Table 3. continued. 
cytokines MEAN SEM MEAN SEM MEAN SEM MEAN SEM MEAN SEM 
IL-
12p40 
10.14 3.64 8.64 4.86 8.61 6.00 +0.48 0.27 2.54 2.44 
IL-
12p70 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
IL-15 2.84 2.20 0.75 0.75 3.61 3.61 5.70 2.38 0.45 0.45 
IL-17 0.00 0.00 0.00 0.00 0.00 0.00 1.53 0.98 0.68 0.68 
IFN-γd 0.00 0.00 d16.52 12.18 d7.62 5.17 *5296.81 1961.75 6403.27 3907.95 
TNF-αd 0.00 0.00 d1.91 1.91 d32.95 28.47 *24.46 7.19 16.17 14.94 
IP-10D 5.46 0.62 D+499.54 166.68 D343.97 104.32 *1395.88 361.91 1326.83 824.72 
Eotaxin 1.61 1.35 11.04 5.01 31.77 24.21 134.21 56.34 135.98 114.69 
KC  15.65 3.89 225.23 171.15 11834.05 11750.12 *163.28 34.03 302.35 196.95 
MCP-1 1.46 1.46 +300.53 265.25 *228.86 120.19 1024.47 485.47 980.60 890.15 
MIP-1α 1.51 1.51 65.27 47.42 103.52 81.80 +66.10 22.66 48.76 34.01 
MIP-1β 3.82 3.82 122.92 83.90 79.72 44.08 202.91 82.12 134.78 100.90 
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Table 5. Day 8 BAL cell count and cell subpopulations. 
  Day 8 BAL Cell Populations 
  Lean 
  Uninfected H2O ECH 
n= 3 4 5 
Cells Mean SEM Mean SEM Mean SEM 
total cells 6229.67 1532.79 30380.25 14341.93 23080.60 4808.80 
alveolar 
macrophages 
%
D
 
33.13 4.30 36.08 2.04 31.80 3.19 
xDC % 0.00 0.00 0.85 0.49 1.06 0.28 
CD4% 0.23 0.09 3.80 0.66 4.96 1.21 
CD3e% 5.77 2.26 1.58 0.43 3.70 1.33 
iMono% 0.03 0.03 1.15 0.21 1.52 0.46 
PMN % 0.00 0.00 0.58 0.11 0.78 0.25 
CD8% 
D*E, D
 0.40 0.06 2.90 1.31 4.66 0.46 
              
  Obese 
  Uninfected H2O ECH 
n= 3 7 3 
Cells Mean SEM Mean SEM Mean SEM 
total cells 4342.67 1361.30 36096.29 9586.01 21111.33 14328.08 
alveolar 
macrophages 
%
D
 
20.53 4.55 27.61 7.41 26.80 6.51 
xDC % 0.03 0.03 0.69 0.29 0.17 0.09 
CD4% 0.20 0.00 2.97 0.52 2.40 1.17 
CD3e%
d*e
 3.47 0.52 1.50 0.32 2.73 1.87 
iMono% 0.00 0.00 0.94 0.18 0.73 0.41 
PMN % 0.00 0.00 0.44 0.14 0.37 0.27 
CD8% 0.87 0.19 3.04 1.04 1.13 0.44 
SEM – standard error of the mean. Diet and extract interaction D*E, p<0.05; d*e, p=0.1; 
effect of obesity D, p<0.05.  
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CHAPTER V. SUMMARY AND CONCLUSIONS FOR THE DISSERTATION 
Influenza is a seasonal respiratory infection that continues to cause significant 
morbidity and mortality in US and also worldwide.  Although a vaccine is available for 
seasonal influenza, the match between viral antigens contained in the vaccine and the 
strain of virus circulating in the population is not always a perfect match. Also vaccine 
efficacy may be reduced in certain populations such as the elderly or obese.  Anti-viral 
medications have been found to useful in treating the infection, but due to the high 
mutation rate and recombination of the Influenza A virus, several anti-viral medications 
have been discontinued due to high probability of influenza resistance. Given these 
limitations, along with the current interest in “alternative therapies” by the public, 
Echinacea has emerged as a popular remedy for treating colds and influenza. There nine 
known species of Echinacea, three of which are commonly used for medicinal purposes: 
E. purpurea, E. angustifolia, and E. pallida.  A variety of preparations have been tested 
for immune enhancing properties.  Most commonly, the root of the plant is used to make 
an extract that is either water-based or ethanol-based.  Due to the chemical composition 
profile of each extract (water or ethanol), a variety of immune changes can be observed.   
In general, water-based extracts tend to exhibit immunomodulatory properties, whereas 
ethanol extracts are considered to have anti-inflammatory properties.   
In this dissertation, we chose to examine the effect of different Echinacea extracts 
on infection with influenza virus.  The overall goal of the research conducted as part of 
this dissertation was to extend the current knowledge base by developing an 
understanding of how Echinacea may impact innate or adaptive immune response to 
influenza, evaluate which types of extracts from which species may be most beneficial in 
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terms of enhanced immune response during influenza infection, and to establish whether 
Echinacea may have additional benefits in an obese model.   
In Chapter II of this dissertation, we used an in vitro modeling system to evaluate 
the effect of Echinacea on influenza infection on viral load, lung epithelial cells, and 
spleen mixed immune cell populations from infected mice.  In this study, we used three 
species of Echinacea: E. purpurea, E. angustifolia, and E. paradoxa var. paradoxa.  
First, we hypothesized that there would be a decrease in viral titer with the Echinacea 
treatments.  To evaluate the effect of Echinacea on the viral titer, we utilized both water 
and ethanol preparations for each Echinacea species given at a high and low dose of each 
extract.  We found that E. purpurea H2O extract demonstrated anti-viral activity in vitro 
at both low and high concentrations tested, whereas Echinacea EtOH extracts 
demonstrated anti-viral activity only at high concentrations of extract.  Next, we 
evaluated the effect of 6 Echinacea extracts on the immune response in lung epithelial 
cells using A549 cell culture given at only one dose.  Both the Echinacea water and 
ethanol extracts increased cytokines/chemokines production by A549 epithelial cells 
(eotaxin, GM-CSF, IL-8, MIP-1α/β), whereas the Echinacea ethanol extracts decreased 
production of IL-6 and IP-10.  Finally to evaluate the effect of Echinacea treatment on 
immune cells, spleen cells from infected mice were cultured in vitro, treated with 
Echinacea extracts, and stimulated with virus.  E. purpurea H2O extracts increased IL-2, 
IL-4, IL-5, and IL-17 as well as chemokines KC and MIP-1α/β.  In contrast, the 
Echinacea EtOH extracts generally decreased cytokine response and demonstrated an 
anti-inflammatory profile.  Based on these findings, it was concluded that Echinacea 
extracts may enhance the immune response to influenza infection by decreasing viral 
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load, enhancing the innate immune responses, and limiting influenza-associated 
inflammation.   
The study presented in Chapter III was designed to evaluate the effect of using a 
combination of extracts delivered at specific times during the course of influenza 
infection in mice.  In this chapter, we evaluated the effects of treating influenza infection 
with an immunostimulatory water extract at the early phase of infection, then treating 
with an anti-inflammatory ethanol extract at the late phase of infection.  In this study, we 
used E. angustifolia water (Eang H2O) and ethanol (Eang EtOH) extracts and E. 
paradoxa var. paradoxa ethanol extract (Epara EtOH) and consisted of two separate 
experiments.  In experiment 1, we evaluated Eang H2O/Eang EtOH treatment on 
immune response against influenza infection.  In experiment 2, we evaluated the effect of 
Eang H2O/Eang EtOH and Eang H2O/Epara EtOH extract treatment on lung lesion 
scores and gene expression of immune parameters in the lung (utilizing the 
bioinformatics data mining program DAVID).  In experiment one, we showed that Eang 
H2O /Eang EtOH decreased cytokines IFN-γ and TNF-α in BAL of treated mice 
compared to the BAL of H2O/EtOH control mice.  In addition, the concentration of 
multiple chemokines tended to be lower in the Eang H20/Eang EtOH mice including 
eotaxin, KC, MCP-1, RANTES, LIX, along with the cytokines IL-12p70 and IL-6, 
suggesting an overall reduction in inflammatory mediators by Echinacea. We also found 
higher serum antibody against influenza (IgG) in Eang H2O/Eang EtOH treated mice 
compared to vehicle control mice, suggesting enhancement of host immunity. In 
experiment two, five different treatment groups were used to compare the effects of two 
different species of Echinacea: H2O/EtOH, Eang H2O/EtOH, Eang H2O/Eang EtOH, 
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Eang H2O/Eang EtOH, and Eang H2O/Epara EtOH.  No change in lesion scores or 
weight loss was observed in any of the treatment groups.  DAVID bioinformatics analysis 
of the gene fold changes compared to H2O/EtOH controls revealed that the Eang 
H2O/EtOH treatment group up regulated more genes involved with lymphocyte 
activation and differentiation, whereas the Eang H2O/Eang EtOH and Eang H2O/Epara 
EtOH groups down-regulated expression of IL-8-like chemokines and genes involved in 
wound healing.  While no changes were observed in illness severity measures, body 
weight and lesion score, there was a modulation of cytokine/chemokines in the BAL of 
treated mice compared to controls.  Gene expression data analysis revealed different 
profiles for each combination analyzed suggesting that the combination selected could 
greatly impact the anti-inflammatory effects in the lung and potential benefit during 
influenza infections.  Increased anti-influenza antibody at day 9 p.i. suggests a potential 
stimulation during the early phases of infection, and the cytokine/chemokine profile 
suggests an anti-inflammatory effect in the late phases of influenza infection for the mice 
treated with a combination of Echinacea water and Echinacea ethanol extracts.  The 
DAVID analysis suggests that there is an immunomodulation in activation of immune 
cells that we were not able to detect with immune measures analyzed at day 8 or day 9, 
but may reflect changes that would be seen at later time points in the infection.    
In Chapter IV, the effect of Echinacea treatment on influenza infection in obese 
mice was evaluated.  Obesity is associated with immune dysfunction in both the innate 
and adaptive immune responses.  Since Echinacea has been shown to modulate influenza 
infection by providing both immune enhancements and decreased lung inflammation, we 
hypothesized that treatment of diet induced obese mice with Echinacea during the course 
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of influenza infection would restore the impaired immune response seen with obesity.  
We chose to study Echinacea purpurea in obese mice because it one of the most 
commonly available extracts, and it also demonstrated increased anti-viral activity and 
enhanced immune activity in lung and spleen cells as shown by in the results we obtained 
in Chapter II of this dissertation.  In this study, we found an overall effect of obesity at 
day 3 p.i.  Infected obese mice had increased IL-5, IP-10 and IFN-γ in the BAL, but 
numbers of decreased plasmacytoid dendritic cells (pDCs), alveolar macrophages, and 
CD8+ cells.  These findings are consistent with other studies in obese mice.  The effects 
of Echinacea treatment at day 3 p.i. were decreased conventional dendritic cells (cDC) 
and CD3+ cells (number and percentage).  At day 8 p.i., the effect of obesity (diet) was a 
reduction in alveolar macrophages, reduced CD8+ cells, and a decreased %CD4+IFNγ+ 
cells.  Also at day 8 p.i., the Echinacea treated obese mice had decreased CD8+ counts 
and percentage and increased alveolar macrophage percentage in the lung at day 8 p.i.  
However, Echinacea treatment increased the production of IFN-γ in CD4 and CD8 cells 
when treated with PMA-ionomycin and with NP stimulation in both lean and obese mice.  
Although total spleen cell counts did not differ between the lean and obese mice, 
Echinacea tended to increase IFN-γ production in cultured spleen cells at 72 hours post 
stimulation, but not at 48 or 96 hours.  IFN-γ production by spleen cells obtained from 
the obese mice was lower than the lean mice.  There was an increase in the CD8+ cell 
population in the Echinacea treated obese mice spleens.  This could result in the 
increased in IFN-γ production seen in the Echinacea treated obese mice and be a result of 
earlier influenza infection resolution.  We concluded that the obesity effects seen in the 
diet induced obesity model used in this study correlated with the findings of previous 
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studies.  To the best of our knowledge, no previous studies have evaluated the effect of 
Echinacea treatment in a diet induced obesity model of influenza infection.  Echinacea 
treatment increased alveolar macrophage percentage, and decreased CD8 in the lungs of 
obese mice, and altered the IFN-γ production in spleen cells.  Overall, Echinacea did not 
correct the obesity associated immune changes seen in diet induced obesity, such as 
impaired cellular recruitment (pDC and CD8) thought to lead to morbidity associated 
with obesity.   
In conclusion, this dissertation further confirms the immunostimulatory properties 
of Echinacea water extracts and anti-inflammatory properties of Echinacea ethanol 
extracts in vitro.  It also suggests that a combination of Echinacea extracts delivered at 
specific times during the course of influenza infection may provide enhanced immunity 
and reduced lung inflammation depending on the Echinacea species utilized.  Lastly, 
Echinacea treatment during influenza infection in obese mice provided no immune 
benefit and may result in decreased CD8 cells necessary for viral clearance and infection 
resolution.   
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APPENDIX 
DAVID output with Enrichment scores, p-values, Genes up- or down-regulated 
for each pathway in the enrichment cluster, and Bonferroni values.  Gene regulation of 
extract combination treated mice compared to the gene regulation of vehicle control 
(H2O/EtOH) treated mice on Day 8 post infection. 
Up-regulation Eang H2O/EtOH relative to H2O/EtOH 
Enrichment Score: 14.7 
Term P-Value Genes Bonferroni 
GO:0045321~leukocyte 
activation 
0.00 
PTPRC, ICOSL, CR2, CD8A, CD3E, PIK3CD, TLR4, 
VAV1, HDAC5, DOCK2, CXCR5, CCND3, CLCF1, 
GADD45G, CD4, IMPDH1, HELLS 
0.00 
GO:0001775~cell 
activation 
0.00 
PTPRC, ICOSL, CR2, CD8A, CD3E, PIK3CD, TLR4, 
VAV1, HDAC5, DOCK2, CXCR5, CCND3, CLCF1, 
GADD45G, CD4, IMPDH1, HELLS 
0.00 
GO:0046649~lymphocyte 
activation 
0.00 
PTPRC, ICOSL, CR2, CD8A, CD3E, PIK3CD, VAV1, 
HDAC5, DOCK2, CXCR5, CCND3, CLCF1, GADD45G, 
CD4, IMPDH1, HELLS 
0.00 
GO:0030098~lymphocyte 
differentiation 
0.00 
HDAC5, PTPRC, DOCK2, CD8A, CLCF1, CD3E, 
GADD45G, CD4, VAV1, HELLS 
0.00 
GO:0002520~immune 
system development 
0.00 
HDAC5, PTPRC, DOCK2, ICOSL, CXCR5, CD8A, CLCF1, 
CD3E, GADD45G, CD4, VAV1, HELLS 
0.00 
GO:0002521~leukocyte 
differentiation 
0.00 
HDAC5, PTPRC, DOCK2, CD8A, CLCF1, CD3E, 
GADD45G, CD4, VAV1, HELLS 
0.00 
GO:0042110~T cell 
activation 
0.00 
PTPRC, DOCK2, ICOSL, CCND3, CD8A, CD3E, 
GADD45G, CD4, VAV1 
0.00 
GO:0048534~hemopoietic 
or lymphoid organ 
development 
0.00 
HDAC5, PTPRC, DOCK2, CXCR5, CD8A, CLCF1, CD3E, 
GADD45G, CD4, VAV1, HELLS 
0.00 
GO:0030097~hemopoiesis 0.00 
HDAC5, PTPRC, DOCK2, CD8A, CLCF1, CD3E, 
GADD45G, CD4, VAV1, HELLS 
0.00 
GO:0030217~T cell 
differentiation 
0.00 PTPRC, DOCK2, CD8A, CD3E, GADD45G, CD4, VAV1 0.00 
Enrichment Score: 5.1 
Term P-Value Genes Bonferroni 
GO:0030217~T cell 
differentiation 
0.00 PTPRC, DOCK2, CD8A, CD3E, GADD45G, CD4, VAV1 0.00 
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GO:0009967~positive 
regulation of signal 
transduction 
0.00 PTPRC, DOCK2, CD8A, CD3E, CD4, TLR4, IL11 0.00 
GO:0010647~positive 
regulation of cell 
communication 
0.00 PTPRC, DOCK2, CD8A, CD3E, CD4, TLR4, IL11 0.00 
mmu05340:Primary 
immunodeficiency 
0.00 PTPRC, CD8B1, CD8A, CD3E, CD4 0.00 
GO:0045058~T cell 
selection 
0.00 PTPRC, DOCK2, CD3E, CD4 0.00 
GO:0045060~negative 
thymic T cell selection 
0.00 PTPRC, DOCK2, CD3E 0.06 
Enrichment Score: 4.9 
Term P-Value Genes Bonferroni 
GO:0046651~lymphocyte 
proliferation 
0.00 PTPRC, DOCK2, CCND3, IMPDH1, HELLS 0.00 
GO:0070661~leukocyte 
proliferation 
0.00 PTPRC, DOCK2, CCND3, IMPDH1, HELLS 0.00 
Enrichment Score: 3.8 
Term P-Value Genes Bonferroni 
GO:0030217~T cell 
differentiation 
0.00 PTPRC, DOCK2, CD8A, CD3E, GADD45G, CD4, VAV1 0.00 
GO:0006955~immune 
response 
0.00 
PTPRC, ICOSL, CR2, CD8B1, CD8A, IL27, GADD45G, 
CD4, TLR4, VAV1 
0.00 
immune response 0.00 ICOSL, CR2, CD8B1, CD8A, IL27, CD4, TLR4 0.00 
GO:0009986~cell surface 0.00 PTPRC, ICOSL, CR2, CD8B1, CD93, CD8A, CD3E, CD4 0.00 
mmu04640:Hematopoietic 
cell lineage 
0.00 CR2, CD8B1, CD8A, CD3E, CD4, IL5RA, IL11 0.00 
GO:0009967~positive 
regulation of signal 
transduction 
0.00 PTPRC, DOCK2, CD8A, CD3E, CD4, TLR4, IL11 0.00 
GO:0009897~external side 
of plasma membrane 
0.00 PTPRC, ICOSL, CR2, CD8B1, CD8A, CD3E, CD4 0.00 
GO:0010647~positive 
regulation of cell 
communication 
0.00 PTPRC, DOCK2, CD8A, CD3E, CD4, TLR4, IL11 0.00 
mmu04660:T cell receptor 
signaling pathway 
0.00 PTPRC, CD8B1, CD8A, CD3E, PIK3CD, CD4, VAV1 0.00 
GO:0050870~positive 
regulation of T cell 
activation 
0.00 PTPRC, ICOSL, CD3E, CD4, SOCS5 0.00 
GO:0050848~regulation of 
calcium-mediated 
signaling 
0.00 CD8A, CD3E, CD4 0.00 
domain:Ig-like V-type 0.00 ICOSL, CD8B1, CD8A, CD4 0.06 
mmu04514:Cell adhesion 
molecules (CAMs) 
0.00 PTPRC, ICOSL, CD8B1, CD8A, CD4 0.07 
m_tcraPathway:Lck and 
Fyn tyrosine kinases in 
initiation of TCR 
Activation 
0.00 PTPRC, CD3E, CD4 0.07 
Enrichment Score: 3.4 
Term P-Value Genes Bonferroni 
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GO:0051249~regulation of 
lymphocyte activation 
0.00 PTPRC, ICOSL, CD3E, IL27, CD4, TLR4, SOCS5 0.00 
GO:0002694~regulation of 
leukocyte activation 
0.00 PTPRC, ICOSL, CD3E, IL27, CD4, TLR4, SOCS5 0.00 
GO:0050865~regulation of 
cell activation 
0.00 PTPRC, ICOSL, CD3E, IL27, CD4, TLR4, SOCS5 0.00 
GO:0009967~positive 
regulation of signal 
transduction 
0.00 PTPRC, DOCK2, CD8A, CD3E, CD4, TLR4, IL11 0.00 
GO:0051251~positive 
regulation of lymphocyte 
activation 
0.00 PTPRC, ICOSL, CD3E, CD4, TLR4, SOCS5 0.00 
GO:0010647~positive 
regulation of cell 
communication 
0.00 PTPRC, DOCK2, CD8A, CD3E, CD4, TLR4, IL11 0.00 
GO:0002696~positive 
regulation of leukocyte 
activation 
0.00 PTPRC, ICOSL, CD3E, CD4, TLR4, SOCS5 0.00 
GO:0050867~positive 
regulation of cell 
activation 
0.00 PTPRC, ICOSL, CD3E, CD4, TLR4, SOCS5 0.00 
GO:0050863~regulation of 
T cell activation 
0.00 PTPRC, ICOSL, CD3E, IL27, CD4, SOCS5 0.00 
GO:0002684~positive 
regulation of immune 
system process 
0.00 PTPRC, ICOSL, CR2, CD3E, CD4, TLR4, SOCS5 0.00 
GO:0050870~positive 
regulation of T cell 
activation 
0.00 PTPRC, ICOSL, CD3E, CD4, SOCS5 0.00 
mmu05340:Primary 
immunodeficiency 
0.00 PTPRC, CD8B1, CD8A, CD3E, CD4 0.00 
GO:0045058~T cell 
selection 
0.00 PTPRC, DOCK2, CD3E, CD4 0.00 
GO:0032944~regulation of 
mononuclear cell 
proliferation 
0.00 PTPRC, ICOSL, CD3E, IL27, TLR4 0.01 
GO:0050670~regulation of 
lymphocyte proliferation 
0.00 PTPRC, ICOSL, CD3E, IL27, TLR4 0.01 
GO:0070663~regulation of 
leukocyte proliferation 
0.00 PTPRC, ICOSL, CD3E, IL27, TLR4 0.01 
GO:0032946~positive 
regulation of mononuclear 
cell proliferation 
0.00 PTPRC, ICOSL, CD3E, TLR4 0.05 
GO:0050671~positive 
regulation of lymphocyte 
proliferation 
0.00 PTPRC, ICOSL, CD3E, TLR4 0.05 
GO:0070665~positive 
regulation of leukocyte 
proliferation 
0.00 PTPRC, ICOSL, CD3E, TLR4 0.06 
GO:0050730~regulation of 
peptidyl-tyrosine 
phosphorylation 
0.00 PTPRC, CD3E, CD4, IL11 0.06 
GO:0042325~regulation of 
phosphorylation 
0.00 PTPRC, CD3E, GADD45G, CD4, TLR4, IL11 0.07 
GO:0019220~regulation of 
phosphate metabolic 
process 
0.00 PTPRC, CD3E, GADD45G, CD4, TLR4, IL11 0.08 
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GO:0051174~regulation of 
phosphorus metabolic 
process 
0.00 PTPRC, CD3E, GADD45G, CD4, TLR4, IL11 0.08 
GO:0042129~regulation of 
T cell proliferation 
0.00 PTPRC, ICOSL, CD3E, IL27 0.08 
GO:0042108~positive 
regulation of cytokine 
biosynthetic process 
0.00 ICOSL, CD3E, TLR4 0.22 
Enrichment Score: 3.2 
Term P-Value Genes Bonferroni 
GO:0009986~cell surface 0.00 PTPRC, ICOSL, CR2, CD8B1, CD93, CD8A, CD3E, CD4 0.00 
transmembrane protein 0.00 PTPRC, CR2, CXCR5, CD8A, PRLR, CD3E, CD4, IL5RA 0.00 
GO:0009897~external side 
of plasma membrane 
0.00 PTPRC, ICOSL, CR2, CD8B1, CD8A, CD3E, CD4 0.00 
Signal 0.00 
PTPRC, ICOSL, CR2, CD8B1, CD8A, CD3E, IL27, TLR4, 
INHA, IL11, PRLR, CD93, CLCF1, CD4, IL5RA 
0.00 
signal peptide 0.00 
PTPRC, ICOSL, CR2, CD8B1, CD8A, CD3E, IL27, TLR4, 
INHA, IL11, PRLR, CD93, CLCF1, CD4, IL5RA 
0.00 
topological 
domain:Extracellular 
0.00 
PTPRC, ICOSL, CR2, CD8B1, CD93, CXCR5, CD8A, 
PRLR, CD3E, CD4, TLR4, IL5RA 
0.02 
disulfide bond 0.00 
ICOSL, CR2, CD8B1, CD93, CXCR5, CD8A, PRLR, CD3E, 
CD4, TLR4, IL5RA, INHA 
0.01 
Glycoprotein 0.00 
PTPRC, ICOSL, CR2, CD8B1, CD8A, IL27, TLR4, INHA, 
PRLR, CD93, CXCR5, CLCF1, CD4, IL5RA 
0.02 
disulfide bond 0.00 
ICOSL, CR2, CD8B1, CD93, CXCR5, CD8A, PRLR, CD3E, 
CD4, TLR4, IL5RA, INHA 
0.04 
Enrichment Score: 3.1 
Term P-Value Genes Bonferroni 
GO:0009986~cell surface 0.00 PTPRC, ICOSL, CR2, CD8B1, CD93, CD8A, CD3E, CD4 0.00 
GO:0009897~external side 
of plasma membrane 
0.00 PTPRC, ICOSL, CR2, CD8B1, CD8A, CD3E, CD4 0.00 
GO:0002252~immune 
effector process 
0.00 PTPRC, ICOSL, CR2, CD8A 0.00 
Enrichment Score: 2.3 
Term P-Value Genes Bonferroni 
GO:0007243~protein 
kinase cascade 
0.00 PTPRC, PRLR, CLCF1, GADD45G, TLR4, SOCS5 0.03 
GO:0042325~regulation of 
phosphorylation 
0.00 PTPRC, CD3E, GADD45G, CD4, TLR4, IL11 0.07 
GO:0019220~regulation of 
phosphate metabolic 
process 
0.00 PTPRC, CD3E, GADD45G, CD4, TLR4, IL11 0.08 
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Enrichment Score: 2.1 
Term P-Value Genes Bonferroni 
innate immunity 0.00 CR2, IL27, TLR4 0.35 
GO:0006954~inflammator
y response 
0.01 HDAC5, CR2, IL27, TLR4 0.98 
GO:0006952~defense 
response 
0.01 HDAC5, PTPRC, CR2, IL27, TLR4 0.98 
GO:0045087~innate 
immune response 
0.01 CR2, IL27, TLR4 1.00 
GO:0009611~response to 
wounding 
0.02 HDAC5, CR2, IL27, TLR4 1.00 
Enrichment Score: 1.5 
Term P-Value Genes Bonferroni 
IPR008957:Fibronectin, 
type III-like fold 
0.02 PTPRC, PRLR, IL5RA 0.89 
Up-regulation Eang H2O/Epara EtOH relative to H2O/EtOH 
Enrichment Score: 4.2 
Term P-Value Genes Bonferroni 
GO:0046649~lymphocyte 
activation 
0.00 HDAC5, PTPRC, DOCK2, CLCF1, PIK3CD, VAV1 0.00 
GO:0045321~leukocyte 
activation 
0.00 HDAC5, PTPRC, DOCK2, CLCF1, PIK3CD, VAV1 0.00 
GO:0001775~cell 
activation 
0.00 HDAC5, PTPRC, DOCK2, CLCF1, PIK3CD, VAV1 0.00 
GO:0030098~lymphocyte 
differentiation 
0.00 HDAC5, PTPRC, DOCK2, CLCF1, VAV1 0.00 
GO:0002521~leukocyte 
differentiation 
0.00 HDAC5, PTPRC, DOCK2, CLCF1, VAV1 0.00 
GO:0030097~hemopoiesis 0.00 HDAC5, PTPRC, DOCK2, CLCF1, VAV1 0.00 
GO:0042113~B cell 
activation 
0.00 HDAC5, PTPRC, CLCF1, PIK3CD 0.00 
GO:0048534~hemopoietic 
or lymphoid organ 
development 
0.00 HDAC5, PTPRC, DOCK2, CLCF1, VAV1 0.00 
GO:0002520~immune 
system development 
0.00 HDAC5, PTPRC, DOCK2, CLCF1, VAV1 0.01 
mmu04666:Fc gamma R-
mediated phagocytosis 
0.00 PTPRC, DOCK2, PIK3CD, VAV1 0.01 
GO:0030183~B cell 
differentiation 
0.00 HDAC5, PTPRC, CLCF1 0.11 
        
Enrichment Score: 1.4       
Term P-Value Genes Bonferroni 
Cytokine 0.00 CLCF1, IL27, IL11 0.15 
        
Down-regulation Eang H2O/EtOH relative to H2O/EtOH 
Enrichment Score: 6.8 
Term P-Value Genes Bonferroni 
Cytokine 0.00 IL1F8, TNF, CCL20, CCL9, CCL19, CCL4 0.00 
GO:0005125~cytokine 0.00 IL1F8, TNF, CCL20, CCL9, CCL19, CCL4 0.00 
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activity 
Secreted 0.00 IL1F8, TNF, CCL20, CRP, CCL9, CCL19, CCL4 0.00 
GO:0006955~immune 
response 
0.00 IL1F8, TNF, CCL20, CCL9, CCL19, CCL4 0.00 
GO:0005615~extracellular 
space 
0.00 IL1F8, TNF, CCL20, CCL9, CCL19, CCL4 0.00 
GO:0044421~extracellular 
region part 
0.00 IL1F8, TNF, CCL20, CCL9, CCL19, CCL4 0.00 
GO:0005576~extracellular 
region 
0.00 IL1F8, TNF, CCL20, CRP, CCL9, CCL19, CCL4 0.00 
Enrichment Score: 6.8 
Term P-Value Genes Bonferroni 
GO:0006954~inflammator
y response 
0.00 IL1F8, TNF, CCL20, CRP, CCL19, CCL4 0.00 
GO:0009611~response to 
wounding 
0.00 IL1F8, TNF, CCL20, CRP, CCL19, CCL4 0.00 
GO:0006952~defense 
response 
0.00 IL1F8, TNF, CCL20, CRP, CCL19, CCL4 0.00 
Secreted 0.00 IL1F8, TNF, CCL20, CRP, CCL9, CCL19, CCL4 0.00 
GO:0005576~extracellular 
region 
0.00 IL1F8, TNF, CCL20, CRP, CCL9, CCL19, CCL4 0.00 
Enrichment Score: 5.0 
Term P-Value Genes Bonferroni 
IPR000827:Small 
chemokine, C-C group, 
conserved site 
0.00 CCL20, CCL9, CCL19, CCL4 0.00 
PIRSF001950:small 
inducible chemokine, 
C/CC types 
0.00 CCL20, CCL9, CCL19, CCL4 0.00 
IPR001811:Small 
chemokine, interleukin-8-
like 
0.00 CCL20, CCL9, CCL19, CCL4 0.00 
GO:0008009~chemokine 
activity 
0.00 CCL20, CCL9, CCL19, CCL4 0.00 
GO:0042379~chemokine 
receptor binding 
0.00 CCL20, CCL9, CCL19, CCL4 0.00 
Chemotaxis 0.00 CCL20, CCL9, CCL19, CCL4 0.00 
SM00199:SCY 0.00 CCL20, CCL9, CCL19, CCL4 0.00 
GO:0006935~chemotaxis 0.00 CCL20, CCL9, CCL19, CCL4 0.00 
GO:0042330~taxis 0.00 CCL20, CCL9, CCL19, CCL4 0.00 
GO:0007626~locomotory 
behavior 
0.00 CCL20, CCL9, CCL19, CCL4 0.02 
mmu04062:Chemokine 
signaling pathway 
0.00 CCL20, CCL9, CCL19, CCL4 0.00 
inflammatory response 0.00 CCL20, CCL19, CCL4 0.01 
GO:0007610~behavior 0.00 CCL20, CCL9, CCL19, CCL4 0.09 
Enrichment Score: 3.8 
Term P-Value Genes Bonferroni 
Secreted 0.00 IL1F8, TNF, CCL20, CRP, CCL9, CCL19, CCL4 0.00 
GO:0005576~extracellular 
region 
0.00 IL1F8, TNF, CCL20, CRP, CCL9, CCL19, CCL4 0.00 
disulfide bond 0.00 TNF, CCL20, CRP, CCL9, CCL19, CCL4 0.01 
disulfide bond 0.00 TNF, CCL20, CRP, CCL9, CCL19, CCL4 0.01 
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Down-regulation Eang H2O/Eang EtOH relative to H2O/EtOH 
Enrichment Score: 6.3 
Term P-Value Genes Bonferroni 
cytokine 0.00 CCL3, TNF, TNFSF14, CCL8, CCL5, CCL4 0.00 
GO:0005125~cytokine 
activity 
0.00 CCL3, TNF, TNFSF14, CCL8, CCL5, CCL4 0.00 
GO:0006955~immune 
response 
0.00 CCL3, TNF, TNFSF14, CCL8, CCL5, CCL4 0.00 
GO:0005615~extracellular 
space 
0.00 CCL3, TNF, TNFSF14, CCL8, CCL5, CCL4 0.00 
mmu04060:Cytokine-
cytokine receptor 
interaction 
0.00 CCL3, TNF, TNFSF14, CCL8, CCL5, CCL4 0.00 
GO:0006954~inflammator
y response 
0.00 CCL3, TNF, CCL8, CCL5, CCL4 0.00 
GO:0044421~extracellular 
region part 
0.00 CCL3, TNF, TNFSF14, CCL8, CCL5, CCL4 0.00 
GO:0009611~response to 
wounding 
0.00 CCL3, TNF, CCL8, CCL5, CCL4 0.00 
Secreted 0.00 CCL3, TNF, TNFSF14, CCL8, CCL5, CCL4 0.00 
GO:0006952~defense 
response 
0.00 CCL3, TNF, CCL8, CCL5, CCL4 0.00 
GO:0005576~extracellular 
region 
0.00 CCL3, TNF, TNFSF14, CCL8, CCL5, CCL4 0.00 
disulfide bond 0.00 CCL3, TNF, TNFSF14, CCL8, CCL5, CCL4 0.00 
disulfide bond 0.00 CCL3, TNF, TNFSF14, CCL8, CCL5, CCL4 0.00 
Enrichment Score: 5.3 
Term P-Value Genes Bonferroni 
IPR000827:Small 
chemokine, C-C group, 
conserved site 
0.00 CCL3, CCL8, CCL5, CCL4 0.00 
PIRSF001950:small 
inducible chemokine, 
C/CC types 
0.00 CCL3, CCL8, CCL5, CCL4 0.00 
IPR001811:Small 
chemokine, interleukin-8-
like 
0.00 CCL3, CCL8, CCL5, CCL4 0.00 
GO:0008009~chemokine 
activity 
0.00 CCL3, CCL8, CCL5, CCL4 0.00 
GO:0042379~chemokine 
receptor binding 
0.00 CCL3, CCL8, CCL5, CCL4 0.00 
GO:0006954~inflammator
y response 
0.00 CCL3, TNF, CCL8, CCL5, CCL4 0.00 
chemotaxis 0.00 CCL3, CCL8, CCL5, CCL4 0.00 
SM00199:SCY 0.00 CCL3, CCL8, CCL5, CCL4 0.00 
inflammatory response 0.00 CCL3, CCL8, CCL5, CCL4 0.00 
GO:0009611~response to 
wounding 
0.00 CCL3, TNF, CCL8, CCL5, CCL4 0.00 
GO:0006935~chemotaxis 0.00 CCL3, CCL8, CCL5, CCL4 0.00 
GO:0042330~taxis 0.00 CCL3, CCL8, CCL5, CCL4 0.00 
GO:0006952~defense 
response 
0.00 CCL3, TNF, CCL8, CCL5, CCL4 0.00 
mmu04620:Toll-like 
receptor signaling pathway 
0.00 CCL3, TNF, CCL5, CCL4 0.00 
225 
 
GO:0007626~locomotory 
behavior 
0.00 CCL3, CCL8, CCL5, CCL4 0.01 
GO:0007610~behavior 0.00 CCL3, CCL8, CCL5, CCL4 0.05 
mmu04062:Chemokine 
signaling pathway 
0.00 CCL3, CCL8, CCL5, CCL4 0.01 
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